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Purpose: Schizophrenia is a common psychiatric disease of impaired perception or 
expression of reality. However the etiology of this disease is still not clear after it 
has been identified for over 100 years, and the current standard schizophrenia 
diagnostic procedures are based on subjective observations on symptoms. We 
aimed to discover the relationship between schizophrenia and the objective and 
quantitative criteria from neuroinformatics data and neuroimaging data, and 
construct schizophrenia classification models based on this unique combination of 
data. This novel approach of combining neuroinformatics and neuroimaging for 
schizophrenia modeling, to our best knowledge, had never been used before by 
others. 
 
Study Subjects and Methods: With the support from the National Healthcare 
Group Research Grant (NHG-SIG/05004) and Singapore Bioimaging Consortium 
Research Grant (SBIC RP C-009/2006), our collaborating hospitals, Institute of 
Mental Health, Singapore and National Neuroscience Institute, Singapore, 
recruited 156 study subjects (92 schizophrenia patients, 64 healthy controls). 
Various types of neuroinformatics data (including demographic data, clinical 
information, clinical scores, and neurocognitive test results) and neuroimaging data 




A subset of study subjects consisting of 84 cases (59 patients and 25 controls) was 
used as training dataset for modeling. Significant features were selected from over 
300 data items. Bayesian Network learning technologies were applied to construct 
various Bayesian Network models for the classification of schizophrenia patients 
and normal controls using the selected features. The 10-fold cross-validation 
method was used for internal model validation. Limited external validation was 
also performed using the test dataset. 
 
Results: The following eight factors were chosen by the feature selection process: 
1) Family history of psychiatric diseases, 2) Raven's Progressive Matrices (RPM) 
test result (RPM raw score), 3) Wechsler Adult Intelligence Scale (WAIS) test 
result (Digit Span backward score), 4) Wisconsin Card Sorting Test (WCST) result 
(Perseverative Responses raw scores), 5-8) Mean Fractional Anisotropy (FA) 
values in four brain structures from neuroimaging results: cingulate gyrus, left 
subcallosal gyrus, left thalamus: lateral dorsal nucleus, and right thalamus: anterior 
nucleus.  
 
The classification accuracies of models built on clinical information (family 
history) plus various combinations of neurocognitive tests (but no neuroimaging 
features) ranged from 75% to 85.7%. On the other hand, the accuracy of the model 
on neuroimaging features alone was 77.4%, and the accuracy of model on clinical 
information and neuroimaging features (but no neurocognitive test) was 84.5%. 
Models built on clinical information and neuroimaging features plus various 
combinations of neurocognitive test further increased accuracy to 85.7%-89.3%.  
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The most comprehensive model consisted of all eight significant factors. The 
accuracy of this model, 89.3%, was the highest among all models. 
 
Contributions: By applying the first ever Talairach brain atlas based FA image 
quantification method developed at Biomedical Imaging Lab, Agency for Science, 
Technology and Research, Singapore, we placed a large amount of Region of 
Interests (144 ROIs for 48 brain structures) on brain images, and quantified their 
image features (mean and standard deviation of FA values) automatically, which 
was usually difficult for manual methods. This method made studies involving 
large amount of patients/controls more consistent and feasible than the manual 
processing. The quantified image features have been used in further model 
constructions and decision support. 
 
We found that schizophrenia was highly related to a person’s family history of 
psychiatric disease, deficit in eductive and reproductive functions, deficit in verbal 
working memory, undue perseverative responses (which is caused by frontal lobe 
deficit), reduced neural connectivity in the cingulate gyrus (which is associated 
with attention function), the subcallosal gyrus (which is associated with the left 
and right prefrontal interhemispheric communication), and the thalamus lateral 
dorsal nucleus and anterior nucleus (which are associated with somatosensory and 
visuo-spatial function and modulation of alertness). 
 
We demonstrated the first ever schizophrenia classification models based on 
objective and quantitative criteria including neurocognitive tests and neuroimaging. 
These models quantified the relationships between schizophrenia and the relative 
 ix
factors, which helped us to achieve a better understanding and management of the 
disease. 
 
Based on our schizophrenia classification models, we made two Decision Support 
Flow Charts to choose suitable tests by using different strategies: the highest 
accuracy gain, and the highest cost effectiveness. These flow charts could help 
clinicians to choose the best further tests in order to achieve a higher diagnostic 
accuracy with or without cost consideration. 
 
We also developed decision support system software for schizophrenia diagnosis. 
This software could classify a person as either a schizophrenia patient or healthy 
(together with probability distribution), using the given clinical information, and 
the neurocognitive and neuroimaging test results. It could also provide suggestions 
on what further tests should be done in order to improve the diagnosis accuracy.  
 
The methodology (modeling using neuroinformatics and neuroimaging) we 
developed in this study has the potential to be applied to other diseases with 
informatics and imaging data. 
 
Conclusions: Schizophrenia classification models can be constructed using 
objective and quantitative criteria from neuroinformatics and neuroimaging data. 
The classification accuracy of the most comprehensive model consisting of all 
eight significant features is 89.3%. These models reveal the quantitative 
relationship between schizophrenia and various intermediate phenotypes (as 
assessed by neurocognitive tests) and brain abnormalities (as assessed by 
 x
neuroimaging). A decision support system based on these models can provide 
additional evidence to clinicians and augment the current schizophrenia diagnostic 
procedures, which may help to improve the diagnosis accuracy. 
 
The approach described in this thesis for the schizophrenia modeling and decision 
support can also be applied to other mental sickness such as schizoaffective 
disorder, bipolar disorder or unipolar depression, where neurocognitive tests and 
neuroimaging test are used. 
 
Despite our data uniqueness, our models and decision support system are still 
tentative and limited due to the relatively small sample size and types of data. Even 
for the most comprehensive model including all eight features, there is a noticeable 
false positive rate (normal control classified as patient) of 20%.  Further 
refinements need to be considered by recruiting more study subjects, using more 
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Chapter 1  
Introduction 
 
In this chapter, we will introduce some background knowledge of schizophrenia 
disease and the difficulties in its diagnosis. We will also propose our approach 
towards a better understanding of schizophrenia, and an alternative way to the 




Schizophrenia is a common psychiatric disease of impaired perception or 
expression of reality, commonly demonstrated through disorganized speech and 
thinking, auditory hallucinations, delusions, or paranoid. It affects about one 
percent of the world population, regardless of societies and geographical areas. It 
usually starts in late adolescence and young adulthood, and can last for the whole 
life (Sadock BJ, 2003). Schizophrenia patients have severe suffering; 30% of them 
have attempted suicide (Radomsky, Haas, Mann, & Sweeney, 1999), and about 
10% of them die by suicide (Caldwell & Gottesman, 1990). 
 
Schizophrenia affects patients’ normal mental functions and behaviors.  Most 
likely, patients could not continue their work or study.  
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Schizophrenia becomes an enormous economic burden to the patients’ family and 
the society. It is ranked the ninth in the global burden of disease (C. Murray & 
Lozpe, 1996). For example, the total expenses including inpatient, outpatient, 
primary care, pharmaceutical, and long-term care, were estimated at US$62.7 
billion in year 2002 in the United State of America (Wu, et al., 2005); and the total 
societal cost of schizophrenia was estimated at ₤6.7 billion in 2004/05 in the 





The study of schizophrenia can be traced back to 19th century. An Austrian-French 
physician, Benedict Augustin Morel (1809-1873) used demence precoce for 
deteriorated patient with illness beginning in adolescence. Emil Kraepelin (1856-
1926), a German psychiatrist, translated it into dementia praecox, which 
distinguishes cognitive process (dementia) and early onset (praecox). Patients 
having dementia praecox were classified as having long-term deterioration in 
addition to hallucinations and delusions. 
 
Paul Eugen Bleuler (1857-1939), a Swiss psychiatrist, started to use schizophrenia 
to express the schisms among thoughts, emotions and behaviors of the patients. 
Since schizophrenia comes from two roots, schizo (meaning split) phrenia 
(meaning mind), it is often confused with split personality (dissociative identity 





Patients with schizophrenia can show positive and/or negative symptoms. Positive 
symptoms include hallucinations (including auditory and visual), delusions (such 
as grandiose: e.g., feeling himself/herself as a great movie star, and delusion of 
being controlled, or passivity: feeling himself/herself being controlled by an 
external party), bizarre behavior (e.g., wearing odd or inappropriate makeup), and 
positive formal thought disorder (such as derailment: ideas slipping off the track 
onto another which is obliquely related or unrelated; tangentiality: replying to 
questions in an oblique, tangential or irrelevant manner).  
 
Negative symptoms include affective flattening (reduction in the range and 
intensity of emotional expression), alogia (difficulty or inability to speak), 
avolition-apathy (reduction, difficulty, or inability to initiate and persist in goal-
directed behavior: e.g. no longer interested in going out and meeting with friends), 
and inattentiveness (difficulty concentrating or focusing). Table 1.1 lists the 




Table 1.1 Positive and negative symptoms of schizophrenia patients 
Positive Symptoms Negative Symptoms 
Hallucination Affective flattening 
        Auditory         Unchanging facial expression 
        Voice commenting         Decreased spontaneous movements 
        Voice conversing         Paucity of expressive gesture 
        Somatic-tactile         Poor eye contact 
        Olfactory         Affective nonresponsivity 
        Visual         Inappropriate affect 
Delusion         Lack of vocal inflections 
        Persecutory Alogia 
        Jealousy         Poverty of speech 
        Guilt, sin         Poverty of content of speech 
        Grandiose         Blocking 
        Religious         Increased response latency 
        Somatic Avolition-apathy 
        Delusion of reference         Grooming and hygiene 
        Delusion of being controlled         Impersistence at work or school 
        Delusion of mind reading         Physical anergia 
        Thought broadcasting Anhedonia-asociality 
        Thought insertion         Recreational interests, activity 
        Though withdrawal         Sexual interest, activity 
Bizarre behavior         Intimacy, closeness 
        Clothing, appearance         Relationship with friends, peers 
        Social, sexual behavior Attention 
        Aggressive/agitated behavior         Social inattentiveness 
        Repetitive/stereotyped behavior         Inattentiveness during testing 
Positive formal thought disorder  
        Derailment  
        Tangentiality  
        Incoherence  
        Illogicality  
        Circumstantiality  
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Positive Symptoms Negative Symptoms 
        Pressure of speech  
        Distractible speech  
        Clanging  
 
In this section, we briefly introduced a very common (affects 1% of population) 
and economically costly psychological disease, schizophrenia, its history, and its 
major symptoms, which can be divided into positive and negative groups. 
However, being such an important disease with long history (more than 100 years), 
its diagnosis problem is not yet solved satisfactorily, as we can see from the next 
section. 
 
1.2 Diagnosis of Schizophrenia 
 
Schizophrenia diagnosis is based on the patient’s self-reported experiences, and 
family members’, friends’, and clinicians’ observed behavior. There is no 
laboratory test for schizophrenia yet.  
 
In 1994, American Psychiatric Association published the Diagnostic and Statistical 
Manual of Mental Disorder, 4th Edition (DSM-IV), which recommended the 
following diagnostic criteria for schizophrenia: 
• Characteristic symptoms. Two or more of the following, each present for a 
significant portion of time during a 1-month period (or less if successfully 
treated) 
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o Delusions (e.g., delusion of grandeur: believing he/she is someone 
very famous or important, such as God) 
o Hallucinations (e.g., visual: seeing something nobody else can see; 
auditory: hearing things nobody else can hear) 
o Disorganized speech (e.g., frequent derailment, incoherence) 
o Grossly disorganized (e.g., shouting or cursing in public) or 
catatonic behavior (e.g., rapid alteration between extreme 
excitement and stupor) 
o Negative symptoms (e.g., affective flattening, alogia) 
• Social/occupational dysfunction 
• Duration. Continuous signs of the disturbance persist for at least six months. 
• Schizoaffective and mood disorder exclusion 
• Substance/general medical condition exclusion (disturbance not due to the 
direct physiologic effects of a substance or general medical condition) 
• Relationship to pervasive developmental disorder 
 
International Statistical Classification of Diseases and Related Health Problems, 
10th Revision (ICD-10) (World Health Organization 2006) presents another 
guideline for diagnosis of schizophrenia.  According to ICD-10, the most 
important psychopathological phenomena include: 1) thought echo, thought 
insertion or withdrawal, 2) thought broadcasting, 3) delusional perception and 
delusions of control, 3) influence or passivity, 4) hallucinatory voices commenting 
or discussing the patient in the third person, 5) thought disorders, and 6) negative 
symptoms. The duration of symptoms presenting clearly should be at least 1 month.  
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Schizophrenia should not be diagnosed in extensive depressive or manic symptoms 
unless it is clear that schizophrenic symptoms antedate the affective disturbance. It 
shall not be diagnosed in the presence of overt brain disease or during states of 
drug intoxication or withdrawal. 
 
Schizophrenia can have different subtypes. Subtypes of schizophrenia can be 
identified by the most predominant and significant symptoms for each patient at 
the evaluation time. For example, according to DSM-IV, there are five subtypes: 
• Catatonic type: when prominent catatonic symptoms are present. 
• Disorganized type: when disorganized speech and behavior and flat or 
inappropriate affect are present. 
• Paranoid type: when preoccupation with delusion or frequent hallucinations 
are prominent. 
• Undifferentiated type: a remaining category describing prominent active-
phase symptoms that are not catatonic, disorganized or paranoid types. 
• Residual type: continuing evidence of disturbance but not meeting active-
phase symptoms criteria. 
 
Subtypes of schizophrenia are not mutually exclusive. Sometimes, patients may 
develop more than one subtypes of schizophrenia. For example, a patient may be 
in both catatonic and paranoid subtypes, if neither subtype trumps another 
significantly. 
 
Patients’ predominant symptoms may change at different stage of the disease. 
Hence, patients’ subtype may also change over time. 
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1.3 Treatment and Prognosis of Schizophrenia 
 
In this section, we will introduce the current treatment options of schizophrenia, 




Treatment of schizophrenia patients needs to be comprehensive since this disorder 
affects many aspects of the patients, including thinking, feeling and behavior.  
Treatment plans should be customized to suit the individual patient’s clinical status, 
and stages (acute stage - a period of intense psychotic symptoms; stabilization 
stage - a period of suffering from psychotic symptoms but less severe than in the 
acute stage; stable stage - severe symptoms are controlled by medication). And 
goals will need to evolve over time. Treatment should be continuous since 
schizophrenia usually affects the patient’s whole life time (Herz MI, 2002). 
 
Currently the following treatment methods are used (Sadock BJ, 2003): 
• Hospitalization 
• Biological therapy, including dopamine receptor antagonist, serotonin-
dopamine antagonist (Resperidone, Clozapine, Olanzapine, Sertindole, 
Quetiapine, Ziprasidone), other drugs (Lithium, Anticonvulsants, 
Benzodiazepines), and other biological therapies (Electroconvulsive 
therapy (ECT)) 
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• Psychosocial therapy (social skill training, family oriented therapy, case 
management, assertive community treatment (ACT), group therapy, 
cognitive behavioral therapy, individual psychotherapy) 




(C. M. Harding, Brooks, Ashikaga, Strauss, & Breier, 1987) reported one-half to 
two-third of schizophrenia patients had achieved considerable improvement or 
recovery in a long term retrospective follow-up study of 118 patients. However, 
another study on 118 (coincidently) schizophrenia or schizoaffective (a mental 
disorder that has symptoms of schizophrenia and affective disorder - either major 
depression or bipolar disorder) patients by (Robinson, Woerner, McMeniman, 
Mendelowitz, & Bilder, 2004) reported a much lower recovery rate of 13.7% when 
stricter criteria of full recovery were used, i.e. sustained improvement in both 
symptoms and social and vocational functioning. 
 
(Lieberman, et al., 1996) and (Davidson & McGlashan, 1997) found that being 
female, being older at the first episode, having acute symptoms, having 
predominantly positive symptoms, and having good premorbid functioning are 
correlated to better prognosis. 
 
Although currently, there are many different treatment plans (hospitalization, 
biological, psychological and vocational), their outcomes are not effective enough. 
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Merely 13.7% patients have sustained improvement in symptoms and functions. 
That is because the direct cause of schizophrenia is still unknown. 
 
1.4 Motivations and Objectives 
 
The definite etiology of schizophrenia is still not clear though the disorder has 
been identified over 100 years. Studies suggest that genetics, early environment, 
neurobiology and psychological and social processes are important contributory 
factors.  
 
Many epidemiological studies have established a set of risk factors of 
schizophrenia. (R. Murray, Jones, Susser, Os, & Cannon, 2003) summarized 18 
factors and their odds ratios (odds ratio: ratio of a factor occurring in schizophrenia 
patients to non-schizophrenia people). All these factors are grouped into the 
following 4 categories: 
 















12. Maternal Depression 
• Obstetric 
13. Rh (rhesus) factor incompatibility 
14. Hypoxia 
15. Central Nervous System (CNS) damage 
16. Low birth weight 
17. Pre-eclampsia 
18. Family history 
 
Among them, family history has the greatest odds ratio of close to 10, followed by 
Central Nervous System(CNS) damage, prenatal bereavement, and rubella 
infection with odds ratios ranging from 5 to 7. All the rest factors have odd ratios 
from 1 to 4. 
 
Modern neuroscientific studies including molecular genetics, molecular 
neuropathology, neurophysiology, various brain imaging, and 
psychopharmacology have suggested that we are now approaching the molecular 
basis of the disorder. Schizophrenia can be identified as a neurodevelopmental and 
progressive disease, which is associated with multiple biochemical abnormalities 
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involving dopaminergic, serotonin, glutamate, and γ-aminobutyric acidergic 
system (Miyamoto, et al., 2003). 
 
(Andreasen, 2000) lists the hypotheses about the etiology of schizophrenia made 
by researchers as the following: 
• “Hypothesis 1. The etiologies are multiple. 
• Hypothesis 2. The pathophysiology is an abnormality in the regulation and 
expression of neurodevelopment. 
• Hypothesis 3. The pathology is a disease of neuroconnectivity. 
• Hypothesis 4. The phenotype is defined by a mental metaprocess rather 
than by clinical symptoms.” 
 
1.4.1 Problems with Existing Diagnostic Procedures 
 
From the above introduction, we notice that the current standard procedures for 
diagnosing schizophrenia (DSM-IV and ICD-10) have the following problems: 
  
Symptom-based: DSM-IV and ICD-10 diagnostic criteria are based on 
heterogeneous symptoms. Most symptoms are from patient’s self reporting, family 
member’s, colleague’s and clinician’s observations, which are subjective (A 
sample page for interviewing question regarding to the delusion symptoms from 
the Structured Clinical Interview for DSM Disorders (SCID) can be found in the 
web link from (SCID-I, 2007)). One common criticism of the diagnosis of 
schizophrenia is the lacking of scientific validity or reliability (Bentall, 1992; 
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Boyle, 2002). (Tsuang, Stone, & Faraone, 2000) argued that psychotic symptoms 
were not a good basis for schizophrenia diagnosis.  
 
Not quantifiable: DSM-IV and ICD-10 diagnostic criteria do not have 
quantification components. For example the severity (degree) of delusion or 
hallucination is difficult to quantify. 
 
Low/moderate diagnosis agreement: Studies show that the reliability of 
schizophrenia diagnosis is typically relatively low. (McGorry, et al., 1995) 
reported that agreement between any two psychiatrists was 66% to 76% when 
diagnosing schizophrenia. This converts to misdiagnosis rate of 23%-34%, 
assuming one psychiatrist is always correct. This misdiagnosis may have harmful 
clinical effect on patients. 
 
A moderate agreement between two psychiatrists is observed by a more recent 
study (Cheniaux, Landeira-Fernandez, & Versiani, 2009). 100 patients are 
diagnosed by two psychiatrists using DSM-IV and ICD-10 procedures separately. 
According to DSM-IV, 39 patients received schizophrenia diagnosis; among them 
only 13 patients (or 33% of 39 patients) received consensus from both psychiatrists. 
The inter-rater agreement measured by Cohen’s kappa statistic (0.59) shows a 
moderate agreement. Similarly, among 68 schizophrenia patients diagnosed 
according to ICD-10, only 24 patients (or 35% of 68 patients) received consensus 




On the other hand, the congruence between DSM-IV and ICD-10, measured by 
Cohen’s kappa statistic (0.61), is just slightly better. The number of schizophrenia 
diagnosis by DSM-IV criteria (39 patients, or 39% of total cases) is much lower 
than that by ICD-10 criteria (68 patients, or 68% of total cases) (Cheniaux, et al., 
2009). Among 39 patients detected by DSM-IV, 38 are also detected by ICD-10. In 
contrast, there are 30 patients (or 44% of 68 patients) receiving ICD-10 diagnosis, 
but not DSM-IV. 
 
The lower rate of diagnosis of schizophrenia according to DSM-IV (or DSM-III-R) 
than ICD-10 has also been reported in two other studies by (Hiller, Dichtl, Hecht, 
Hundt, & von Zerssen, 1994) and (Wciorka, et al., 1998).  The reason for that may 
lie in the more strict criteria in DSM-IV than in ICD-10. Six months of symptom 
duration is required by DSM-IV, whereas only one month is required by ICD-10. 
 
Neuroimaging is not included: The pathology of schizophrenia is believed to be a 
disease of neuroconnectivity. Although the modern neuroimaging techniques have 
been developed to quantify the brain grey and white matter abnormalities, they are 
still not routinely applied in diagnosis of schizophrenia. 
 
As we can see that, since the current two standard procedures of schizophrenia 
diagnosis (DSM-IV and ICD-10) are generally based on objective criteria, such as 




In fact, personal criteria are usually applied in the diagnosis of schizophrenia in 
addition to the standard DSM-IV/ICD-10 procedures. As (Edlund, 1986) and 
(Peralta & Cuesta, 2000) have pointed out, diagnosis made by psychiatrists were 
actually based on the their theoretical background, clinical experience, and 
preference for diagnostic criteria.  
 
For example, the initial diagnosis may be enforced or altered by medical records 
(including progress reports, physician orders, hospital admission and discharge 
summaries), following-up interviews, and/or by using some clinical scoring 
systems, such as the Positive And Negative Syndrome Scale (PANSS). This 




Accuracy of a diagnosis is defined as the ratio of total number of correctly 
diagnosed cases (patient and non-patient) to the total number of cases. 
 
Nr
CorAcc =         (1.1) 
 
where Cor is total number of correctly diagnosed cases, Nr is the total number of 
cases. 
 
We hypothesized that the accuracy of schizophrenia diagnosis can be improved by 
using objective and quantitative criteria from a wider spectrum of modalities 
including neuroinformatics and neuroimaging.  
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As we can see that schizophrenia is a complicated disease and its economic burden 
to the patients and society is enormous, we attempt to explore the disease from 
both neuroimaging and neuroinformatics directions in order to achieve a better 
understanding of the quantitative relationships between schizophrenia and 
intermediate phenotypes (as assessed by neurocognitive tests) and brain 
abnormalities (as assessed by neuroimaging). We will also try to develop a 
decision supporting system in order to provide classification results (derived from 
a person's neuroinformatics and neuroimaging data) as additional evidence to the 
current standard schizophrenia diagnostic procedures. Even though currently there 
is no efficient treatment, more accurate diagnosis would be useful in identification 
of patients and healthy persons, and might be also helpful in future potential drug 
development that targets at specific brain structures defects revealed by our 




There are a few assumptions underlying this research project. We discuss them 
briefly here. 
 
1) There are enough subjects, including schizophrenia patients and healthy controls. 
The study subjects’ demographic data should always be collected. Neurocognitive 




We estimate that our classification models will have about 5 to 20 (the typical 
range of clinical prediction models (Steyerberg, 2009)) factors. At the 
recommended minimum subject to factor ratio of 10 to 1 (Bartlett, et al., 2001), the 
number of subjects required will be at least 50 to 200. 
 
2) The ground truth (whether a subject is a schizophrenia patient or a healthy 
control) in the study dataset should be already diagnosed by domain experts 
(psychiatrists from Institute of Mental Health, Singapore) and is available to us. 
The ground truth diagnosis is achieved by not only DSM-IV criteria, but also on all 
medical records reviews (including progress reports, physician orders, hospital 
admission and discharge summaries), following-up interviews and some clinical 
scoring systems such as the Positive and negative Syndrome Scale (PANSS). 
 
1.4.4 Major Works 
 
Our major works consist of three parts:  
 
1) To apply an automatic Region of Interests (ROI) selection method based on 
a brain atlas for neuroimaging quantification and analysis in schizophrenia 
study. 
 
Patients will be scanned by using structural MRI and DTI imaging. When 
analyzing these medical images by Regions of Interests (ROI) methods, the 
placement of ROIs is usually done manually. For this study, we will apply a new 
method developed at Biomedical Imaging Lab, Agency of Science, Technology 
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and Research, Singapore using the Fast Talairach Transformation (FTT) method 
for electronic Talairach brain atlas registration to select ROIs and quantify the 
neuroimaging features automatically. 
 
2) To discover the relationships between schizophrenia and brain 
abnormalities and intermediate phenotypes using neuroimaging (Diffusion 
Tensor Imaging (DTI)) and neuroinformatics data.  
 
Schizophrenia is a complicated disease. Since schizophrenia was identified over 
100 years ago, many efforts have been put in order to understand its etiology. It is 
hypothesized that schizophrenia is related to pathological neuroconnectivity 
through neuronal circuits (Andreasen, 2000). After the pioneer work of using DTI 
to study schizophrenia by (Buchsbaum, et al., 1998), researchers have found that 
various brain structures are associated with schizophrenia pathology. DTI has 
shown promise as a method to examine the brain white matter abnormalities.  
 
 
Figure 1.1 Conceptual diagram of schizophrenia modeling and decision support system 
 
We will combine all factors from neuroinformatics data and neuroimaging data to 
build up schizophrenia models (Figure 1.1), which will help people to understand 
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this disease in a wider perspective. Multiple models of schizophrenia will be 
generated according to different combinations of data. 
 
(3) To develop a decision support system based on the image analysis results 
and the neuroinformatics data. 
 
Based on our schizophrenia models, we will develop a decision support system 
(Figure 1.1). It will choose the appropriate model automatically according to the 
availability of input information of new cases, and classify the cases as either 
patients or normal controls. It will assist clinicians by providing additional 
objective evidence in the schizophrenia diagnosis. Psychiatrists would be able to 
gain more confidence from using the objective diagnosis criteria in addition to the 
existing diagnosis process that rely on subjective criteria, provided that the 
decision support system and its underlying models have been validated in future 
large scale trials. 
 
1.4.5 Major Contributions 
 
The major contributions of this work will be: 
 
1) The first ever schizophrenia classification models based on objective and 
quantitative criteria including neurocognitive tests and neuroimaging. These 
models quantify the relationship between schizophrenia and the relative factors 
from neurocognitive results and neuroimaging features, which help us to achieve a 
better understanding of the disease. 
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2) A decision support system based on our schizophrenia models that can provide 
the classification results as more objective evidences to clinicians in addition to the 
current standard diagnostic procedures. It can also help clinicians to choose the 
suitable further tests in order to improve the diagnosis accuracy. Our solution tries 
to tackle the objective criteria problems of existing diagnosis procedures. We use 
quantitative and objective criteria, including neurocognitive tests and 
neuroimaging analysis results. We think our classification results will augment the 
current diagnostic procedures. 
 
3) Atlas-assisted analysis of DTI data. The structural MRI images of 156 study 
subjects are registered to the Talairach brain atlas. FA images are generated from 
the DTI images and co-registered with the structural MRI images. The automatic 
atlas-based ROI selection method is applied to quantify the FA image features 
within 48 brain anatomical structures. 
 
1.5 Organization of the Thesis 
 
In the rest of this thesis, we will first do a literature survey on neuroimaging 
analysis technologies and findings in schizophrenia, existing schizophrenia models 
and decision support systems in Chapter 2. 
 
In Chapter 3, we will describe the neuroinformatics data acquisition, data items 
from different categories, including demographic data, clinical data, clinical 
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scoring systems, and neurocognitive tests, data pre-processing, data feature 
distribution and analysis, and schizophrenia modeling using these data. 
 
In Chapter 4, we will introduce our novel neuroimaging analysis method for FA 
image quantification and results, and construct a schizophrenia model based on the 
image features. We will also interpret the clinical significance of the image 
features.  
 
Since we have both neuroinformatics data and neuroimaging data, in Chapter 5, we 
will use both data to create more comprehensive models of schizophrenia, and 
compare their results. Effects of individual neurocognitive test and neuroimaging 
in improving diagnosis accuracy will be also discussed here. 
 
In Chapter 6, we will employ various models constructed in the previous chapters 
to make two decision support flow charts for helping clinicians to choose the best 
further tests in different strategies. We will also develop a decision support system 
that will classify input case as either schizophrenia patient or normal control and 
provide suggestions to clinicians on what further tests should be done in different 
situations. 
 
Finally we will conclude our work and discuss about model accuracies, validations, 




Chapter 2  
Literature Review 
 
Since our work involves neuroimaging, schizophrenia modeling, and decision 
support, we review all these aspects in the following sections. 
 
2.1 Neuroimaging Analysis in Schizophrenia Study 
 
Various neuroimaging techniques and modalities have been used in schizophrenia 
study, from the very early pneumoencephalography, echoencephalography, to 
modern computer tomography (CT), magnetic resonance imaging (MRI), until the 
most recent diffusion tensor imaging (DTI). We will review all these methods and 
the related findings in the following sections. 
 
2.1.1 Early Neuroimaging Techniques 
 
In the early studies of schizophrenia to examine the anatomy of nervous system, 
neuropathology was the only tool. The in vivo method, pneumoencephalography 
(PEG) was introduced in 1919, and in 1970s non-invasive technologies, 
echoencephalography  and computer tomography (CT), were used to study the 
brain (Lawrie SM, 2004). 
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PEG is a technology used in brain imaging. It drains cerebrospinal fluid (CSF) in 
the brain to a very low level, then fills the space with air to make brain X-ray 
images clearer. This procedure is painful and dangerous to patients. An example of 
PEG applied in a study by (Jacobi & Winkler, 1927) showed a high prevalence of 
cortical and subcortical abnormality in schizophrenia.  
 
Echoencephalography is another early technology to scan the brain by using 
ultrasound. In a study at 1973, echoencephalography was used to examine 79 
chronic schizophrenia patients and 79 normal controls; (Holden, Forno, Itil, & Hsu, 
1973) found schizophrenia patients with ventricular widening were significantly 
less likely to respond to antipsychotic medication. 
 
The first CT schizophrenia study in schizophrenia was performed by (Johnstone, 
Crow, Frith, Husband, & Kreel, 1976), which demonstrated schizophrenia patients 
had an increased lateral ventricle area compared to the normal controls.  
 
2.1.2 Morphology Study Based on Structural MRI 
 
In 1984, the first study in schizophrenia using magnetic resonance imaging (MRI) 
was carried out by (Smith, et al., 1984).  The images produced by MRI are much 
clearer than those from CT. Since MRI doesn’t require ionizing radiation, repeated 
scanning can be performed with less risk to the patients. Therefore MRI 
superseded CT in a few years time. 
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Since then, structural MRI (sMRI) has been applied to schizophrenia study for 
over 20 years. Much more knowledge about schizophrenia has been discovered, 
and over 100 studies have been conducted to compare schizophrenia patients with 
controls (Lawrie SM, 2004). The whole brain and various related brain structures 
have been studied, including: ventricles, cerebrospinal fluid (CSF), prefrontal 
cortex, temporal lobes, amygdala, hippocampus, parahippocampus, thalamus, basal 
gangalia, nucleus accumbens, and insula. Table 2.1 summarizes some findings 
using structural MRI (sMRI). 
 
Table 2.1 Summary of structural magnetic resonance imaging findings in schizophrenia  
A combined result of (Wright, et al., 2000) and (Shenton, Dickey, Frumin, & McCarley, 2001). 
From (McIntosh & Lawrie, 2004) 
Regions No. of Cases Findings 
Whole brain volume 50+ Reduced by 2-3%; Grey matter reduced by 4%; White matter no 
difference. 
Frontal lobes 50+ Reduced by 3% 
Temporal lobes 100+ Reduced by 5-6% 
Hippocampus 10+ Reduced by 4% 
Parahippocapus 10+ Reduced by 10% 
Amygdala 10+ Reduced by 4% 
Basal gangalia 20+ Globus pallidus increased by 20% 
Thalamus 10+ Significant difference (no quantitative results) 
Lateral ventricles 20+ Increased by 20% 
Third ventricle 30+ Increased by 26% 
 
From those studies, we see some hints on the neuroanatomical profiles of 
schizophrenia. But the numbers and types of cases studied are not large enough to 
be more convincing.  
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The most replicable brain morphometric phenomenon from MR imaging are 
enlarged ventricles and reduced cerebral volume, but the changes are relatively 
subtle. Although white matter may also be affected by schizophrenia, the white 
mater abnormalities are not reported since ordinary MRI images are not good at 
detecting white matter connectivity. 
 
2.1.3 White Matter Study Based on Diffusion Tensor Imaging 
 
Fortunately with the introduction of Diffusion Tensor Imaging (DTI), this situation 
has been changed. By using DTI, researchers can study neural fibers, spinal cord 
white matter and brain white matter. DTI is based on the principle that water 
diffusion is highly anisotropic in the nervous tissue. Since water molecules diffuse 
preferentially along axons rather than across them, by the diffusion tensor 
anisotropy, we can get detailed information on neural fiber direction and other 
architectural features of brain tissue.  
 
The apparent diffusion tensor describes the molecule mobility along each direction 

















D       (2.1) 
 
where Dxx, Dyy and Dzz are the diffusion fluxes along x, y, z directions; Dxy, Dxz,Dyx, 
Dyz , Dzx and Dzy are correlations between diffusion fluxes in orthogonal directions. 
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The tensor is symmetric, i.e., Dxy=Dyx, Dxz=Dzx and Dyz=Dzy for uncharged moiety, 
water molecular. 
 
The diffusion coefficients along three principal directions are represented by the 
eigenvalues of the tensor, λ1, λ2, and λ3. 
  
Mean diffusivity (MD) is a measurement of the overall evaluation of the diffusion, 
which is defined as the arithmetic average of the eigenvalues of the tensor.  
 
3
321 λλλ ++=MD         (2.2) 
where λ1, λ2, λ3 are the eigenvalues of the diffusion tensor. 
 
Another scalar index is fractional anisotropy (FA) (Pierpaoli & Basser, 1996), 
which provides a quantitative rotationally invariant assessment of diffusion 



















−+−+−=FA      (2.3) 
 
(Buchsbaum, et al., 1998) reported significantly reduced diffusion anisotropy in 
prefrontal cortex, internal capsule and temporal lobe in a study of five chronic 
schizophrenia patients and six normal controls. Since then many researches have 
been done to study the white matter abnormalities in schizophrenia using DTI. 
Table 2.2 shows a summary of these studies. 
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Table 2.2 Summary of schizophrenia studies using DTI 
Study Subjects  
(Patient/Control) 
Findings 
(Buchsbaum, et al., 
1998) 
5/6 Reduced FA in frontotemporal peri-putamen 
(Lim, et al., 1999) 10/10 Reduced FA in whole brain white matter 
(Foong, et al., 2000) 20/20 Reduced FA in splenium of CC 
(Agartz, Andersson, & 
Skare, 2001) 
20/24 Reduced FA in splenium of CC 
(Steel, et al., 2001) 10/10 No significant differences in prefrontal and occipital regions 
(Foong, et al., 2002) 14/19 No significant differences  
(Kubicki, et al., 2002) 15/18 Loss of asymmetry in uncinate fasciculus 
(Hoptman, et al., 2002) 14/0 No control group; Right inferior frontal white matter FA was 
correlated with higher motor impulsiveness 
(Wang, et al., 2003) 29/20 No significant difference in middle and superior cerebellar 
peduncles 
(Z. Sun, et al., 2003) 30/19 Reduced FA in anterior cingulum 
(Ardekani, Nierenberg, 
Hoptman, Javitt, & Lim, 
2003) 
14/14 Reduced FA in bilateral CC, AC, MTG, parahippocampal 
gyri (PHG), left STG 
(Burns, et al., 2003) 30/30 Reduced FA in left arcuate fasciculus 
(Wolkin, et al., 2003) 10/0 No control group; Inferior frontal FA was correlated with 
negative symptoms 
(Minami, et al., 2003) 12/11 Reduced FA in frontal, parietal, temporal, occipital regions 
(Kubicki, et al., 2003) 17/18 Reduced FA in cingulum 
(Begre, et al., 2003) 7/7 No significant differences in hippocampus 
(Wang, et al., 2004) 21/20 Reduced FA in anterior cingulum 
(Okugawa, et al., 2004) 25/21 Reduced FA in middle cerebellar peduncles 
(Kalus, et al., 2004) 15/15 Reduced FA in bilateral posterior hippocampus, left total 
hippocampus 
(Kumra, et al., 2004) 12/9 Reduced FA in bilateral frontal WM, and right occipital WM 
on AC-PC plane 
(Park, et al., 2004) 23/32 Significant differences in anisotropic asymmetry pattern in 
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Study Subjects  
(Patient/Control) 
Findings 
left and right hemisphere 
(Hubl, et al., 2004) 26/13 Reduced FA in left and right temporoparietal section of the 
arcuate fasciculus; uncinate fasciculus, corpus callosum, 
inferior longitudinal fasciculus 
(Price, Bagary, 
Cercignani, Altmann, & 
Ron, 2005) 
20/29 No significant differences in splenium and genu of CC 
(Szeszko, et al., 2005) 10/13 Reduced FA in left internal capsule, left middle frontal 
gyrus, posterior superior temporal gyrus 
(Kumra, et al., 2005) 26/34 Reduced FA in the left anterior cingulate region in close 
proximity to caudate nucleus 
(Okugawa, Nobuhara, 
Sugimoto, & Kinoshita, 
2005) 
25/21 Reduced FA in middle cerebellar peduncle 
(Jones, et al., 2006) 14/14 Young schizophrenia patients have reduced FA in left 
superior longitudinal fasciculus than controls; old patients, 
the difference is less 
(Buchsbaum, et al., 
2006) 
64/55 Reduced FA in frontal white matter, CC, and frontal 
longitudinal fasciculus 
(Shergill, et al., 2007) 33/40 Reduced FA in superior longitudinal fasciculi, and genu of 
CC 
(Schlosser, et al., 2007) 18/18 Reduced FA in right medial temporal lobe adjacent to the 
right parahippocampal gyrus 
(Cheung, et al., 2008) 25/25 Reduced FA in left fronto-occipital fasciculus, left inferior 
longitudinal fasciculus 
(Kyriakopoulos, Vyas, 
Barker, Chitnis, & 
Frangou, 2008) 
19/20 Reduced FA in the white matter of the parietal association 
cortex bilaterally and in the left middle cerebellar penduncle 
(Hoptman, et al., 2008) 23/37 Reduced FA in left superior and middle temporal gyri, left 
ILF, left cingulate gyri, and left inferior frontal gyrus and 
right perilentiform regions. Increased FA in left lingual and 
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Study Subjects  
(Patient/Control) 
Findings 
insular gyri, and right deep frontal white matter 
(Rametti, et al., 2009) 25/24 Reduced FA in left sub-gyral WM of  temporal lobe, 
involving posterior part of the fornix 
(Rotarska-Jagiela, et al., 
2009) 
24/24 Reduced FA in the prefrontal regions, external capsule, 
pyramidal tract, occipitofrontal fasciculus, superior and 
inferior longitudinal fasciculi, and corpus callosum. 
Increased FA in arcuate fasciculus  
(Moriya, et al., 2009) 19/19 No significant difference in FA 
(Sussmann, et al., 2009) 28/38 Reduced FA in the anterior limb of the internal capsule, 
anterior thalamic radiation, uncinate fasciculus 
Abbreviations: see Appendix B 
 
It can be seen that studies using DTI have produced various findings at many 
different brain structures, but haven’t drawn consistent conclusions yet. For 
example, (Foong, et al., 2000) and (Agartz, et al., 2001) reported the reduced FA in 
CC splenium, but (Price, et al., 2005) reported no significant changes in the same 
region. The limitations may have resulted from small sample size, inhomogeneous 
sample characteristics, insufficient image quality, and image processing techniques. 
 
In this section, we reviewed various imaging technologies in schizophrenia, 
especially the most recent DTI imaging which helps to determine the neural fiber 
abnormalities. We found that DTI is a promising technology; however current 
findings are not consistent. 
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2.2 Schizophrenia Models 
 
The schizophrenia etiology and development are very complicated. Only few 
research works have attempted to build up some schizophrenia models. 
 
(Andreasen, 1999) describes a general model defining the development of 
schizophrenia. This model has an hour glass shape, which illustrates a many to 
many relationship between etiologic factors and phenomenology: multiple etiology 
(such as DNA, gene expression, virus, toxins, nutrition,birth injury and 
psychological experiences) fan in at the input level and multiple  impairments in 
fundamental and second order cognitive processes including attention, memory 
language, executive functions, emotion and symptoms (such as hallucination, 
delusions, negative symptoms, disorganized speech and behavior) fan out at the 
output level. Between the input etiology and output phenomenology, there is a 
single lathomenologic process of anatomical and functional disruption in neuronal 
connectivity and communication that unifies the sickness. However this is a 
conceptual model only. It doesn’t describe any quantitative relationships between 
etiology factors and symptoms. Hence it is not meant to be applied clinically. 
 
(Hoffman & McGlashan, 2001) establishes neural network models to explore 
functional consequences of reduced corticocortical connectivity. The models 
simulate the auditory hallucinations of speech.  
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2.3 Decision Support System in Schizophrenia 
 
In this section, we will briefly introduce some major types of decision support 
systems in schizophrenia from current literature. Typically, they include decision 
support in treatment planning and diagnosis.  
 
2.3.1 Decision Support in Treatment Planning 
 
Many works have been done on the schizophrenia decision support system, 
especially on the treatment planning evaluation.  
 
For example, (Palmer, Brunner, Ruiz-Flores, Paez-Agraz, & Revicki, 2002) set up 
a decision tree model to evaluate different schizophrenia treatment plans by using 
3 different medications (Haloperidol, Olanzapine and Risperidone) for a 5 year 
period. They discovered that Olanzapine therapy resulted in more symptom 
improvement, fewer relapses and was more cost-effective. 
 
(Hansen, Lancon, & Toumi, 2006) pointed out that pharmacoeconomic evaluations 
were important in the decision making process. Five different decision tree models 
are developed to compare any two different strategies (A and B): relapse model 
(by comparing the incremental cost and the cost effectiveness of two strategies), 
compliance model (taking into consideration of patient's compliance with the 
treatment plans) , institution model (by including another factor reflecting the fact 
that some schizophrenia patients are not able to live with their families, and require 
 32
institutionalization), drop-out model (by adding one more factor for patients who 
drop out of treatment) and switch model (for patients who change treatment plans 
at halfway). Different models can be used at different conditions to evaluate the 
treatment plans based on their cost effectiveness and clinical outcome.  
 
2.3.2 Decision Support in Diagnosis 
 
Some other works focus on the diagnosis. (Razzouk, Mari, Shirakawa, Wainer, & 
Sigulem, 2006) developed a decision support system for diagnosis of 
schizophrenia spectrum disorders (a group psychiatric diagnoses similar to 
schizophrenia, such as schizoaffective disorder).  The decision support system 
consists of four stages: knowledge acquisition, knowledge organization, computer 
assisted model construction (based on the parsimonious cover approach (Mitchell, 
1997), which defines possible diagnosis as all diseases that can explain a patient's 
existing symptoms), and system performance evaluation. The decision criteria of 
this system are symptom based. It aims to differentiate schizophrenia from 
schizophreniform disease (a disease which is close related to schizophrenia, but the 
required length of symptoms presence is less than 6 months as in the case of 
schizophrenia, and some of the functional impairments of schizophrenia may not 
present). The system achieved an accuracy rate at 66-82% on 38 clinical cases.  
 
(Yana, et al., 1994; Yana, et al., 1997) also proposed a classifier for the diagnosis 
of psychiatric disease including schizophrenia. From the 136 simple yes/no 
questions set by domain experts in Tokyo Medical and Dental University Hospital, 
80 questions are selected to build a Pseudo Bayesian Network classifier and a 
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Neural Network classifier. Among the 80 selected questions, the first 32 are 
subjective symptoms, and the rest are items supposed to be important for 
prediction. Table 2.3 shows the first 20 questions. 100 cases are used for the 
classifier model construction. By using the 10-fold cross-validation method, the 
correct schizophrenia diagnosis rates are measured at 73.3% and 77.3% for the 
Pseudo Bayesian Network classifier and the Neural Network classifier, 
respectively.  
 
Table 2.3 Question items (partial) 
No. Question No. Question 
1 Headache 11 Became dull (decrease in brain power) 
2 Nausea 12 Incorrect behavior 
3 Cannot see clearly 13 Personality changes 
4 Shaking 14 Irritated 
5 Difficult in speech 15 Anxiety 
6 Numbness 16 Difficult in thinking 
7 Difficult to control arms / legs 17 Difficult in sleep 
8 Convulsion 18 Diminished appetite 
9 Lost consciousness 19 Lack of sexual desire 
10 Amnesia 20 Lack of motivation 
 
In this section, we introduced two decision support systems in pharmacoeconomic 
evaluation, and two in schizophrenia diagnosis. Among the two diagnosis systems, 
one tries to differentiate schizophrenia spectrum disorders, and the other diagnoses 
schizophrenia, mood disorder (disease where the patient's mood disturbance is the 
main feature) and neurosis (disorder involving distress but no delusions and 
hallucinations). However, the two diagnosis systems were still based on subjective 
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symptoms and questions, and no lab test results (such as neuroimaging) were used 
in the decision support. 
 
2.4 Machine Learning Technology 
 
Machine learning techniques need to be applied in order to extract knowledge from 
the neuroimaging and neuroinformatics data and set up the schizophrenia model 
and decision supporting systems. Decision Trees (Raiffa, 1968), Bayesian 
Networks (also known as Belief Networks) (Pearl, 1988) (Jensen, 2001), and 
Neural Networks (Bishop, 1996) are some common modeling representation forms. 
 
Based on the Iterative Dichotomiser 3 (ID3) algorithm, (Quinlan, 1993) developed 
the C4.5 algorithm to generate a decision tree from a set of training data using the 
concept of information entropy (Shannon, 1948). The training data is a set of 
classified samples. Each sample contains multiple features and a class to which 
that sample belongs. At each node of the tree, C4.5 algorithm chooses a feature 
with the causes the highest information gain, and splits the training samples into 
subsets. It will apply the same rule recursively on each subset until each node 
contains only one class. 
 
Learning a Bayesian Network involves the parameter learning and structure 
learning. (Neapolitan, 2004) introduced some basic concepts and methods in 
constructing the Bayesian Network, including learning with missing data items 
(incomplete datasets). Parameters (probability distribution) can be estimated by 
using the likelihood function. However, there is no efficient algorithm for structure 
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learning when the networks become complex since finding optimal structure is 
NP-hard when multiple parent nodes are allowed. Hence researchers developed 
many different heuristic techniques such as Greedy hill-climbing (Chickering, 
2002) and K2 search (Cooper & Herskovitz, 1992). 
 
There are many ways of training neural networks. Most of them are based on some 
form of gradient descent, which takes the derivative of the cost function with 
respect to the network parameters and then changes those parameters in a gradient-
related direction (Haykin, 1998). 
 
In this chapter, we briefly reviewed the current status of schizophrenia modeling 
and decision support systems. In the following two chapters, we will introduce our 
work on neuroinformatics data and neuroimaging data analysis and schizophrenia 




Chapter 3  
Neuroinformatics-Based Analysis and Modeling  
 
This chapter will cover the neuroinformatics data acquisition (what sorts of data 
are collected, and their characteristics), pre-processing (missing value processing, 
exclusion of irrelevant data, data error correction), analysis (feature selection), and 
model construction. 
 
3.1 Study Subjects 
 
Schizophrenia patients and healthy controls are recruited from Institute of Mental 
Health / Woodbridge Hospital, Singapore, the national psychiatric hospital and 
main treatment center. This project is supported by the National Healthcare Group 
Research Grant (NHG-SIG/05004) and Singapore Biomedical Imaging 
Consortium (Agency for Science, Technology and Research) Research Grant 
(SBIC RP C-009/2006). 
 
We collect 156 study subjects, including 92 schizophrenia patients and 64 normal, 
healthy controls for this study. 
 
The selection criteria for the patients are: diagnosis of schizophrenia (based on 
clinical history, medical record review, interview with the significant others when 
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necessary as well as the Structured Clinical Interview for DSM IV), age between 
21-65 years old, and English speaking. The patients with the following criteria will 
be excluded: history of significant head injury, neurological diseases such as 
epilepsy, cerebrovascular accident, impaired thyroid function, steroid use, DSM-IV 
alcohol or substance use or dependence, and contraindications to MRI. 
 
The selection criteria for the normal controls are: having no history of any 
neurological or psychiatric disorders. Controls should match patients on age, 
gender, years of education and handedness. 
 
All patients and controls are screened for co-morbid medical and psychiatric 
conditions by clinical assessment and physical and neurological examination (K 
Sim, 2005). 
 
3.2 Demographic Data 
 
Demographic data are collected for patients and controls. A brief summary of the 
characteristics of study subjects can be found in Table 3.1. Pearson Chi-Square is 
used to test the independency of two categorical factors such as sex, handedness, 
and ethnicity, while Independent Sample T Test (2-tailed) is used to compare the 
mean score of two continuous factors, such as age, years of duration (yrsedu), 
weight and height. 
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The age range of patients is from 18 to 56 years old, whereas the age range of 
healthy controls is 21 to 58 years old. The mean ages of patients and controls are 
34 and 32 years old, respectively, their difference is not statistically significant.  
 
Table 3.1  Characteristics of study subjects (N=156) 





Age, years 34.28 (SD 9.20) 32.33 (SD 10.20) 0.214 (NS)* 






























Education level, years 11.40 (SD 2.49) 13.97 (SD 2.10) < 0.001 (SIG)* 
Father’s education level, years 7.21 (SD 3.63) 8.33 (SD 3.91) 0.068 (NS)* 
Mother’s education level, 
years 
6.43 (SD 3.80) 7.88 (SD 4.16) 0.027 (SIG)* 
Weight, kg 64.30 (SD 14.10) 64.84 (SD 11.12) 0.80 (NS)* 
Height, m 1.68 (SD 0.07) 1.67 (SD 0.08) 0.60 (NS)* 
Age of first onset, years 25.37 (SD 6.92) - - 
Duration of illness, years 8.69 (SD 8.41) - - 
Note: ^ Pearson Chi-Square; * Independent Sample T Test; Abbreviations: SD, Standard 
Deviation; F, Female; M, Male; SIG, Significant (P<0.05); NS, Not Significant 
 
The percentage of sex of patients is 19.6%/80.4% (female/male). The handedness 
distribution (Left/Right/Ambidextrous) of our patients and controls are similar: 
10.9%/88.0%/1.1% for patients, and 10.9%/89.1%/0% for controls. 
 39
 
Note that the mean education level of patients (11.40 years) is significantly less 
than that of healthy controls (13.97 years) by 2.57 years. This can be considered as 
the consequence of schizophrenia – the patients’ intelligence quotient (IQ) and 
capability of education are affected by the disease. 
 
For patients, the mean age of first onset is 25.37 years (SD 6.92), and the average 
duration of illness is 8.69 years (SD 8.41). The mean weight and height of patients 
and controls have no significant difference in our study. 
 
 
Figure 3.1 Demographic data distribution (N=156) (partial) 
(Blue: Patient; Red: Control. 1: pt_ctrl (patient/control), 2: handedness 
(right/left/ambidextrous), 3: sex (male/female), 4: ethnic (Chinese/Indian/Malay/Others), 5: 
age (years), 6: marital status (single/married/divorced/widowed), 7: years of education, 8: 
height (in m), 9: weight (in kg). Descriptions for the data items, see Appendix A) 
 
Figure 3.1 illustrates the distribution of major demographic data (age, sex, ethnics, 
handedness, years of education, weight, height, and marital status) for our samples 
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subjects (64 controls and 92 patients). Ethnic distribution looks severely skewed, 
but it is not far away from that of Singapore population in recent years 
(Chinese/Malay/Indian/Others: 74.2%/13.4%/9.2%/3.2%) (Singapore, 2009). 
 
In this section, we describe the demographic data of the subjects collected. We also 
compare some of them (such as age, sex, handedness, weight, and height) between 
the patient and control group. We find that these two groups are basically matched 
in terms of major demographic characteristics. However since our study is 
conducted in Singapore, our sample contains mainly Singaporean Chinese due to 
the limitations in population distribution of the country. 
 
3.3 Other Clinical Data 
 
In addition to the demographic data, other clinical data are also collected, which 
include clinical information (such as date of admission to ward (patient only), 
medical problems, surgical problems, drug use, alcohol use, family history of 
psychiatric disease), medication information of patients, clinical scores (such as 
Positive and Negative Syndrome Scale (PANSS) (S. Kay, Opler, & Fiszbein, 
1986.), and World Health Organization Quality of Life Bref-Scale (WHOQOL-
BREF) (WHOQOL, 1998). A detailed list of all clinical data features can be found 
in Table 3.2. 
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Table 3.2 List of clinical data features 
Feature Feature 
Diagnosis: patient or control Medication 
 Antipsychotics 1 (Type/ Dose) 
Demographic CPZ Equivalents 1 
Sex Typical/ Atypical/ Depot Antipsychotic 
Age Antipsychotics 2 (Type/ Dose) 
Weight CPZ Equivalents 2 
Height Typical/ Atypical/ Depot Antipsychotic 
Handedness Antipsychotics 3 (Type/ Dose) 
Ethnicity CPZ Equivalents 3 
Father's Ethnicity Typical/ Atypical/ Depot Antipsychotic 
Mother's Ethnicity Anticholinergics (Type/ Dose) 
Paternal Grandfather's Ethnicity Antidepressants (Type/ Dose) 
Paternal Grandmother's Ethnicity Mood Stabilizers (Type/ Dose) 
Maternal Grandfather's Ethnicity Benzodiazepines (Type/ Dose) 
Maternal Grandmother's Ethnicity Other Medications 1 (Type/ Dose) 
Marital Status Other Medications 2 (Type/ Dose) 
Educational Level  
Years of Education Clinical Scores 
Educational Level of Mother 
Scale for the Assessment of Passivity Phenomena 
(SAPP) 
Educational Level of Father 1a - Time Frame 
Occupation 1- Made Emotions 
Father's Occupation 2 - Made Movements 
Mother's Occupation 3 - Made Impulses / Decisions to Act 
Living Arrangements 4 - Somatic Passivity 
Living Arrangements (specify) Total Score 
Brought By Positive and Negative Syndrome Scale (PANSS) 
Brought By (specify) PANSS Positive (1-7) 
 PANSS Negative (1-7) 
Clinical PANSS General Psycopathology Scale (1-16) 
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Feature Feature 
Date of Admission to Ward Global Assessment of Functioning Scale (GAF) 
Diagnosis Axis 1 (DSM IV) Total 
Medical Problems (past or current) Symptoms 
Medical Problems (specify) Disability 
Surgical Problems (past or current) 
Scale to Assess Unawareness of Mental Disorders 
(SUMD) 
Surgical Problems (specify) 1 - Awareness of Mental Disorder 
Alcohol Use (past or current) 2 - Awareness of Consequences of Mental Disorder 
Drug Use (past or current) 3 - Awareness of Effects of Medication 
Duration of Psychiatric Illness (years) 4 - Awareness of Hallucinatory Experiences 
Age of First Onset of Illness 5 - Awareness of Delusions 
Duration of Untreated Psychosis (in years) 6 - Awareness of Thought Disorder 
Number of Hospitalizations 7 - Awareness of Flat or Blunt Affect 
Number of Hospitalizations in Last 12 Months 8 - Awareness of Anhedonia 
Regularity of Outpatient Attendance in Last 12 
Months 9 - Awareness of Asociality 
Family History of Mental Illness WHO Quality of Life (WHO QOL-BREF) 
Family History of Mental Illness (specify) WHO QOL-BREF 1-26 
 
The Scale for the Assessment of Passivity Phenomena (SAPP) identifies passivity 
phenomena of patients on the basis of their total scores equal or greater than 4 on 
four items (Spence, et al., 1997). 
 
The Positive and Negative Syndrome Scale (PANSS) is a medical scale to measure 
severity of positive and negative symptoms for schizophrenia patients. It was 
originally published in 1987 (S. R. Kay, Fiszbein, & Opler, 1987). It is widely 
used in the study of antipsychotic therapy. It consists of 30 items, which are 
grouped into 3 sub-categories: 7 were chosen to assess positive symptoms, 7 for 
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negative symptoms, and the remaining 16 for general psychopathology scale. The 
PANSS interview usually requires about 45 to 50 minutes to administer.  
 
The Global Assessment of Functioning (GAF) is a 100-point scale used by mental 
health clinicians and physicians to subjectively evaluate the social, psychological 
and occupational functioning of a patient. It reports the clinician's judgment of the 
patient's overall level of functioning and carrying out daily activities. The scale is 
described in the DSM-IV-TR (American Psychiatric Association: Diagnostic and 
Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision), 
2000).  
 
The Scale to Assess Unawareness of Mental Disorder (SUMD) (Amador, et al., 
1993)  is an assessment that measures the patient’s discrete and global aspects of 
insight awareness of the his/her illness, including the awareness of 9 aspects: 
mental disorder, consequences of mental disorder, effects of medication, 
hallucinatory experiences, delusions, thought disorder, flat or blunt affect, 
anhedonia (lack of pleasure), and asociality. 
 
The World Health Organization Quality of Life Bref-Scale (WHOQOL-BREF) is 
developed as an assessment instrument for the international cross-culturally 
comparable quality of life. It consists of 26 questions, which assess the 
participant's perceptions in the following four major aspects: physical health, 
psychological health, social relationships, and environment.(WHOQOL, 1998). 
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In this section, we introduced other clinical information collected, especially 
various clinical scoring systems. Next we will come to the neurocognitive tests 
performed for this study. 
 
3.4 Neurocognitive Tests 
 
Schizophrenia is a neurodevelopmental and progressive disease. We aim to build 
up schizophrenia models to reveal the relationship of the disease with the 
underlying neaurocognitive defects that can be assessed by various neurocognitive 
tests.  
 
Patients and controls are administered some neurocognitive tests by psychometrists 
trained in standardized assessment and scoring procedures.  
 
Table 3.3 lists the neurocognitive tests performed and the scores collected. They 
include Raven's Progressive Matrices (RPM) (Lezak, 1995), Wisconsin Card 
Sorting Test (WCST) (Heaton, Chelune, Talley, Kay, & Curtiss, 1993), 
Continuous Performance Task (or Continuous Performance Test) II (CPT II) 
(Conners, 2000),  and Wechsler Adult Intelligence Scale III (WAIS-III) (D 
Wechsler, 1997). 
 
The complete set of tests (4 of them) takes about 1.5–2 hours. These tests can be 
done in separate sessions. They assess the patients/controls’ various neurocognitive 
functions (expressed as intermediate phenotypes) including: intelligence, attention, 
executive functioning, working memory, and visuo-spatial skills.  
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Table 3.3 List of neurocognitive tests and features 
Test Feature Test Feature 
Raven's Progressive Matrices (RPM) Continuous Performance Task, II (CPT-II) 
RPM Raw (Raven's raw score) Number of Omissions t score 
 Number of Commissions t score 
Wechsler Adult Intelligence Scale, III (WAIS-III) Hit Reaction Time t score 
Block design raw score  
Digit span forward score Wisconsin Card Sorting Test (WCST) 
Digit span backward score Trials administered 
Digit span total score Total correct 
Spatial span forward raw score Total errors raw scores 
Spatial span backward raw score Perseverative Responses raw scores 
Spatial span total score Perseverative Errors raw scores 
 Nonperseverative Errors raw scores 
 Categories completed raw scores 
 Trials to complete 1st category raw scores 
 
 
Figure 3.2 A sample RPM matrix 
From (Wikipedia, 2011a) 
 
Specifically RPM measures abstract reasoning and intelligence. It was originally 
developed by Dr John C. Raven in 1936 (Raven, 1936).  In each test item, a 
candidate is required to identify the missing pattern of a series (see example in 
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Figure 3.2).  It tests two important components of intelligence: eductive ability and 
reproductive ability. 
 
The Wechsler Adult Intelligence Scale (WAIS) is used to test the intelligence of 
adult and adolescent (David Wechsler, 1939). The version we used in this study, 
WAIS-III, was published in 1997, while the latest version, WAIS-IV was 
published in 2008. The main difference between WAIS-III and WAIS-IV is that 
the later includes 5 more supplementary subtests, and the General Ability Index. 
As a successor and an enhanced version of WAIS-III, WAIS-IV still needs some 
time to be widely adopted and implemented by all hospitals. None the less, the 
subtests used in our study, as described in the next paragraph, remain unchanged in 
WAIS-III and WAIS-IV. 
 
Specifically, in the Block Design subtest of the WAIS-III, the patient/control is 
required to take blocks with all white sides, all red sides, and red and white sides 
and arrange them according to a pattern. This test assesses the visuospatial and 
motor skills, which are linked to the functioning of the parietal and frontal lobes. 
Digit Span subset of the WAIS-III, assesses verbal working memory (or short term 
memory). It is the longest list of digits that a person can repeat back in correct 
order after they are announced. Backward digit span is a more difficult subtest 
which requests a person to recall digits in reverse order. Spatial Span subtest of the 
WAIS-III, on the other hand, assesses spatial working memory.  
 
Continuous Performance Task (or Test) (CPT) measures a person's sustained and 
selective attention and impulsivity or vigilance. A person is required to click a 
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button when he sees the pre-set target (for instance, letter “A”) appearing on the 
computer screen. He must not click the button if he sees any other letters. In CPT 
scores, Omission Errors indicates the number of times the patient failed to respond. 
Commission Errors indicates the number of times the patient responded to false 
target. Reaction time measures the amount of time between the presentation of the 
target and the client's response. 
 
Wisconsin Card Sorting Test (WCST) measures the ability to form abstract 
concepts, shift and maintain set, and utilize feedback. Without being told on how 
to match cards, the participant is required to find the rule and match the stimulus 
cards presented in front of him (see example in Figure 3.3). The rule may change 
after some trials. It generates a number of psychometric scores, including numbers, 
percentages, and percentiles of: categories achieved, trials, errors, and 
perseverative errors. It has been considered as a measure of executive function 
because of its reported sensitivity to frontal lobe dysfunction. 
 
 
Figure 3.3 A sample WCST test 
From (Wikipedia, 2011b) 
 
The time needed to perform each neurocognitive tests varies from 15 minutes to 1 
hour depending on the test setting and participant’s reaction time. In Singapore, the 
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costs for the neurocognitive tests are charged at two different rates, depending on 
whether the participants are considered as private patients or government 
subsidized patients.  However, in this research project, as the neurocognitive tests 
are performed by the research assistants of Institute of Mental Health, clinical 
charges do not apply. In addition, some tests are not performed routinely even at 
the hospital clinics. We try to estimate the costs, by using information of similar 
tests from other hospitals, and the time required to complete them. Table 3.4 
summarizes the major function tested for each neurocognitive test, as well as the 
time required to complete them and the costs at both government subsidized rate 
and private rate.  
 
Table 3.4 Neurocognitive tests  
Cost Test Function Tested Time Needed 
Subsidized Rate Private Rate 
RPM Eductive, 
reproductive 
30 min – 1 hour $130* $400* 
WAIS-III Visual spatial, 
motor, memory 
15 min – 30 min $65 $240 
CPT-II Attention, 
impulsivity 
15 min – 30 min $65^ $200^ 
WCST Executive 15 min - 20 min $65^ $200^ 
Note: *Estimated Cost; ^Estimated by dividing the total cost of CPT-II and WCST ($130 for subsidized, $400 
for private) equally. 
 
In this section, we introduced the four neurocognitive tests performed on the study 
subjects. We briefly described the functionalities, scores collected, and time and 
costs involved for each of them. In the next section, we will describe our method 
used in data pre-processing. 
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3.5 Data Preprocessing 
 
We collect many data items for each study subject, and put them into a large table 
(156 rows by 211 columns), with each row representing a subject (patient or 
control), and each column representing a data item. Unfortunately, not all data 
items are available for each subject. Some columns are missing, for example, 
PANSS scores are only for patients; hence they are not collected for all healthy 
controls. Before we start to analyze the data, irrelevant items need to be filtered out, 
and errors need to be corrected. 
 
Data Feature Extraction 
 
We study the nature of each column of the dataset, and exclude data items that are 
not useful or suitable for the later analysis in schizophrenia modeling. Since the 
purpose of this study is to build schizophrenia models using objective criteria only. 
No matter whether subjective factors are relevant or not, they are excluded at the 
step of feature extraction. Specifically, the following items are removed: (Data 
item names and their descriptions can be found in Appendix A) 
• ‘study-id’ is removed, since it serves as a key of each subject, and we 
already have CDNo (Compact Disk No) for this purpose. 
• All columns of medication information are removed, since they are relevant 
to patients, but not controls, and our aim is to compare patients with 
controls. 
• ‘Date admin’ (date of admission to hospital) is removed since only patients 
have this value but not controls. 
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• ‘live-spec’ (living arrangement, specify) is removed, because it is the 
specific detailed text information on living arrangement, and it only has 
values when ‘livingar’ (living arrangement) is 8 (other). 
• ‘brought-sp’ (brought by, specify) is removed for the similar reasons as 
‘live-spec’ (only has values when ‘brought’ is 9 (other)). 
• Similarly, ‘med-spec’ (medical problems, specify) is removed. It only has 
value when ‘med-prob’ (medical problems) is 1 (yes). 
• Similarly, ‘sur-spec’ (surgical problems, specify) is removed. It only has 
value when ‘sur-prob’ (surgical problems) is 1 (yes). 
• Similarly, ‘fam-hxsp’ (family history of mental illness, specify) is removed. 
It only has value when ‘fam-hx’ (family history of mental illness) is not 1 
(Nil). 
• ‘dsmaxis1’ (Diagnosis Axis 1 (DSM IV)) is removed, since it specifies the 
schizophrenia sub-types, and we don’t deal with sub-types in this study. 
• ‘first-ep’ (first episode) is removed, since it is only relevant to patients, and 
for all controls, this column is blank. 
• ‘brought’ (brought by) is removed. Generally controls are brought by 
themselves. This is not rational for the patient’s disease, but rather than a 
consequence of the disease – patients lost the ability of taking care of 
themselves. 
• Hospitalization features are removed, since they are relevant to patients 
only; and for controls, all are blank. 
• ‘dur-psyc’ (duration of psychiatric illness (years)) is removed for the 
similar reason as above. 
• Similarly ‘age-onset’ is removed. 
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• Similarly ‘dup-yrs’ (duration of untreated psychosis (in years)), is removed. 
• Similarly ‘tcu-reg’ (visiting regularity), is removed. 
• All medication information is removed, since they are relevant to patients 
only; and for controls, all are blank. 
• All features in SAPP are removed, since they are relevant to patients only; 
and for controls, all are blank. 
• All features in PANSS are removed, since they are relevant to patients only; 
and for controls, all are blank. 
• All features in GAF are removed, since they are relevant to patients only; 
and for controls, all are blank. 
• All features in SUMD are removed, since they are relevant to patients only; 
and for controls, all are blank. 
• All features in WHO QOL (1-26) are removed, since they are for quality of 
life questionnaires for the last four weeks, and moreover they are subjective 
expressions of patients/controls’ feeling. 
• ‘comments’ is removed, since it is a short text field for recording notes. 
 
Missing Values Handling 
 
After the removal of unnecessary data items, there are still some blank cells. We 
try to fill up the missing values cases by case as described below: 
• ‘fam-hx’ (family history), for almost all controls (except for 2 of them) are 
blanks. After consulting the research assistant in charge of data entry, all 
blanks are filled with the default value 1 (Nil). For a patient (CDNo=1), the 
value is missing, and we set it to the default value 1 (Nil). 
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• There are two missing values in column ‘yr_momedu’ (years of education:  
mother) and ‘yr_fatedu’ (years of education: father) for two patients 
(CDNo=54, 62). We fill the blank with the most likely value – the mean 
value of yr_momedu (6.77, rounded to 7), yr_fatedu(7.2, rounded to 7) in 
the patient group. 
• ‘occ_dad’ (father’s occupation) is missing for three cases (CDNo=83, 84, 




Some data items are input wrongly by the data input officer. The fam_hx (family 
history) information is initially collected in the fam_hxsp (family history specify), 
and later coded into the fam_hx item. We find some inconsistency between these 
two items. For example, in the family history, “paternal aunt” should be coded as 
“2nd degree” (a relative who shares about 25% of genes with an individual in a 
family, e.g., uncle, aunt, cousin), instead of “1st degree” (a relative who shares 
about 50% of genes with an individual in a family, e.g., father, mother, siblings). 
Hence we correct errors in the fam_hx according to its original information 




Table 3.5 Data corrections 
CD No Originally Collected Data 
Fam_hxsp (famiy history specify) 
Encoded Data 
Fam_hx: change from → to 
2 Paternal uncle – schizophrenia 1st degree → 2nd degree 
12 Cousin, aunt 1st degree → 2nd degree 
26 Paternal aunt 1st degree → 2nd degree 
47 Maternal grandmother committed suicide 1st degree → 2nd degree 
55 Maternal uncle 1st degree → 2nd degree 
57 Maternal aunt 1st degree → 2nd degree 
75 Maternal aunt and uncle 1st degree → 2nd degree 
93 Nephew 1st degree → 2nd degree 
124 Uncle 1st degree → 2nd degree 
130 Paternal grandpa 1st degree → 2nd degree 
134 Paternal nephew/niece (OCD) Other → 2nd degree 
138 Paternal uncle Other → 2nd degree 
139 Paternal uncle – schizophrenia Other → 2nd degree 
Note: 1st degree: a relative who shares about 50% of genes with an individual in a family; 2nd degree: a 
relative who shares about 25% of genes with an individual in a family. Abbreviation: CD No, Compact Disk 
Number (used as case number). 
 
 
Neurocognitive Tests Data 
 
A total of 76 columns of information are collected for the 4 neurocognitive tests. 
We keep all raw scores, and remove derived ones such as percentage or percentile 
of the former scores. As a result of this exercise, 19 columns remain for further 
analysis (as listed in Table 3.3). 
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Table 3.6 Number of uncompleted and completed cases of neurocognitive test 
Test Total Case Uncompleted Completed 
RPM 156 63 93 
WAIS 156 61 95 
CPT 156 67 89 
WCST 156 63 93 
 
Besides that, not all subjects take all four tests for various reasons. Some are 
unable to complete them, while some are uncooperative. The number of completed 
cases (ranging from 89 to 95) for all neurocognitive tests is listed in Table 3.6. 
Among all completed cases, 84 cases remain in common for all 4 tests. The 
completed cases consist of 59 patients (70.2%) and 25 controls (29.8%). The 
distributions of the remaining cases are illustrated in Figure 3.4. We will use these 




Figure 3.4 Distribution of neurocognitive test after removing missing values (N=84) 
(Blue: patient; Red: control. 1: RPM_raw, 2: BlockDesign_raw, 3: DigitSpan_fwd, 4: 
DigitSpan_bwd, 5: DigitSpan_total, 6: SpatialSpan_fwd, 7: SpatialSpan_bwd, 8: 
SpatialSpan_total, 9: Omissions_tscore, 10: Commissions_tscore, 11: HitRT_tscore, 12: 
Trials_administered, 13: Total_correct, 14: TotalErrors_raw, 15: PersResponses_raw, 16: 
PersErrors_raw, 17: NonpersErrors_raw, 18: Categories_raw, 19: Trials_raw. 20: pt_ctrl 
(patient/control). Descriptions of the items can be found in Appendix A) 
 
In this section, we described the data preprocessing exercise. Specifically, we 
removed irrelevant columns, filled up missing values, corrected wrongly input data, 
and came up with clean datasets ready for further analysis. 
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3.6 Modeling Using Demographic Data and Clinical Data 
 
The demographic data include patient’s age, sex, weight, height, etc (see previous 
introduction in section 3.2). The clinical data include drug use, alcohol use and 
family history of psychiatric diseases, etc (see introduction in section 3.3). They 
are basic information collected at subjects recruiting time. They are available in all 
cases.  
 
Table 3.7 Demographic and clinical data features 
handed (handedness) yrsedu_mum (years of education mum) 
sex yrsedu_dad (years of education dad) 
ethnic occupant (occupation) 
father (father's ethnicity) occ_dad  (father's occupation) 
pgfather (paternal grandfather's ethinicity) occ_mum  (mother's occupation) 
pgmother (paternal grandfather's ethinicity) med_prob (medical problems (past or current)) 
mother (mother's ethnicity) sur_prob (surgical problems (past or current)) 
mgfather (maternal grandfather's ethinicity) alcohol (alcohol use (past or current)) 
mgmother (maternal grandmother's ethnicity) drug_use (drug use (past or current)) 
age fam_hx (family history of mental illness) 
marital (marital status) height 
edulevel (educational level) weight 
yrsedu (years of education)  
 
 
We start building our first schizophrenia classification model based on the 
demographic data and clinical data. There are 25 data features (Table 3.7), and 84 
cases (see distribution in Figure 3.5). The characteristics of these cases are listed in 
Table 3.8. Pearson Chi-Square is used to test the independency of two categorical 
factorsand Independent Sample T Test (2-tailed) is used to compare the mean score 
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of two continuous factors. We can see that in the selected 84 cases, the patients and 
controls match on sex, handedness, ethnics, marital status, height and weight, 
except for age and education levels. The age is significantly different; and the 
education levels of the subject himself/herself and parents are significantly lower 
in patients than in controls. 
 
Table 3.8 Characteristics of selected cases (N=84) 





Age 34.24 (SD 9.15) 28.56 (SD 6.89) 0.003 (SIG)* 




























Education level, years 11.22 (SD 2.67) 14.52 (SD 1.42) < 0.001 (SIG)* 
Father’s education level, years 7.22 (SD 3.57) 9.04 (SD 3.31) 0.032 (SIG)* 
Mother’s education level, 
years 
6.08 (SD 3.87) 8.72 (SD 3.79) 0.005 (SIG)* 
Weight, kg 63.22 (SD 12.18) 66.70 (SD 11.39) 0.226 (NS)* 
Height, m 1.69 (SD 0.07) 1.70 (SD 0.07) 0.494 (NS)* 
Note: ^ Pearson Chi-Square; * Independent Sample T Test; Abbreviations: SD, Standard 





Figure 3.5 Distribution of demographic and clinical features (N=84) 
(Blue: patient; Red: control. 1:handedness (right/left), 2: sex (male/female), 3: ethnic 
(Chinese/Indian/Malay), 4: father's ethnic (Chinese/Other), 5: paternal grandfather's ethnic 
(Chinese/Other), 6: paternal grantmother's ethnic (Chinese/Other), 7: mother's ethnic 
(Chinese/Other), 8: maternal grandfather's ethnic (Chinese/Other), 9: maternal 
grandmother's ethnic (Chinese/Other), 10: age (years), 11: marital status 
(single/married/divorced), 12: education level 
(Secondary/JC/Primary/University/Polytechnic/Vocational), 13: years of education, 14: years 
of education: mother, 15: years of education: father, 16: occupation (unemployed/manual 
labor/admin/homemaker/professional/other), 17: father's occupation 
(admin/unemployed/other/manual labor/professional/unspecified/passed away/home maker), 
18: mother's occupation (admin/homemaker/unemployed/other/professional/manual 
labor/passed away), 19: medical problem (no/yes), 20:surgical problem (yes/no), 21: alcohol 
use (abuse/no/dependence), 22: drug use (no/abuse), 23: family history of mental illness 
(Nil/2nd degree/1st degree), 24: height (in m), 25: weight (in kg), 26: pt_ctrl (patient/control). 
Descriptions of data items can be found in Appendix A) 
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During data pre-processing, we have already removed irrelevant features such as 
medication and hospitalization information. If a model is constructed on all 25 data 
features for 84 cases, the case to feature ratio is about 3.4 to 1, which is 
substantially less than 10 to 1 (rule of 10), as suggested by many studies, for 
example (Arrindell & Ende, 1985; Bartlett, et al., 2001; Everitt, 1975; Nunnally, 
1978). The model tends to be over-fitting or over-specific to the study samples and 
causes the lacking of generalizability due to too many parameters (Hair, Anderson, 
Tatham, & Black, 1995) or “the curse of dimensionality” (Hastie, Tibshirani, & 
Friedman, 2001). We will apply the feature selection technology to select only 
important features. 
 
3.6.1 Feature Selection 
 
Weka (Ver 3.4.13, University of Waikato, New Zealand) (Holmes, Donkin, & 
Witten, 1994; Witten & Frank, 2005) is an open source software package written 
in Java programming language. It contains implementations of many machine 
learning algorithms for data mining tasks. It also contains tools for data pre-
processing, classification, regression, clustering, association rules, and 
visualization. 
 
Correlation-based Feature Subset algorithm selects significant features by 
evaluating and comparing each feature’s predictive ability and degree of 
redundancy (M. A. Hall, 1998). We apply this algorithm implemented in the Weka 
software package for feature selection.  
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The features selected by this algorithm are: age, yrsedu (years of education), 
occupatn (occupation of patient), and fam_hx (family history of mental illness).  
 
Some other feature selection algorithms have also been used, such as, Info Gain  
(Mitchell, 1997; Y. Yang & Pedersen, 1997), and Support Vector Machine (Bishop, 
1996; Guyon, Weston, Barnhill, & Vapnik, 2002). The results are the same for our 
study. We will use the Correlation-based Feature Subset algorithm for the feature 
selection process throughout this work. 
 
Among the selected features, yrsedu and occupatn are socioeconomic status of the 
patient; they are considered as the consequence of the sickness instead of reasons. 
Hence they shall be excluded from the selected feature list. 
 
After removing another similar socioeconomic feature (edulevel: education level), 
the remaining selected features become: age and fam_hx. However, age difference 
is caused by the selection of subjects who have completed the neurocognitive tests; 
hence it shall not be included in model construction. Finally the only relevant 
feature to be used in model construction is the fam_hx (family history). 
 
3.6.2 Definitions and Terminologies  
 
Before we start to build up the classification models, we recall some definitions 
and terminologies here. 
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We want to identify “Patient”. In other words, our target is “Patient”. When we 
describe the status of a case, we mean its ground truth, or what it is actually. So 
when we say the status is true, we mean the subject is actually a patient; when we 
say the status is false, we mean the subject is actually a control. 
 
When describing the test result, we use the terms: positive and negative. When we 
say the test result is positive, we mean the test result classifies it as a patient. When 
we say the test result is negative, we mean the test result classifies it as a control. 
 
In this situation, we define true positive (TP), false positive (FP), true negative 
(TN), false negative (FN) as follows: 
 
• True Positive (TP) test result: the test result classifies this case as a patient, 
and ground truth is actually a patient;  
• False Positive (FP) test result: the test result classifies this case as a patient, 
and ground truth is actually a control;  
• True Negative (TN) test result: the test result classifies this case as a 
control, and ground truth is actually a control;  
• False Negative (FN) test result: the test result classifies this case as a 
control, and ground truth is actually a patient.  
 
The following Table 3.9 shows the format of the confusion matrix of the 
supervised learning that will be used throughout the rest of thesis. For example, the 
total number of ground truth patients correctly classified as patients will be filled 
in the True Position (TP) blank. 
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Table 3.9 Confusion matrix of supervised learning 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
True Positive (TP) False Negative (FN) Patient 
False Positive (FP) True Negative (TN) Control 
Ground Truth 
 
The True Positive Rate, False Positive Rate, True Negative Rate, and False 
Negative Rate are defined as follows: 
 
True Positive Rate: TP Rate = TP / (TP + FN)     (3.1) 
 
False Positive Rate: FP Rate = FP / (FP + TN)     (3.2) 
 
True Negative Rate: TN Rate = TN / (FP + TN)     (3.3) 
 
False Negative Rate: FN Rate = FN / (TP + FN)     (3.4) 
 
True Positive Rate is also known as Sensitivity. True Negative Rate is also known 
as Specificity. 
 
Type I Error (also known as α error, False Positive Rate) and Type II Error (also 
known as β error, or False Negative Rate) are used to describe possible errors 
made in a statistical decision process. 
 
Accuracy is defined as a measurement of how well a binary classification test 
correctly identifies or excludes a condition.  
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Accuracy = (TP + TN) / (TP + FP + TN + FN)     (3.5) 
 
Error Rate is the ratio of incorrectly classified cases to the total number of cases. 
 
Error Rate = (FP + FN) / (TP + FP + TN + FN)     (3.6) 
 
3.6.3 Bayesian Network Classifier Evaluation 
 
We choose the format of models from point of usefulness. Bayesian network 
model, alternating tree model and logistic regress model are considered. Different 
formats of models are generated and compared, but alternating tree model and 
logistic regression model produce lower classification accuracy than the Bayesian 
Model (see Section 7.2.5). Besides that, suitable presentation format is also a 
concern. Bayesian Network model is good for its simple graphical format (Acyclic 
Directed Graph (DAG)) to represent and understand the relationship between 
schizophrenia and the significant factors. 
 
Bayesian Network is a graphic model that shows a set of interrelated factors 
(random variables) and their joint probability distributions. It is expressed as a 
Directed Acyclic Graph (DAG). Each node in the graph represents a random 
variable. Each arc represents a direct qualitative dependence relationship. And the 
local distribution of a node represents the quantitative strength of the dependence 
relation. (Cooper & Herskovitz, 1992; Howard, 1990; Jensen, 2001) 
 
To classify a new case using the Bayesian Network Classifier, we first calculate 
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where Pdist is the distribution probability of patient or control; v takes value of 
“Patient” or “Control”; F is a chance node (a node in the Bayesian network that 
represents a factor, for example a test result) other than target node (pt_ctrl); u is 
the possible value for a chance node (factor); n is the number of chance nodes 
except for the target node pt_ctrl. 
 
In case of Naïve Bayesian network (which consists of one target node and several 
child nodes, and no links between child nodes), since all factors are conditionally 









)_|()_()(    (3.8) 
 




classify =       (3.9) 




3.6.4 Baseline Model Construction 
 
We use cases that complete all tests to construct our models. The total number of 
such cases is 84, including 59 patients and 25 controls. Hence the prior probability 
of patient in our sample space is 70.2%. 
 
Weka software is used for model construction. We have tried different forms of 
model including Logistic Regression, Decision Tree and Bayesian Network (see a 
discussion in Chapter 7). It appears that Bayesian network models perform quite 
well in terms of classification accuracy. In addition, the Bayesian Network model 
has a simpler and clearer presentation format and is easier to interpret compared to 
the other two models. Hence, we decide to use Bayesian Network for all our model 
construction.  
 
Based on the selected feature (fam_hx), we construct a Bayesian Network 
classification model with the heuristic local K2 searching algorithm (Cooper & 
Herskovitz, 1992) by using the simple Bayes estimator (Bouckaert, 2004) to 
calculate the conditional probability table and comparing the posterior probabilistic 
ratio of any pair of possible Bayesian Network structure at the given dataset, which 
learns the structure effectively. Other searching algorithms, such as Greedy Search 
(Chickering, 2002), which searches for local maximum from initial structure, are 
also attempted. However, In our study, the same results are generated. K2 
algorithm is often used by researchers since it can be implemented easily and 
evaluated fast. We will use the K2 searching algorithm throughout all Bayesian 




Figure 3.6 Bayesian network model on clinical data 
 
A Bayesian Network model is generated, as illustrated in Figure 3.6. This is a very 
basic model, which has only two nodes. This over simplified model demonstrates 
the fact that there is a stronger association between schizophrenia and the family 
history than other features (such as sex, ethnic), as people have already pointed out 
in (R. Murray, et al., 2003).  
 




Table 3.10 Probability distribution of fam_hx 
fam_hx Pt_ctrl 
Nil 2nd degree 1st degree 
Patient 0.5702 0.2231 0.2066 
Control 0.9623 0.0189 0.0189 
Note: 1st degree: a relative who shares about 50% of genes with an individual in a family; 2nd degree: a 
relative who shares about 25% of genes with an individual in a family. 
 
Since the sample data collection is very costly ($1,497 per case at private rate, see 
Section 7.1), the validation of the model is done by using the 10-fold cross-
validation method, where all cases are randomly split into 10 subsets, and every 
subset is used as validation set to validate the model generated from the other 9 
subsets (as training set) (Kohavi, 1995). From the validation results (Table 3.11, 
Table 3.12), we can see that all cases are classified as patients, so that the Type I 
error is 100%. The accuracy is 70.2%, which is actually the same as the prior 
probability of patient. We will use this model as the baseline model, and gradually 
enhance it by adding other features. 
 
Table 3.11 Confusion matrix (clinical data: fam_hx) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
59 (TP) 0 (FN) Patient (59) 




  Table 3.12 Summary of model (clinical data: fam_hx)           
Item Value 
Total Number of Instances               84  
Correctly Classified Instances           59  
Incorrectly Classified Instances 25 
Accuracy 70.2% 
Error Rate 29.8% 
True Positive Rate (Patient classified as patient) 100% 
Type I Error Rate (Control classified as patient) 100% 
True Negative Rate (Control classified as control) 0% 
Type II Error Rate (Patient classified as control) 0% 
 
As a comparison, we tried to use the feature yrsedu (years of education) to build 
another model. The results are listed in Table 3.13 and Table 3.14. This model 
does not classify all cases as patients (as the baseline model does); actually it can 
correctly classify 7 control cases (TN). It also incorrectly classifies 11 patients as 
controls (FN). However, the total correctly classified number of cases is 55 
(TP+TN). Though this model has a lower Type I error (72.0%) than the baseline 
model (100%), its accuracy is only 65.5%, which is worse than that of the baseline 
model (70.2%). 
 
From the comparison, we can see that, even though the baseline model has a Type 
I error of 100%, it can still be considered as the best choice for the aim of high 
accuracy, at the current restriction (with only one feature: fam_hx). In other words, 
the extremely high Type I error (100%) of the baseline model is not a coincidence, 




In fact, because of the availability of the feature it used (family history is 
considered as also available), this model serves as a starting point (the meaning of 
baseline). We can add additional features into the baseline models: (1) to increase 
the accuracy and (2) to decrease the Type I error. Since the baseline model’s Type 
I error is 100%, we have to point out that this model alone shall not be applied in 
practice. 
 
As we have discussed earlier, being a consequence of the schizophrenia disease, 
yrsedu shall not be included into our classification models as a predictor, and we 
will not consider it in our further model constructions.  
 
Table 3.13 Confusion matrix (yrsedu) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
48 (TP) 11 (FN) Patient (59) 





  Table 3.14 Summary of model (yrsedu)           
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           55 
Incorrectly Classified Instances 29 
Accuracy 65.5% 
Error Rate 34.5% 
True Positive Rate (Patient classified as patient) 81.4% 
Type I Error Rate (Control classified as patient) 72.0% 
True Negative Rate (Control classified as control) 28.0% 
Type II Error Rate (Patient classified as control) 18.6% 
 
In this section, we first use the feature selection method to select the important 
features from demographic data and clinical data. Then we build a baseline 
Bayesian Network model with accuracy rate 70.2%. Next we will include 
neurocognitive test results in the model. 
 
3.7 Modeling Using Neurocognitive Tests Results 
 
Four neurocognitive tests on study subjects, namely RPM, WAIS, CPT and WCST 
have been done, which generates 19 data features (See Table 3.3). Among all 156 
cases, 84 participants have completed all 4 tests, including 59 patients (70.2%), 
and 25 controls (29.8%). We will use this subset for model construction. 
 
In the previous section, we select only one significant feature from demographic 
data and clinical data, the fam_hx (family history). Since any neurocognitive test 
can be done separately and independently, various models should be constructed to 
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reflect this situation. In this section, we will use fam_hx and various combinations 
of neurocognitive tests to build more comprehensive models. However, we will 
examine these tests individually before we combine them with clinical data. 
 
3.7.1 Neurocognitive Tests Only 
 
By using the method described in section 3.6, we select significant features from 
each of the 4 neurocognitive tests, and build 4 Bayesian Network models based on 
each of them separately by using the same approach described in Section 3.6.4. 
 
Specifically, feature RPM_raw is selected from the RPM test, since it is the only 
result in the test. Feature DigitSpan_bwd is selected from the WAIS test results 
(BlockDesign_raw, DigitSpan_fwd, DigitSpan_bwd, DigitSpan_total, 
SpatialSpan_fwd, SpatialSpan_bwd, and SpatialSpan_total); feature 
Omissions_tscore is selected from the CPT test results (Omissions_tscore, 
Commissions_tscore, HitRT_tscore); and features PersResponses_raw and 
PersError_raw are selected from the WCST test results (Trials_administered, 
Total_correct, TotalErrors_raw, PersResponses_raw, PersErrors_raw, 
NonpersErrors_raw, Categories_raw, Trials_raw). 
 
Four Bayesian Network classification models are constructed by using significant 
features from the neurocognitive tests separately, and their results are summarized 
in Table 3.15, Table 3.16, Table 3.17 and Table 3.18 for RPM, WAIS, CPT and 
WCST tests respectively. 
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The model on RPM test has an accuracy of 66.7%, which is even lower than the 
baseline model (70.2%). This shows that when this test is applied alone, the effect 
in reaching correct diagnosis is worse than the family history. However, the Type I 
error (56.0%) decreases compared to the baseline model (100%), which means it 
can correctly identify some control cases, whereas the baseline model never does. 
 
The model on WAIS test results (DigitSpan_bwd) alone has the same accuracy 
(70.2%) as the baseline model. In fact, it also classifies all controls as patients 
incorrectly as the baseline model does; hence it’s Type I error is also 100%. This 
test alone has the same effect in terms of classification accuracy as the family 
history. Again, this model shall not be applied in practice because of its high Type 
I error. 
 
Similarly, the model on CPT test results alone generates a classification accuracy 
of 70.2%, and a Type I error of 100%. 
 
In the case of WCST test, the model accuracy is 56.0%, which is the lowest of all 4 
models. However, it is able to correctly identify some controls (21 cases), which 
makes it’s Type I error 16.0%, also the lowest of all. This shows its ability of being 
a potential predictor in further model construction. 
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Table 3.15 Summary of model on RPM test results (RPM_raw) 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           56 
Incorrectly Classified Instances 28 
Accuracy 66.7% 
Error Rate 33.3% 
True Positive Rate (Patient classified as patient) 76.3% 
Type I Error Rate (Control classified as patient) 56.0% 
True Negative Rate (Control classified as control) 44.0% 
Type II Error Rate (Patient classified as control) 23.7% 
 
 
Table 3.16 Summary of model on WAIS test results (DigitSpan_bwd)  
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           59 
Incorrectly Classified Instances 25 
Accuracy 70.2% 
Error Rate 29.8% 
True Positive Rate (Patient classified as patient) 100.0% 
Type I Error Rate (Control classified as patient) 100.0% 
True Negative Rate (Control classified as control) 0.0% 




Table 3.17 Summary of model on CPT test results (Omission_tscore) 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           59 
Incorrectly Classified Instances 25 
Accuracy 70.2% 
Error Rate 29.8% 
True Positive Rate (Patient classified as patient) 100.0% 
Type I Error Rate (Control classified as patient) 100.0% 
True Negative Rate (Control classified as control) 0.0% 
Type II Error Rate (Patient classified as control) 0.0% 
 
Table 3.18 Summary of model on WCST test results (PersResponse_Raw + PersError_raw)  
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           47 
Incorrectly Classified Instances 37 
Accuracy 56.0% 
Error Rate 44.0% 
True Positive Rate (Patient classified as patient) 44.1% 
Type I Error Rate (Control classified as patient) 16.0% 
True Negative Rate (Control classified as control) 84.0% 
Type II Error Rate (Patient classified as control) 55.9% 
 
In summary, four neurocognitive tests are investigated separately. Two tests show 
similar contribution to classification accuracy as the baseline model. The other two 
tests show lower classification accuracy, however they can correctly identify some 
normal controls. In the next few sections, we will add these tests into the baseline 
model, and construct new models based on the combined features. 
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3.7.2 Clinical Data + RPM 
 
We first combine all the clinical data and the RPM test results (RPM_raw). The 




Weka software is used for model construction. Based on the selected features, we 
construct a Bayesian Network classification model with the local K2 searching 
algorithm (Cooper & Herskovitz, 1992).  
 
The model is illustrated in Figure 3.7. A classification accuracy of 82.1% is 
achieved, which is substantially higher than the baseline model accuracy (70.2%). 
This is a promising result, as we start to see the power of combining factors from 
different categories. Other rates are listed in Table 3.20. Compared to the baseline 
model's Type I error (100%), this model is able to classify 20 cases of controls 
correctly (Table 3.19), and it's Type I error drops to 20%. Note that this Bayesian 
Network model degenerates to Naïve Bayesian Network. That is because the two 
features (fam_hx and RPM_raw) are conditionally independent given pt_ctrl, since 
only highly independent features remain after the feature selection step (which 




Figure 3.7 Model on clinical data + RPM 
 
Table 3.19 Confusion matrix (clinical data + RPM) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
49 (TP) 10 (FN) Patient (59) 




Table 3.20 Summary of model on clinical data + RPM           
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           69 
Incorrectly Classified Instances 15 
Accuracy 82.1% 
Error Rate 17.9% 
True Positive Rate (Patient classified as patient) 83.1% 
Type I Error Rate (Control classified as patient) 20.0% 
True Negative Rate (Control classified as control) 80.0% 
Type II Error Rate (Patient classified as control) 16.9% 
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3.7.3 Clinical Data + WAIS 
 
Now we add the WAIS test results (BlockDesign_raw, DigitSpan_fwd, 
DigitSpan_bwd, DigitSpan_total, SpatialSpan_fwd, SpatialSpan_bwd, and 
SpatialSpan_total) to all clinical data. The following features remain after the 




A Bayesian Network model is built on these features (as illustrated in Figure 3.8). 
It contains 3 nodes. Since fam_hx and DigitSpan_bwd are conditionally 
independent given pt_ctrl, the model degenerates to a Naïve Bayesian network 
model. The accuracy of this model is 79.8%, which is substantially higher than the 
baseline model accuracy (70.2%). Other rates are listed in Table 3.22. This model 
further increases the number of correctly classified controls to 24 (Table 3.21), 
which leads to an even lower Type I error of 4%. As a trade-off, 16 patients are 
incorrectly classified as controls, which causes a 27.1% Type II error. This model 




Figure 3.8 Model on clinical data + WAIS 
 
 
Table 3.21 Confusion matrix (clinical data + WAIS) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
43 (TP) 16 (FN) Patient (59) 




Table 3.22 Summary of model on clinical data + WAIS  
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           67 
Incorrectly Classified Instances 17 
Accuracy 79.8% 
Error Rate 20.2% 
True Positive Rate (Patient classified as patient) 72.9% 
Type I Error Rate (Control classified as patient) 4.0% 
True Negative Rate (Control classified as control) 96.0% 
Type II Error Rate (Patient classified as control) 27.1% 
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3.7.4 Clinical Data + CPT 
 
We next combine all clinical data and the CPT test results (Omissions_tscore, 
Commissions_tscore, HitRT_tscore). The following features remain after the 
feature selection:  
• fam_hx 
 
No CPT test result appears in the selected feature list. This means CPT test’s 
contribution to the classification is insufficient. However we can still examine the 
effect of CPT, by including fam_hx and CPT test results as factors to build a 
Bayesian Network classification model.  The following results are generated as in 
Table 3.23 and Table 3.24. We can see that it does not change the classification 
results of model on fam_hx alone. The accuracy is still 70.2%.  
 
In fact, by examining the conditional probabilities of all factors from CPT test 
(Table 3.25), we notice that the probability distribution of classification result 
(pt_ctrl) is always 1 when it takes value of either "patient" or "control", regardless 
of the value of Omissions_tscore, Commissions_tscore and HitRT_tscore. That 
means the CPT test results have no relation with the classification target node 
(pt_ctrl), and they don't affect the probability distribution at all. Hence, the CPT 
test shall be excluded from the model construction.  
 
From clinical point of view, the result of this model suggests that the attention and 
impulsivity functions assessed by the CPT test do not show significant difference 
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between patients and controls. These two functions do not increase the 
classification accuracy when combined with other factor (fam_hx). 
 
Table 3.23 Confusion matrix (clinical data + CPT) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
59 (TP) 0 (FN) Patient (59) 




Table 3.24 Summary of model on clinical data + CPT 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           59 
Incorrectly Classified Instances 25 
Accuracy 70.2% 
Error Rate 29.8% 
True Positive Rate (Patient classified as patient) 100.0% 
Type I Error Rate (Control classified as patient) 100.0% 
True Negative Rate (Control classified as control) 0.0% 
Type II Error Rate (Patient classified as control) 0.0% 
 
 
Table 3.25 Probability distribution tables of factors from CPT 
Pt_ctrl Omissions_tscore  Pt_ctrl Commissions_tscore  Pt_ctrl HitRT_tscore 
Patient 1  Patient 1  Patient 1 
Control 1  Control 1  Control 1 
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3.7.5 Clinical Data + WCST 
 
We combine clinical data with the WCST test results (Trials_administered, 
Total_correct, TotalErrors_raw, PersResponses_raw, PersErrors_raw, 
NonpersErrors_raw, Categories_raw, Trials_raw). The following features remain 




A model is built on these features (as illustrated in Figure 3.9). Its accuracy is 
75.0%. Other results are listed in Table 3.26 and Table 3.27. The low Type I error 
(4.0%) shows its good ability in identifying controls. In contrast, a big portion of 
patients (20) are wrongly classified as controls, which causes a high Type II error 
(33.9%). This model seems to be more biased to controls. 
 
 
Figure 3.9 Model on clinical data + WCST 
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Table 3.26 Confusion matrix (clinical data + WCST) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
39 (TP) 20 (FN) Patient (59) 




Table 3.27 Summary of model on clinical data + WCST 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           63 
Incorrectly Classified Instances 21 
Accuracy 75.0% 
Error Rate 25.0% 
True Positive Rate (Patient classified as patient) 66.1% 
Type I Error Rate (Control classified as patient) 4.0% 
True Negative Rate (Control classified as control) 96.0% 
Type II Error Rate (Patient classified as control) 33.9% 
 
3.7.6 Clinical Data + RPM + WAIS 
 
We combine all clinical data with two neurocognitive tests, namely, RPM test 
result (RPM_raw) and the WAIS test results (BlockDesign_raw, DigitSpan_fwd, 
DigitSpan_bwd, DigitSpan_total, SpatialSpan_fwd, SpatialSpan_bwd, and 






A model is built on these features (as illustrated in Figure 3.10). Its accuracy is 
84.5%. This is substantially higher than the baseline model (70.2%). Other results 
are listed in Table 3.28 and Table 3.29. 
 
 
Figure 3.10 Model on clinical data + RPM + WAIS 
 
 
Table 3.28 Confusion matrix (clinical data + RPM + WAIS) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
52 (TP) 7 (FN) Patient (59) 




Table 3.29 Summary of model on clinical data + RPM + WAIS 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           71 
Incorrectly Classified Instances 13 
Accuracy 84.5% 
Error Rate 15.5% 
True Positive Rate (Patient classified as patient) 88.1% 
Type I Error Rate (Control classified as patient) 24.0% 
True Negative Rate (Control classified as control) 76.0% 
Type II Error Rate (Patient classified as control) 11.9% 
 
3.7.7 Clinical Data + RPM + WCST 
 
We combine all clinical data with another two neurocognitive tests, namely, WAIS 





A model is built on these features (as illustrated in Figure 3.11). Its accuracy is 
83.3%. Again a substantial increment in accuracy is achieved compared to the 




Figure 3.11 Model on clinical data + RPM + WCST 
 
Table 3.30 Confusion matrix (clinical data + RPM + WCST) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
51 (TP) 8 (FN) Patient (59) 
6 (FP) 19 (TN) Control (25) 
Ground Truth 
 
Table 3.31 Summary of model on clinical data + RPM + WCST 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           70 
Incorrectly Classified Instances 14 
Accuracy 83.3% 
Error Rate 16.7% 
True Positive Rate (Patient classified as patient) 86.4% 
Type I Error Rate (Control classified as patient) 24.0% 
True Negative Rate (Control classified as control) 76.0% 
Type II Error Rate (Patient classified as control) 13.6% 
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3.7.8 Clinical Data + WAIS + WCST 
 
We combine all clinical data with another two neurocognitive tests, namely, WAIS 





A model is built on these features (as illustrated in Figure 3.12). Its accuracy is 
84.5%. Compared to the baseline model, the accuracy improvement is also 
substantial. Other results are listed in Table 3.32 and Table 3.33. 
 
 
Figure 3.12 Model on clinical data + WAIS + WCST 
 
Table 3.32 Confusion matrix (clinical data + WAIS + WCST) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
48 (TP) 11 (FN) Patient (59) 




Table 3.33 Summary of model on clinical data + WAIS + WCST 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           71 
Incorrectly Classified Instances 13 
Accuracy 84.5% 
Error Rate 15.5% 
True Positive Rate (Patient classified as patient) 81.4% 
Type I Error Rate (Control classified as patient) 8.0% 
True Negative Rate (Control classified as control) 92.0% 
Type II Error Rate (Patient classified as control) 18.6% 
 
3.7.9 Clinical Data + RPM + WAIS + WCST (All Tests) 
 
Finally we combine all clinical data with all three tests: RPM, WAIS and WCST. 






A model is built on these features (as illustrated in Figure 3.13). Its accuracy is 
85.7%. Other results are listed in Table 3.34 and Table 3.35. This model has the 
highest accuracy among all models based on clinical information and various 
combinations of neurocognitive tests. It also achieves the highest sensitivity 
(91.5%), which seems to be very sensitive to patients. However, as a trade-off, 7 




Figure 3.13 Model on clinical data + RPM + WAIS + WCST 
 
 
Table 3.34 Confusion matrix (clinical data + RPM + WAIS + WCST) 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
54 (TP) 5 (FN) Patient (59) 




Table 3.35 Summary of model on clinical data + RPM + WAIS + WCST 
Item Value 
Total Number of Instances               84 
Correctly Classified Instances           72 
Incorrectly Classified Instances 12 
Accuracy 85.7% 
Error Rate 14.3% 
True Positive Rate (Patient classified as patient) 91.5% 
Type I Error Rate (Control classified as patient) 28.0% 
True Negative Rate (Control classified as control) 72.0% 
Type II Error Rate (Patient classified as control) 8.5% 
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3.7.10 Summary of All Models 
 
Since neurocognitive tests may be done on patients separately, not all testes results 
are always available. So we tried to build models on clinical data plus different 
combinations of neurocognitive tests. 
 
We found that CPT test results do not contribute to the model performance. The 
patients and controls' test results have no differences. Hence this test is not 
necessary in differentiating patients with controls. 
 
We summarize the results for various models in Table 3.36. The baseline model on 
clinical data only (Model C) has an accuracy of 70.2%, which is the same as the 
prior probability of patient in our sample space. In fact, it classifies every case as 
patient, so the sensitivity and type I error are both 100%. Hence clinical 
information alone is not practically sufficient in schizophrenia diagnosis by using 
this model.  
 
All other models have accuracy higher than the baseline probability. Their 
accuracy gains range from 4.8% (Model C+WC) to 15.5% (Model 
C+R+WA+WC). 
 
We observe that when a model contains 2 or more neurocognitive tests, its 
accuracy is usually more than 10% higher than the baseline model (Figure 3.14). In 
general, models containing two neurocognitive tests achieve higher accuracy than 
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models containing one. Also, the model with 3 tests has higher accuracy than 
models with two, though the increase is not as big as the former. 
 
 Table 3.36 Summary of models on clinical data + neurocognitive tests  








Nr              84 84 84 84 84 84 84 84 
Cor           59 69 67 63 71 70 71 72 
Incor 0 15 17 21 13 14 13 12 
Acc 70.2% 82.1% 79.8% 75.0% 84.5% 83.3% 84.5% 85.7% 
Err 29.8% 17.9% 20.2% 25.0% 15.5% 16.7% 15.5% 14.3% 
Sen 100.0% 83.1% 72.9% 66.1% 88.1% 86.4% 81.4% 91.5% 
Type I  100.0% 20.0% 4.0% 4.0% 24.0% 24.0% 8.0% 28.0% 
Spe 0.0% 80.0% 96.0% 96.0% 76.0% 76.0% 92.0% 72.0% 
Type II  0.0% 16.9% 27.1% 33.9% 11.9% 13.6% 18.6% 8.5% 
Abbreviations: Nr, Total Number of Instances; Cor, Correctly Classified Instances; Incor, Incorrectly 
Classified Instances; Acc, Accuracy; Err, Error Rate; Sen, Sensitivity; TPR, True Positive Rate (Patient 
classified as patient); Type I, Type I Error Rate (Control classified as patient); Spe, Specificity, TNR, True 
Negative Rate (Control classified as control); Type II, Type II Error Rate (Patient classified as control); C, 
Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test 
 
Most models have Type II error below 30% except for Model C+WC (Figure 3.15), 
which has the highest Type II error of 33.9%. This model tends to classify patients 
as healthy controls.  
 
One model has extremely high Type I error. Model C’s Type I error is 100%. It 
always classifies controls as patients in our cross-validation test. This simple 
model takes into consideration of only patient’s family history, and its prediction is 

































Figure 3.14 Accuracy chart for models on clinical data + neurocognitive tests 
 


































Type I Error Rate (Control classified as patient) Type II Error Rate (Patient classified as control)
 




We have recruited 156 subjects (92 patients, and 64 healthy controls). Their 
neuroinformatics data are collected: including demographic information, clinical 
information such as family history, medication information, clinical scores and 
neurocognitive tests results. In total there are 211 data features. 
 
Data preprocessing is done to eliminate features that are not appropriate in 
constructing schizophrenia classification models. Forty-five features remain as 
candidate predictors for the classification model. Then the missing values in the 
datasets are filled up by reasonable estimations from domain knowledge (such as 
most likely values). Errors in data input (fam_hx) are corrected according to the 
original data (fam_hxsp). 
 
Feature selection is done on demographic and clinical information. Only fam_hx 
(family history of psychiatric disease) is selected to be the significant feature. After 
feature selection, a basic classification model in the form of Bayesian Network is 
generated on the significant feature. Then various combinations of neurocognitive 
tests results together with clinical data features are used to build a set of 
classification models. PCT test is found not contributing to model accuracy gain at 
all.  
 
All classification models built on clinical data plus neurocognitive tests have better 
accuracy than the baseline model. Their accuracy gain ranges from 4.8% to 15.5%. 
The best performing model has an accuracy of 85.7%. It consists of features from 
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clinical data, and all three neurocognitive tests (RPM test, WAIS test, and WCST 




• PersResponses_raw  
 
We notice that, family history always remains in all the models. This means it is an 
important factor in distinguishing patients and controls. This finding aligns well 
with literature (R. Murray, et al., 2003). 
 
The summary of the three significant neurocognitive tests comparison results 
between patients and controls is displayed in Table 3.37 and Figure 3.16. 
Independent Sample T Test (2-tailed) is used to compare the mean score between 
patients and controls. 
 
Table 3.37 Neurocognitive tests results comparison 
Neurocognitive Mean Mean Difference P Value 
Test Patient (N=59) Control (N=25) (Patient – Control) (2-tailed) 
RPM_raw 45.85 (SD 9.28) 54.48 (SD 3.50) -8.633 <0.001 (SIG)^ 
DigitSpan_bwd 7.05 (SD 2.66) 8.64 (SD 2.25) -1.589 0.007 (SIG)^ 
PersResponse_raw 29.20 (22.97) 13.16 (SD 9.23) 16.04 0.001 (SIG)^ 





Figure 3.16 Box plot of selected neurocognitive tests results grouped by patient / control 
Upper left: RPM_raw; Upper right: DigitSpan_bwd; Lower-left: PersRepsonses_raw. Note 
that scales for each box plot are different. 
 
We find that RPM (RPM_raw) and WAIS (DigitSpan_bwd) are significant factors 
in our schizophrenia model; they are related to a person’s intellectual abilities.  
 
RPM_raw is the number of missing patterns correctly identified by a person in a 
test. DigitSpan_bwd is the longest of number of digits that a person can repeat 
correctly in the reverse order after they are announced. In our study subjects, 
patients' mean RPM_raw score (45.85, SD: 9.28) is significantly lower by 8.63 
than that of controls (54.48, SD 3.50). Likewise, patients' mean DigitSpan_bwd 
(7.05, SD 2.66) is also significantly lower by 1.59 than controls (8.64, SD: 2.25). 
That means patients have significantly lower intellectual abilities in terms of non-
verbal logic (as assessed by RPM) and memory capacity (as measured by Digit 
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Span sub-test of WAIS) than normal controls. Some other studies (David, 
Malmberg, Brandt, Allebeck, & Lewis, 1997), (Zammit, et al., 2004) also 
demonstrated low intellectual ability as a risk factor for schizophrenia. 
 
WCST (PersResponses_raw) is a significant factor in schizophrenia classification 
too. Reduced executive capability (tested by WCST), is believed to relate to frontal 
lobe dysfunction of schizophrenia patients. Our study results show that 
schizophrenia patients (29.20, SD: 22.97) have significantly higher perseverative 
response (by 16.04) than normal controls (13.16, SD: 9.23), which suggests 
patients show lower adaptability in learning new rules.  Many studies have also 
shown the similar trends (Abbruzzese, Bellodi, Ferri, & Scarone, 1995; Mahurin, 
Velligan, & Miller, 1998; Pae, et al., 2004).  
 
CPT test doesn’t affect the model, which suggests that the differences in capability 
of attention and impulsivity between patients and controls are not significantly 
enough when compared with other factors (Table 3.38).  Independent Sample T 
Test (2-tailed) is used to compare the mean scores between patients and controls. 
Actually even if we include CPT test into our models, the accuracy does not 
increase, as discussed in section 3.7.4 before.  
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Table 3.38 CPT test results comparison 
CPT Test Results Mean Mean Difference P Value 















(SD 10.54) 6.77 0.024 (SIG)^ 
Note: ^Independent Samples T-Test. Abbreviations: SD, Standard Deviation; SIG, significant (P<0.05); NS, 
Not significant. 
 
We notice all our Bayesian Network models degenerate to Naïve Bayesian 
Network. This is because after feature selection (which selects features with lowest 
redundancy on highest prediction ability), all factors remaining for model 
construction contribute significantly and independently to the target pt_ctrl. They 
are conditionally independent to each other given the target node (pt_ctrl). 
 
In summary, we have developed a data analysis and model construction approach 
and successfully applied it in building a set of schizophrenia classification models 
based on various neuroinformatics data. We will use this approach in modeling 




Chapter 4  
Neuroimaging-Based Analysis and Modeling 
 
In this chapter, we will first describe the neuroimaging acquisition procedure and 
parameters. Then we will introduce our brain atlas based automatic ROI placement 
method for the MRI and DTI image analysis. Statistics of Fractional Anisotropy 
(FA) values within all selected brain structures are calculated for further analysis.  
 
We will follow the procedure as we have used in Chapter 3, to select significant 
image features. These features will be used in the schizophrenia classification 
model construction. 
 
4.1 MRI and DTI imaging 
 
As we can see from the literature review in section 2.2 that schizophrenia is 
associated with not only the brain morphometric changes but also the white matter 
abnormalities, and MRI and DTI imaging are useful tools to quantify the 
neuroconnectivities.  
 




MRI Scan: Single session MRI scans are performed on a clinical 3-Tesla MRI 
scanning system (Intera 3T, Philips Medical Systems, Netherlands) with whole 
brain, high resolution, using 3D MP-RAGE (Magnetisation-Prepared Rapid 
Acquisition with a Gradient Echo) protocol. The volumetric scans parameters are 
TR/TE/TI (repetition time, echo time and, and inversion time) 8.4/3.8/3000; flip 
angle 8; matrix 256x204; Field of View (FOV) 240 mm2, with axial orientation, 
covering the whole brain for structural-anatomic detail.  
 
DTI Scan: In the same session, the diffusion tensor imaging (DTI) in 15 directions 
are also performed using single-shot, spin-echo EPI (echo planar imaging) 
sequence, b value (a diffusion weighted sequences factor, which summarizes the 
influence of the gradient) of 0 and 800 s/mm2, at TR/TE (repetition time and echo 
time) 10,000/80, matrix 128x128, slice thickness 3 mm with no gap and field of 
view 240 mm2 (K Sim, 2005). 
 
A sample structure MRI image set is shown in Figure 4.1. Only the images in axial 
orientation are available. The coronal and sagittal images are reconstructed by the 




Figure 4.1 Structural MRI images 
Upper right corner shows the original image scanned in axial orientation; lower right, coronal 
image; lower left, sagittal image; upper left, triplanar display 
 
Figure 4.2 shows a set of Diffusion Weighted Images (DWI) in one of the 15 





Figure 4.2 DWI images 
Upper right corner shows the original image scanned in axial orientation; lower right, coronal 
image; lower left, sagittal image; upper left, triplanar display 
  
4.2 Image Analysis Methods 
 
Generally there are two different approaches in analysis of DTI images, the voxel 
based morphometry (VBM) (Ashburner & Friston, 2000) (Honea, Crow, 
Passingham, & Mackay, 2005) and region of interested (ROI) method (Giuliani, 
Calhoun, Pearlson, Francis, & Buchanan, 2005). VBM compares local 
concentration of brain images of two groups of patients voxel by voxel, while ROI 
method studies images within a specific ROI, usually selected manually. 
 
In our previous study of computer aided diagnosis for acute stroke, image 
morphormetry based segmentation method was developed (G. L. Yang, et al., 2005)  
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to quantify brain CT images. However, it lacks the ability of automatically 
identifying multiple ROIs for FA quantification. Hence we propose a novel image 
analysis algorithm – brain atlas-based automatic ROI selection in DTI study, as 




Figure 4.3 Image analysis algorithm 
 







MD, color map... 
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Step 1. Registering Brain Atlas to the structural MRI images 
 
Structural MRI images contain the brain morphological information. The images 
are used to identify the anatomical structures, including anterior commissural (AC), 
posterior commissural (PC), and brain extends, which are useful for registration 
with the brain atlas. The structural images are in high resolution. In our current 
study, the pixel size is 0.9x0.9 mm, and the slice distance is also 0.9 mm, which 
makes cubic voxels. 
 
Talairach-Tournoux brain atlas (W. L. Nowinski, 2005; W. L. Nowinski, et al., 
1997; Talairach & Tournoux, 1988) is overlaid on top of the MRI structural images, 
as demonstrated in Figure 4.4. Brain atlas is registered by setting the original 
Talairach landmarks: anterior commissural (AC), posterior commissural (PC), and 
brain extends in all three directions, i.e. Right extend (R), Left extend (L), Anterior 
extend (A), Posterior extend (P), Superior extend (S) and Inferior extend (I), as 
well as the extended Talairach landmarks: Superior Midway (SM) and Inferior 
Midway (IM) (W. L. Nowinski & Prakash, 2005). The registration can be done 
automatically by using the Fast Talairach transformation algorithm (W. L. 
Nowinski, Qian, Bhanu Prakash, Hu, & Aziz, 2006), or by setting the landmarks 
manually.  
 
Currently, the setting of Talairach landmarks is done by manual operation. The 
Fast Talairach Transformation (W. L. Nowinski, Qian, et al., 2006) can be used to 
accelerate the registration process and achieve more consistent registration results. 
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However, in our study, the time for registering brain atlas is not critical; we choose 
to place the landmarks manually in order to get a higher precision.   
 
Step 2. Generating FA images 
 
Diffusion Tensor Images (DTI) contains the diffusion tensor information, which 
can be used to calculate the Mean Diffusivity (MD), Fractional Anisotropy (FA), 
etc according to the method described in (Pierpaoli & Basser, 1996). Currently 
DTI Studio (Version 2.10,  Johns Hopkins University, USA) (Jiang, van Zijl, Kim, 
Pearlson, & Mori, 2006) is used to generate the FA images. Figure 4.5 shows FA 
images displayed in axial, coronal, sagittal directions and the 3D view. 
 
Step 3. Co-registering DTI/FA images and structural images 
 
Structural images and the DTI images are scanned in the same session without 
changing the patient’s position. Their geometric relation can be retrieved from the 
scanning parameters. This information is used to co-register the DTI images and 
the structural MRI images, because only rigid transformation is needed for the 
same subject's MRI and DTI images. 
 
As structural images are already registered with the brain atlas in step 1, DTI 
images and FA images are also registered to the brain atlas. Figure 4.6 shows the 
registered brain atlas overlaid on the FA images.  
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Step 4. ROI selection and Statistical Analysis 
 
Since the brain atlas delineated anatomical and functional regions of the brain, 
single or multiple region of interests (ROI) can be selected by just simply 
specifying their anatomical structure names. Figure 4.7 demonstrates FA images 
with some selected ROIs overlaid. 
 
Statistics can then be calculated in each ROI. Currently we are interested in the 
volume (number of voxels), mean value, standard deviation of the FA images in 
the selected ROIs.  
 
 
Figure 4.8 FA image with significant brain structures overlaid 
Green: IFG; Brown: CG; Pink: ThLP. (Abbreviations: see Appendix B) 
 
This image analysis algorithm has also been applied on a subset of the study 
subjects that consists of 36 patients (11 with passivity and 25 without passivity) 
and 32 age, gender and handedness matched controls. This sub-study identifies 
brain structure difference between schizophrenia with and without passivity. The 
results (K. Sim, et al., 2009) show that passivity is associated with the increased 
FA in right inferior frontal gyrus (IFG), cingulate gyrus (CG), left globus pallidus 
 109
(GP) and the decreased FA in left latero-posterior thalamic nuclei (ThLP) (Figure 
4.8). 
 
In this section, we introduced our image analysis algorithm. We will use this 
algorithm to quantify the FA images in the next section. 
 
4.3 Quantification of FA Images 
 
From literature review in Section 2.1.3, we notice that the Fractional Anisotropy 
changes of schizophrenia patients have been found almost all over the brain, from 
frontal, parietal, temporal, occipital regions, till deep brain structures such as 
corpus callosum, thalamic regions, and brain connections such as superior 
longitudinal fasciculus, inferior longitudinal fasciculus. We also notice that those 
finding are not consistent which might be due to the insufficient number of cases 
(mostly less than 50 to 60), and image processing methods – by using manual ROI 
(region of interest) placement, which may cause inconsistency in the regions 
identification studied. After discussion with a group of domain experts including 
neuroradiologist, neurologist, neuroscientist and psychiatrists, we select a wide 
spectrum of brain structure as potential relevant factors to schizophrenia in order 
not to miss potential findings. Our selected brain structures cover almost all brain 
regions found in the previous studies. Specifically, they include: 
• Frontal (inferior frontal gyrus, medial frontal gyrus, middle frontal 
gyrus, and superior frontal gyrus) 
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• Parietal (angular gyrus and inferior parietal lobule, inferior parietal 
lobule, supramarginal gyrus and inferior parietal lobule, and superior 
parietal lobule) 
• Corpus callosum  
• Subcallosal gyrus 
• Cingulate gyrus 
• Cingulum 
• Tracts (inferior longitudinual fasciculus, superior longitudinual 
fasciculus, fronto-occipital fasciculus, and uncinate fasciculus) 
• Thalamus (all thalamic nucleus) 
• Subthalamic nucleus 
• Inter-thalamic adhesion 
• Lateral geniculate body 
• Medial geniculate body 
 
According to above list, 48 brain structures from the brain atlas are chosen for our 
study. Each brain structure can be further subdivided into the portions in the left 
and right brain hemispheres. So each structure will generate 3 results: as a whole, 
as well as the left and right parts. Hence the total number of ROIs becomes 144 (48 
x 3). The complete list of brain structures can be found in Table 4.1. Their full 
names can be found in Appendix B. 
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Table 4.1 Complete list of ROIs for the study 
No Structure No Structure No Structure 
1 IFG 17 Th 33 MOG 
2 MeFG 18 ThCM 34 OG 
3 MiFG 19 ThDM 35 SOG 
4 SFG 20 ThLD 36 Cu 
5 AGIPL 21 ThLP 37 LG 
6 IPL 22 ThNA 38 ITG 
7 SmGIPL 23 ThO 39 MTG 
8 SPL 24 ThP 40 STG 
9 CC 25 ThVA 41 U 
10 ScG 26 ThVL 42 CN 
11 CG 27 ThVPL 43 GPL 
12 Ci 28 ThVPM 44 GPM 
13 ILF 29 IA 45 Pu 
14 SLF 30 LGB 46 STN 
15 FOF 31 MGB 47 FG 
16 UF 32 IOG 48 AB 
Abbreviations: see Appendix B. 
 
FA images are registered to the brain atlas by using the method described in the 
previous section. With brain atlas, 48 ROIs are placed, and their statistics are 
calculated. Table 4.2 shows a part of the statistical results calculated in the selected 
brain structures. In each ROI, the number of voxels is proportional to its volume, 
since the size of each voxel is 0.9mm x 0.9mm x 3mm. The mean and stdev values 
are the mean and stdev FA values of all voxels within the specific ROI in all slices. 
These results will be used in the learning of schizophrenia model. 
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Table 4.2 Statistical results for the selected ROIs (partial) 
IFG MeFG MiFG 
CDNo Voxel mean stdev  voxel  mean  stdev voxel mean stdev 
1 5804 0.2642 0.1773 5816 0.2507 0.1393 8918 0.2675 0.1597 
2 7923 0.2192 0.1448 7837 0.2304 0.1320 12131 0.2153 0.1183 
3 8330 0.2297 0.1566 8245 0.2743 0.1475 11960 0.2437 0.1693 
4 9077 0.2429 0.1758 8420 0.2557 0.1337 13213 0.2458 0.1790 
5 6854 0.2110 0.1511 6387 0.2224 0.1268 9781 0.2262 0.1417 
6 9007 0.2220 0.1529 7813 0.2415 0.1529 12351 0.2146 0.1630 
7 7574 0.2571 0.1604 7084 0.2351 0.1438 9956 0.2290 0.1469 
8 8835 0.2220 0.1628 8586 0.2314 0.1370 12372 0.2125 0.1460 
9 7981 0.2224 0.1713 7374 0.2232 0.1149 10791 0.2222 0.1614 
10 7750 0.2407 0.1754 7621 0.2433 0.1428 9989 0.2312 0.1576 
Abbreviations: CDNo: Compact Disk No (used as case number); IFG: Inferior frontal gyrus; MeFG: Medial 
frontal gyrus; MiFG: Middle frontal gyrus. Note: for each brain structure, voxel presents total number of 
voxels in all slices; mean is the mean FA values of all voxels in all slices; stdev is the standard deviation. 
 
4.4 Model Construction 
 
Our study involves 48 brain structures and 144 features (the mean of FA value in 
all the 144 ROIs). In order to build up a robust model, a subset of highly relevant 




We apply the method described in chapter 3 for feature selection. The following 
ROIs remain after feature selection: 
• CG (cingulate gyrus) 
• ScG_left (left subcallosal gyrus) 
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• ThLD_left (left thalamus: lateral dorsal nucleus) 
• ThNA_right (right thalamus: anterior nucleus) 
 
Table 4.3 Mean FA values of selected ROIs 
Brain Mean Mean Difference P Value 
Structure Patient (N=59) Control (N=25) (Patient – Control) (2-tailed) 
CG 0.2547 (SD 0.0214) 0.2662 (SD 0.0133) -0.0115 0.004 (SIG)^ 
ScG_left 0.2319 (SD 0.1032) 0.2840 (SD 0.0757) -0.0521 0.013 (SIG)^ 
ThLD_left 0.2829 (SD 0.0750) 0.3497 (SD 0.0857) -0.0668 0.002 (SIG)^ 
ThNA_right 0.3310 (SD 0.0522) 0.3595 (SD 0.0408) -0.0285 0.009 (SIG)^ 




Figure 4.9 Box plot of FA values in selected image ROIs 
FA values are groupped by patients and controls. Upper-left: CG; Upper-right: ScG_left; 




We compare the mean FA values using Independent Sample T Test (2-tailed) 
between patients and controls in the 4 selected ROIs, CG, ScG_left, ThLD_left and 
ThNA_right and display the results in Table 4.3, and show their box plots in 
Figure 4.9. We find that there is consistent decrease in FA across the four regions 
in patients compared to controls. That means in these brain structures, the brain 
connectivity is weaker in patients than in controls. Figure 4.10 illustrates the 
locations of the selected brain structures. Though ThLD_left and ThNA_right are 
tiny brain structures, they are still clearly visible and identifiable in the DTI images 
with the help of brain atlas. In our sample data, their mean volumes are 99.9 mm3 
(SD 35.5 mm3) and 241.8 mm3 (SD 47.1 mm3), respectively. 
 
From the anatomy point of view, the cingulate gyrus (CG) is important for 
focussed attentional tasks (Carter, et al., 2000; Sharp, Scott, Mehta, & Wise, 2006; 
Whittle, Allen, Lubman, & Yucel, 2006). Patient’s mean FA value in cingulate 
gyrus, 0.2547 (SD 0.0214), is 0.0115 lower than that of controls, 0.2662 (SD 
0.0133) (P=0.004). The reduced FA value in this region suggests that 
schizophrenic patients may have an anatomical basis for poorer attention capability 
than healthy controls. Besides some similar findings from (Kumra, et al., 2005) 
and (Hoptman, et al., 2008),  recent functional magnetic resonance imaging (fMRI) 
study also shows schizophrenia patients having a reduction in blood oxygenated 
level dependent (BOLD) in cingulate gyrus compared to the healthy participants 
during attention processes (Filbey, Russell, Morris, Murray, & McDonald, 2008). 
A study also reported that schizophrenia patients and subjects of higher genetic 
risk for schizophrenia (with family history of schizophrenia) are found to have 
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reduced FA in cingulate gyrus, which suggests the cingulate gyrus as a good 
predictor even before the onset of psychotic sickness (Hoptman, et al., 2008).  
 
The thalamus in the human brain is an important “way station” for many pathways 
and connections (Cipolotti, et al., 2008). The lateral dorsal nucleus (LD) in the 
thalamus is reported to have contributions to the links between hippocampus and 
thalamus (Aggleton & Brown, 1999). It connects to the parahippocampal and 
posterior cingulate cortex (Yeterian & Pandya, 1988) as well as medial temporal 
regions (including the hippocampus, presubiculum and entorhinal cortex) 
(Aggleton, Desimone, & Mishkin, 1986) (Saunders, Mishkin, & Aggleton, 2005), 
LD is involved in higher order somatosensory and visuo-spatial functions (Broman, 
1994). Patient’s mean FA value in LD thalamus, 0.2829 (SD 0.0750), is 
significantly lower than that of controls 0.3497 (SD 0.0857) (P=0.002). The 
reduced FA value suggests that deficits in visuo-perceptual tasks (Green, et al., 
2009) or reported psychopathology such as passivity phenomenon may be related 
to disruptions in white matter integrity involving the LD thalamus.   
 
On the other hand, the anterior nuclei (NA) thalamus has reciprocal connections 
with limbic regions subserving functions such as memory and emotional memory 
(A. Harding, Halliday, Caine, & Kril, 2000). It is reported that NA receives a key 
input from the hippocampus via the mamillothalamic tract (Saunders, et al., 2005). 
We find that patients’ mean FA value in this region, 0.3310 (SD 0.0522), is 0.0285 
lower than that of controls, 0.3595 (SD 0.0408) (P=0.009). The reduced FA value 
in this region points towards possible neural basis underlying memory deficits 
found not uncommonly in schizophrenia (Barch, Csernansky, Conturo, & Snyder, 
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2002; J. Hall, Harris, McKirdy, Johnstone, & Lawrie, 2007; Herbener, 2008; 
Lysaker, Bell, Greig, & Bryson, 2000). 
 
Similarly, the subcallosal gyrus is part of corpus callosum and located immediately 
anterior to the anterior commissure of the brain. It is responsible for left and right 
prefrontal interhemispheric communication (Belin, Faure, & Mayer, 2008; Milner, 
1982; Milner & Lines, 1982).Thus, the observation that patients’ mean FA value in 
this region, 0.2319 (SD 0.1032), is 0. 0521 lower than that of controls 0.2840 (SD 
0.0757) (P=0.013), is probably related to poorer connectivity between cerebral 
hemispheres. Disruption of white matter integrity involving this region may affect 
the information processing between the cerebral cortices and underlie information 
processing deficits implicated in the origin of symptoms such as delusions and 
hallucinations (Doty, 1989; Wright, et al., 1995). 
 
 
Figure 4.10 Selected brain structures 
(a) CG (Cingulate Gyrus) (b) ThLD_left (Thalamus: Lateral dorsal nucleus, in left 
hemisphere) and ThNA_right (Thalamus: Anterior nucleus, in right) (c) ScG_left (Subcallosal 
gyrus, in left hemisphere). Note the images are displayed in the neuroradiology convention, 





In order to combine with other neurocognitive tests, we use cases that complete all 
tests to construct our models. The total number of cases is 84, including 59 patients 




Figure 4.11 Bayesian network model on image features 
 
Based on the 4 selected features, we construct a Bayesian Network classification 
model. This model (as illustrated in Figure 4.11) degenerates to a Naïve Bayesian 
network, since selected features are conditionally independent to each other on 
pt_ctrl target node. 
 
Validation of the model is done by using the 10-fold cross-validation method. 
From the validation results (Table 4.4, Table 4.5, Table 4.6), we can see that 46 
cases are correctly identified as patient, and 19 cases are correctly identified as 
control. The total number of correctly identified instances is 65. The accuracy is 
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77.4%, which is higher than the prior probability of patient. That shows image 
features are good predictors even without clinical data.  
 
Table 4.4 Confusion matrix of model on image features 
Test Outcome   
Patient (Positive) Control (Negative) ← Classified As   
46 (TP) 13 (FN) Patient (59) 












(Type II Error) 
Class 
0.78 0.24 0.76 0.22 Patient 
0.76  0.22 0.78 0.24 Control 
 
 
  Table 4.6 Summary of model (image features) 
Item Value 
Total Number of Instances               84      
Correctly Classified Instances           65                
Incorrectly Classified Instances 19 
Accuracy 77.4% 
Error Rate 22.6% 
True Positive Rate (Patient classified as patient) 78% 
Type I Error Rate (Control classified as patient) 24% 
True Negative Rate (Control classified as control) 76% 
Type II Error Rate (Patient classified as control) 22% 
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For the identification of patient, the True Positive rate is 78%, and the True 
Negative rate is 76%. This shows imaging features have balanced abilities in 
identifying patients and controls. We will enhance this model by adding other 




In order to determine the brain structure abnormalities, patients and controls are 
scanned to obtain their brain images in structural MRI and DTI formats. We 
developed an image analysis algorithm to automatically place 144 ROIs on the 
brain images. The ROIs are used to quantify the FA values. 
 
Our image analysis algorithm has the following advantages over the conventional 
manual ROI placement: 
• It introduces a systematic way for ROI selection. All ROIs are placed 
automatically after the brain atlas is registered to the patient’s brain images. 
Human errors in placing ROIs are avoided. It also increases the consistency 
of image data quantification among multiple researchers and multiple 
centers. 
• The results are more consistent among different studies, since the ROI 
placement is done by a computer program that implements our method. 
• With the help of brain atlas, tiny structures such as subthalamic nucleus, 
which are usually difficult to identify from the image, can also be 
quantified.   
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• Diffusion Tensor Imaging (DTI) images can be warped to the Talairach 
space, image values can be compared among studies, and averaging of 
values in the Talairach space can be also performed. 
• Large amount of ROIs and studies can be performed automatically, which 
is usually difficult for manual methods. This makes studies involving large 
amount of patients/controls more feasible. 
 
We first apply this technique to examine the brain structure differences between 
schizophrenia patients with and without passivity (K. Sim, et al., 2009), and then 
use it in our study to extract 144 image features for all patients and controls.  
 
Four significant features are chosen from the 144 features using a feature selection 
algorithm, namely, CG, ScG_left, ThLD_left and ThNA_right. Reduced FA values 
are found in the above 4 brain structures in schizophrenia patients compared to 
healthy controls. From the anatomy point of view, cingulate gyrus is important for 
attentional tasks, LD thalamus for higher order somatosensory and visuo-spatial 
functions and anterior nuclei for connections with limbic regions (memory, 
emotional memory etc) and subcallosal gyrus is part of corpus callosum (which 
plays a role in the left and right prefrontal interhemispheric communication).  
 
We build a Bayesian Network classification model on these image features alone. 
A higher accuracy (77.4%) is achieved compared to the baseline model accuracy 
(70.2%) as described in Chapter 3. Based on this result, the image features appear 
to be promising factors in schizophrenia classification. 
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In summary, an image analysis algorithm is developed to extract features (FA 
values in brain structures) from the brain images. The image features are used as 
objective and quantifiable criteria in building the schizophrenia classification 
model. 
 
In the next chapter, we will use the image features together with the 




Chapter 5  
Neuroinformatics and Neuroimaging Data Based 
Modeling 
 
In chapters 3 and 4, we created some schizophrenia models based on 
neuroinformatics and neuroimaging data separately. In this chapter, we will 
combine them, and build more comprehensive models. 
 
5.1 Model Construction 
 
We have already identified the 8 significant features (Table 5.1). They break down 
into: 1 feature from the clinical data, 3 features from different neurocognitive tests, 
and 4 from neuroimaging. 
 
Various models have already been created based on different combinations of 
neuroinformatics features. Now, we add the neuroimaging features, and build more 
comprehensive models by using the same approach as discussed in chapters 3 and 
chapter 4. The complete list of models and their characteristics (including total 
number of correctly classified cases, total number of wrongly classified cases, 
model accuracy, sensitivity, specificity and Type I and Type II errors) are 
summarized in Table 5.2.  
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Table 5.1 Significant neuroinformatics and neuroimaging features 
Category Feature 
Clinical Data 1) fam_hx 
RPM 2) RPM_raw 
WAIS 3) DigitSpan_bwd 
Neuroinfomatics 
Neurocognitive Tests  
 
 WCST 4) PersResponses_raw 





The top half of the Table 5.2 contains 8 models, all of them are built on clinical 
information (fam_hx: family history of psychiatric disease) and neurocognitive 
tests results. Their accuracies range from 70.2% to 85.7%. The first model is the 
baseline model which contains only one factor (fam_hx), and it has the lowest 
accuracy among all models (70.2%). It also has the highest Type I error (100%), 
which means it is completely biased to patient - all cases are classified as patient. It 




Table 5.2 Summary of models on neuroinformatics and neuroimaging 
Model
→ 









Nr              84 84 84 84 84 84 84 84 
Cor            59 69 67 63 71 70 71 72 
Incor  0 15 17 21 13 14 13 12 
Acc  70.2% 82.1% 79.8% 75.0% 84.5% 83.3% 84.5% 85.7% 
Err  29.8% 17.9% 20.2% 25.0% 15.5% 16.7% 15.5% 14.3% 
Sen  100.0% 83.1% 72.9% 66.1% 88.1% 86.4% 81.4% 91.5% 
Type I   100.0% 20.0% 4.0% 4.0% 24.0% 24.0% 8.0% 28.0% 
Spe  0.0% 80.0% 96.0% 96.0% 76.0% 76.0% 92.0% 72.0% 
Type II   0.0% 16.9% 27.1% 33.9% 11.9% 13.6% 18.6% 8.5% 
Model
→ 














Nr             84   84 84 84 84 84 84 84 84 
Cor           65   71 74 74 72 73 72 74 75 
Incor 19 13 10 10 12 11 12 10 9 
Acc 77.4% 84.5% 88.1% 88.1% 85.7% 86.9% 85.7% 88.1% 89.3% 
Err 22.6% 15.5% 11.9% 11.9% 14.3% 13.1% 14.3% 11.9% 10.7% 
Sen 78% 84.7% 98.3% 89.8% 88.1% 91.5% 93.2% 91.5% 93.2% 
Type I  24% 16.0% 36.0% 16.0% 20.0% 24.0% 32.0% 20.0% 20.0% 
Spe 76% 84.0% 64.0% 84.0% 80.0% 76.0% 68.0% 80.0% 80.0% 
Type II  22% 15.3% 1.7% 10.2% 11.9% 8.5% 6.8% 8.5% 6.8% 
Abbreviations: Nr, Total Number of Instances; Cor, Correctly Classified Instances; Incor, Incorrectly 
Classified Instances; Acc, Accuracy; Err, Error Rate; Sen, Sensitivity; TPR, True Positive Rate (Patient 
classified as patient); Type I, Type I Error Rate (Control classified as patient); Spe, Specificity, TNR, True 
Negative Rate (Control classified as control); Type II, Type II Error Rate (Patient classified as control); C, 
Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test; I, Imaging  
 
The bottom half of the table contains 9 models. The first one (model I) is built on 
imaging features only (as discussed in Chapter 4). The rest of the 8 models are 
built on clinical features and various combinations of neurocognitive tests results 
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plus the neuroimaging features. There is a one to one relationship between the top 
half of the table and the bottom half, except for model I, namely, a column in the 
bottom half is the result of a column in the top half plus the imaging features. 
 
We can see that, starting from model I+C, till model I+C+R+WA+WC, all models 
with imaging features plus some other features can achieve accuracy of more than 
about 85%. This is a big improvement compared to the baseline model (70.2%). 
All sensitivities are improved too. The lowest sensitivity (84.7%) is observed at 
model I+C, which is still reasonably good; the rest are close to or higher than 90%. 
This makes these models good in predicting schizophrenia. On the other hand, 
specificities range from 64% to 84%, which shows a generally lower ability in 
detecting controls than patients. 
 
Among all models, the most comprehensive one is the model with all the 8 
significant features, fam_hx, RPM_raw, DigitSpan_bwd, PersResponses_raw, CG, 
ScG_left, ThLD_left, and ThNA_right, which has the highest accuracy of 89.3%. 
This model is illustrated in Figure 5.1. As we can see, it has the form of Naive 
Bayesian Network with one target node (pt_ctrl) and 8 child nodes, each 




Figure 5.1 The Most comprehensive model on all information 
 
5.2 Results and Conclusions 
 
We have constructed 17 models on different combinations of input features. Since 
clinical information is considered to be always available (our assumption), we use 
it as the baseline model for comparing model accuracies. 
 
Figure 5.2 shows the accuracies of all models. Most models can achieve accuracy 
from about 80% to 90%, which is about 10%-20% gain compared to the baseline 
model (model with family history only). We also notice that in general, the 
accuracy has an increasing trend by adding more and more tests. 
 
The model on image features alone is a special case. Its accuracy is 77.4%. It is 
used to demonstrate the usefulness of neuroimaging in schizophrenia classification. 
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When combined with clinical information, the accuracy increased to 84.5%, a gain 
of 14.3% compared to the baseline model. 
 
The other models have accuracy of less than 80%. They are models on clinical data 
plus a single neurocognitive test (WAIS or WCST). This shows that single 
neurocognitive test plus clinical information (without imaging) are not sufficient to 
get good diagnosis accuracy. 
 
  
Figure 5.2 Accuracy chart of all models 
Accuracy of the baseline model is 70.2%. The most comprehensive model with all features has the 
highest accuracy of 89.3%. Most other models have accuracy of about 80-90%. Abbreviations: I, 
Imaging; C, Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test  
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Type I Error (Figure 5.3) of baseline model (clinical data only) is 100%, meaning 
all cases are classified as patient. That restricts its usefulness in practice. Other 
models have Type I error below 30%, except for model I+C+R, and model 
I+C+R+WC, whose type I error reaches 36% and 32% respectively. Almost all 
Type II errors are below 30%, with an exception of model C+WC, whose Type II 
error reaches 33.9%. 
 






























































Figure 5.3 Type I and II error chart of all models 
Abbreviations: I, Imaging; C, Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test 
 
Effect of Neuroimaging 
 
We examine the effect of neuroimaging, by comparing model accuracy with and 
without neuroimaging features (Figure 5.4). We notice a substantial increment in 
 129
accuracy (from 6.0% to 14.3%) is obtained when adding neuroimaging feature into 
any models with none or single neurocognitive test only. However, if a model 
already contains multiple neurocognitive tests, the accuracy gain is only marginal 
(2.4% to 3.6%).  
 










































Figure 5.4 Accuracy (effect of neuroimaging) 
Abbreviations: I, Imaging; C, Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test 
 
Effect of RPM Test 
 
We also examine the effect of RPM test by comparing the accuracy of models with 
and without RPM (Figure 5.5). Adding RPM test to existing models that contain 
none or only one neurocognitive test (mode C, C+WA, C+WC), the accuracy gain 




On the other hand, if existing model already contains two other neurocognitive 
tests (WA+WC), the accuracy gain is merely 1.2%.  
 
For models that already contain neuroimaging features, adding RPM doesn’t 
increase their accuracy substantially. For instance, adding RPM to model I+C+WA 
doesn’t increase the accuracy at all. For model I+C+WA, adding RPM test even 
decreases its accuracy marginally by 1.2%. Since the validation is done on 84 
cases, 1.2% decreasing means just 1 case difference (1/84 = 1.2%). This 
fluctuation may be caused by the small number of validation cases. In this situation, 
RPM test's additional contribution to the classification accuracy is already small; 
when the number of cases is small, the irregularity of the sample data may affect a 
small number (e.g., 1 or 2 cases) of classification results, and cause the decreased 
accuracy. In other words, the model generated from the training cases represents a 
classification rule for the objective of optimal probability of Bayesian Network 
structure given the current training dataset. However the test subset of the sample 
data may not always follow the distribution pattern that the optimal model required, 
hence the model accuracy can be reduced by a small amount sometimes. 
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Figure 5.5 Accuracy (effect of RPM test) 
Abbreviations: I, Imaging; C, Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test 
 
Effect of WAIS Test 
 
Similar accuracy change effect can be observed in the case of WAIS test (Figure 
5.6). Adding WAIS test into models with none or one neurocognitive test (WCST) 
does boost the accuracy substantially by 9.6% and 9.5% respectively. For the rest 
of the models, it doesn’t contribute much to models accuracy: accuracy gains are 
2.4%-3.6%. 
 
In the worst situation (for model I+C+R), the accuracy even drops 1.2%. Since the 
validation is done on 84 cases, 1.2% decreasing means just 1 case difference. This 















































Figure 5.6 Accuracy (effect of WAIS test) 
Abbreviations: I, Imaging; C, Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test 
 
Effect of WCST 
 
The contribution of WCST is the smallest among all 3 other tests (RPM, WAIS, 
neuroimaging) (Figure 5.7). It only increases the accuracy by 4.8% and 4.7% for 
model C and model C+WA, respectively.  
 
For the rest of the models, WCST doesn’t contribute much, or even decreases the 
model accuracy. Again, this fluctuation may be caused by the small number of 
validation cases as discussed earlier. 
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Figure 5.7 Accuracy (effect of WCST test) 
Abbreviations: I, Imaging; C, Clinical Data; R, RPM Test; WA, WAIS Test; WC, WCST Test 
 
In summary, combined schizophrenia models are constructed based on 
neuroinformatics and neuroimaging data. Models with two or more neurocognitive 
tests or the neuroimaging data can achieve classification accuracy at about 80%-
90%, an increase of 10%-20% compared to the baseline model (with clinical 
information only). 
 
In the next chapter, we will use the models that we have already built to develop a 




Chapter 6  
Decision Support System for Schizophrenia 
 
The models we have built in previous chapters are based on clinical information 
(fam_hx), neurocognitive tests (RPM, WAIS, WCST), and neuroimaging.  
 
All the features selected for model construction are objective. They are also 
quantifiable (their values are integer numbers or real numbers), except for fam_hx 
(which takes three possible nominal values: Nil, 1st degree and 2nd degree). Hence 
they are more reliable than the subjective criteria used in DSM-IV and ICD-10.  
 
In this chapter, we will develop a schizophrenia diagnosis decision support system 
based on the features we selected and various models we constructed. 
 
6.1 Decision Support System 
 
In order to augment the exiting standard diagnosis and provide a diagnosis result 
based on objective criteria that they are lacking of, we decide to construct a 




In previous chapters, we have built some 17 models (see Table 5.2). Different 
model can be applied at different situation depending on availability of the test 
results. For example, when patient clinical information is only available, model C 
can be applied. After the person does the WAIS test, model C+WA can be applied 
to generate the classification results.  
 
All models data are stored in Bayesian Interchange Format (BIF) (Cozman, 1998) 
files. A BIF file is a text file using XML schema, which stores all the nodes 
information, including their names, possible nominal values, and ranges of 
numeric values. It also stores the relationship (arcs) between nodes, and the 
conditional probability tables for all nodes.  
 
We develop computer software to provide the decision support in schizophrenia 
diagnosis based on all models. The decision support system consists of 4 
components: a model repository, a data input GUI, a decision support engine, and a 




Figure 6.1 Decision support system block diagram 
 
The Model Repository: This component stores all Bayesian Network models, and 
their properties, as well as some other information like the cost for the tests. We 
have collected the cost information for various neurocognitive tests in previous 
chapter; we compile them together with the cost information for the neuroimaging 
(Table 6.1). The cost information will be used by the decision support engine to 
calculate the cost effectiveness of models. The model repository provides 
accessing functions to models and their properties. 
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Table 6.1 Cost of tests 
Cost Test Time Needed 
Subsidized Rate Private Rate 
RPM 30 min – 1 hour $130* $400* 
WAIS-III 15 min – 30 min $65 $240 
CPT-II 15 min – 30 min $65^ $200^ 
WCST 15 min - 20 min $65^ $200^ 
Neuroimaging 
(MRI+DTI) 
30 min – 1 hour $220 $457 
Note: * Estimated; ^Estimated by dividing total cost of CPT and WCST by 2. 
 
The Data Input Component: It is a simple Graphical User Interface (GUI) that 
allows the user to input patient’s clinical information, various neurocognitive tests 
results, and neuroimaging results.  
 
The Decision Support Engine: This component receives the user input data, and 
automatically chooses an appropriate Bayesian network model from the Model 
Repository, depending on the availability of different types of data. (For example, 
if the RPM test and WAIS test results are available, the model C+R+WA will be 
chosen.) Then the model is queried to generate the probability distribution of the 
input case by using Equation (6-1) (because all our models are in the form of 
Naïve Bayesian Network). The classification result is calculated using Equation (6-
2).  In addition, the decision support engine also searches in the model repository 









)_|()_()(    (6.1) 
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where Pdist is the distribution probability of patient or control; v takes value of 
“Patient” or “Control”; F is a chance node (factor) in the Naïve Bayesian network 
(other than the target); u is the possible value of a chance node; n is the number of 




classify =       (6.2) 
where pt_ctrlclassify is the classification result of a case: either “Patient” or 
“Control”; Pdist is the distribution probability of patient or control; v takes value of 
“Patient” or “Control”. 
 
 
Figure 6.2 Component diagram of decision support system 
 
Figure 6.2 illustrates the component diagram for the decision support engine. The 
target node is the classification result, pt_ctrl, which is related to two types of data, 
neuroinformatics data and neuroimaging data. More specifically, chance node 
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pt_ctrl is related to chance node fam_hx, RPM_raw, DigitSpan_bwd and 
PersResponse_raw (in the neuroinformatics domain), and CG, ScG_left, 
ThLD_left, ThNA_right (in the neuroimaging domain). There are four decision 
nodes (RPM Test, WAIS Test, WCST Test and Neuroimaging Test). Each 
generates it respective test results (chance nodes). The value node represents the 
classification accuracy of the specific Bayesian Network model used in the 
classification for a given combination of input data. For example, when only RPM 
test is done, model C+R will be used for classification, and hence the value node, 
classification accuracy takes the value of accuracy of model C+R. 
 
We describe the algorithm for searching suggested models (with further tests) that 
have higher accuracy than any given model as follows: 
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Model searching algorithm (pseudo code) 
 // ---------------------------------------------- 
 // Find suggested models to improve the accuracy 
 // Input parameter: M0: the given model 
 // Output: a list of suggested models 
 // ---------------------------------------------- 
 create an empty list for the suggested models 
 FOR each model M in the model repository 
  check the tests contained in existing model M0 
  check the tests contained in existing model M 
  compare the model M with existing model M0  
  IF M contains one more test than M0 THEN 
   compare their classification accuracies 
   IF accuracy of M is greater than that of M0 THEN 
    add M into the suggested model list 
   END IF 
  END IF 
 END FOR 
 RETURN the suggested model list 
 
The Report Display Component: This is a simple Graphical User Interface (GUI) 
to display the report generated by the decision support engine. It also provides a 
save function allowing the user to save the report in a text file, and a print function 




6.2.1 Decision Support Flow Charts 
 
Based on all schizophrenia classification models, their accuracies, their tests 
included, and relationships between them, we make a decision support flow chart 
(Figure 6.3) that can help clinicians to decide what test to choose in order to 
increase the diagnosis accuracy in various situations.  
 
In the flow chart, a circle represents a model; the size of the circle represents its 
accuracy: the larger the size, the higher the accuracy. An arrow represents a test 
with different colors representing different tests: brown for RPM, green for WAIS, 
blue for WCST and pink for Imaging.  
 
Models are arranged in 5 different layers. The “Baseline” layer contains model C, 
which does not include any test. The “1 Test” layer contains models with any 
single test, namely models C+R, C+WA, C+WC and C+I. The “2 Tests” layer 
contains models with any combinations of two tests, for example C+R+WA. The 
“3 Tests” layer contains models with any combinations of 3 tests such as model 
C+R+WA+WC. Finally the “4 Tests” layer contains the most comprehensive 




In each layer, models are sorted by accuracy from left to right. For example, at "1 
Tests" layer, models C+WC (75%), C+WA (79.8%), C+R (82.1%) and I+C 
(84.5%) are arranged from the lowest accuracy to the highest accuracy. 
 
 
Figure 6.3 Decision support flow chart (strategy: highest accuracy gain) 
Circles represent models, with size representing accuracy. Models are arranged in layers 
according to the number of tests (baseline: 0 test, other layers: 1 to 4 tests) they contain, and 
they are sorted by accuracy in each layer. Arrows of different colors represent different tests. 




Starting from any model, if a test is done, it will flow to a new model along the 
arrow representing that test. For example, at model C+R, if test WCST is done, it 
will flow to model C+R+WC, by following the blue arrow (representing WCST 
test).  
 
An arrow of thick line represents the locally best choice test (meaning it leads to a 
model with highest accuracy gain). For example, if a person has already done the 
RPM test, then the clinician can choose the next test from WAIS, WCST and 
Imaging. In the flow chart, we can see that starting from model C+R (accuracy 
82.1%), there are three outgoing arrows pointing out to other models. The best 
choice is the arrow with thick line, in this case, the pink colored arrow, which 
represents Imaging Test. That means, the Imaging Test should be chosen as the 
next test. After the Imaging Test, the classification accuracy will become 88.1% 
(model I+C+R). 
 
If a model has two (or more) thick arrows pointing out, it means doing these two 
tests will have the same accuracy gain. For example, from model I+C, a brown 
arrow (representing RPM test) and green arrow (WAIS test) are both in thick line. 
That means, doing these two tests will lead to two models (model I+C+R, and 
model I+C+WA) with same accuracy (88.1%).  
 
An arrow with dashed line represents a test which is not recommended (meaning it 
does not increase the accuracy at all). For example, from model I+C+R (accuracy 
88.1%), doing test WCST (blue arrow) or WAIS (green arrow) leads to new 
models with lower accuracy, hence they are not suggested. 
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In addition, this flow chart can also be used by clinicians to choose combinations 
of multiple tests directly since it give the clinicians a global view of all possible 
tests. For example, if clinicians want to do two tests, they can immediately find the 
best combinations (model I+C+R, and model I+C+WA) from the "2 Tests" layer. 
Another example is that if the clinicians  want to find out what combinations of 
tests can give more than 88% of accuracy, they can directly locate model I+C+R, 
I+C+WA, I+C+WA+WC, and I+C+R+WA+WC from the chart by looking at 
areas with large circles. 
 
Although from the baseline model C (accuracy 70.2%) to the most comprehensive 
model I+C+R+WA+WC (accuracy 89.3%), the accuracy increment is at 
substantial level of 19.1%, this increment is not always noticeable for each test 
added. For example, from model C+R+WC (accuracy 83.3%), to model 
I+C+R+WC (accuracy 85.7%), the accuracy increment is only 2.4% by adding the 
imaging test. In such a case with small steps of accuracy increment, clinicians 
should consider the effectiveness of the test recommended in the flow chart. 
 
We also make another Decision Support Flow Chart (Figure 6.4) based on a 
different strategy. We choose the best further test by selecting the test that has the 
highest cost effectiveness. Cost effectiveness (CE) is a measurement of a test. It is 
defined as accuracy gain from a model to new model (in terms of percentage) 
divided by the cost of the additional test that the new mode has. Throughout the 






AccAccCE −= +,        (6.3) 
 
where CEt,m is the Cost Effectiveness of test t from model m; Accm is the accuracy 
of model m, Accm+t is the accuracy of another model m+t (a model with additional 
test t), and Costt is the cost of test t. 
 
The unit of Cost Effectiveness is percent/$. For example a Cost Effectiveness of 
0.02%/$ means, for every dollar ($) spent on the test, an accuracy gain of 0.02% 
can be achieved. 
 
A more meaningful measurement is Relative Cost, which is defined as the 










      (6.4) 
 
where RCt,m is the Relative Cost of test t from model m; CEt,m is the Cost 
Effectiveness of test t from model m; Accm is the accuracy of model m, Accm+t is 
the accuracy of another model m+t (a model with additional test t), and Costt is the 
cost of test t. 
 
The unit of Relative Cost is $/percent. It can be interpreted as: for each percent of 
accuracy gain, how much money is spent. In the decision support flow chart, the 





Figure 6.4 Decision support flow chart (strategy: highest cost effectiveness) 
Circles represent models, with size representing accuracy. Models are arranged in layers 
according to the number of tests (baseline: 0 test, other layers: 1 to 4 tests) they contain, and 
they are sorted by accuracy in each layer. Arrows of different colors represent different tests. 
The number along a thick arrow is the relative cost, cost per percent of accuracy gain. This 
flow chart helps clinicians to choose the most cost effective test in different situations by 
following the thick arrows. 
 
The cost effectiveness based flow chart helps clinicians to select a suitable test at 
situations when the cost is a concern. For example, from model C+WC, the most 
cost effective test is WAIS, which flows to model C+WA+WC. A 9.5% of 
accuracy gain (from 75% to 84.5%) is achieved, and the relative cost is $25/pct. 
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Compared to the best choice (Imaging test) from previous flow chart (on strategy 
of highest accuracy gain), a different decision (WAIS test) is suggested. 
 
However, even the flow chart can recommend a most cost effective test among all 
possible further tests for each step theoretically; the clinicians shall also consider 
the absolute accuracy increment before a test is performed. For example model 
C+WA+WC (accuracy 84.5%), the flow chart recommends the imaging test which 
leads to model I+C+WA+WC (accuracy 88.1%), but the accuracy increment is 
3.6% only. Clinicians shall make decision on if such an increment is practical 
useful according to their needs. 
 
In summary, the decision support flow charts provide useful tools for clinicians in 
selecting suitable tests on patients after classification models are validated in large 
scale trials. 
 
6.2.2 Decision Support System Software 
 
We develop the Decision Support System software in pure Java programming 
language. Java Swing is used to build the GUI part. We use the Weka library (Ver 
3.4.13, University of Waikato, New Zealand) to perform functions such as 




Figure 6.5 Decision support system user input GUI 
  
We have tested run the software on Window XP platform. Figure 6.5 is a screen 
capture of the data input GUI. Users can select family history from a dropdown list. 
Only selected data are required to be input for neurocognitive tests, and 
neuroimaging test. If a test is not done, the relevant fields can be left blank. The 




Figure 6.6 Report with classification results and suggested further tests  
 
After inputting necessary information from the Data Input GUI, the user clicks the 
Query button. The Decision Support Engine uses the user input data to select a 
suitable schizophrenia classification model to use. Then the selected Bayesian 
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Network model is used to classify the user’s case. A report based on the 
classification results will be generated and shown to the user. An example of a 
report is shown as in Figure 6.6. Along with the classification result (in this case, a 
normal control) and the probability distribution, the decision support system shows 
three suggested further tests (RPM, WCST and Imaging) that will increase the 
classification accuracy. Finally it shows the best choices according to different 
strategies (highest accuracy gain and highest cost effectiveness).  
 
In summary, we made two Decision Support Flow Charts that helps clinicians to 
choose suitable tests in order to improve the diagnostic accuracy with or without 
the cost consideration. We also developed a decision support system. It provides 
support in schizophrenia diagnosis by using objective criteria, such as family 
history and various quantifiable neurocognitive tests results, and neuroimaging 
features.  In order to achieve higher diagnosing accuracy, it also gives suggestions 
on what tests should be done, and shows their accuracy gains and cost 
effectiveness. 
 
6.3 Performance of Decision Support System 
 
We estimate the overall performance of the decision support system. We use 
average accuracy to represent the accuracy of the decision support system, based 
on the assumption that all models have the same opportunity to be applied. That is 
because all neurocognitive tests and neuroimaging tests are independent and we 
assume there is no preference in selecting any tests. Hence, we define the overall 









=        (6.5) 
 
where Accm is a model’s accuracy; N is the number of models. 
 
Since our decision support system uses 16 models (Acc16) (The 16 models come 
from clinical data plus all combinations of 4 independent tests, i.e., 3 
neurocognitive tests and 1 neuroimaging test,  24=16). The overall accuracy 
Accoverall is calculated as: 
 
Accoverall = Acc16 = 83.8% 
 
Model C takes into account of clinical information only (family history). As we 
have pointed out previously, this model classifies all cases as patients, and so its 
type I error is 100%. Hence it shall not be applied in practice. If we exclude this 
model from decision support system (a more realistic situation because diagnosis 
should not solely depends on family history), the mean accuracy of all the other 
models becomes 84.8%.  
 
Accoverall = Acc15 = 84.8% 
 
In summary, a schizophrenia decision support system is developed by using all 
models we constructed. The models are based on subjective criteria, such as family 
history of psychiatric disease, neurocognitive tests results, and neuroimaging 
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results. The performance of the decision support system can be measured by the 
overall classification accuracy.  
 
6.4 Performance of Cost Based Decision Support System 
 
Based on the private rated cost of all test (Table 6.1), the cost of all models can be 
calculated by their component individual tests. The Accuracy Gain (AccGain) is 
defined as the increased accuracy of a model compared with the baseline model 
(Model C). Relative Cost (RC) for each model is calculated as the cost of the 
model divided by the AccGain. The results are shown in the Table 6.2: 
 













Acc  70.2% 82.1% 79.8% 75.0% 84.5% 83.3% 84.5% 85.7% 
AccGain   11.9% 9.6% 4.8% 14.3% 13.1% 14.3% 15.5% 
Cost   $400 $240 $200 $640 $600 $440 $840 
RC    $33.61 $25.00 $41.67 $44.76 $45.80 $30.77 $54.19 
Model
→ 














Acc 77.4% 84.5% 88.1% 88.1% 85.7% 86.9% 85.7% 88.1% 89.3% 
AccGain 7.2% 14.3% 17.9% 17.9% 15.5% 16.7% 15.5% 17.9% 19.1% 
Cost $457 $457 $857 $697 $657 $1,097 $1,057 $897 $1,297 
RC  $63.47 $31.96 $47.88 $38.94 $42.39 $65.69 $68.19 $50.11 $67.91 
Abbreviations: Acc, Accuracy; AccGain, Accuracy Gain; RC, Relative Cost; C, Clinical Data; R, RPM Test; 
WA, WAIS Test; WC, WCST Test; I, Imaging  
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We define the overall relative cost (RCoverall) as the mean relative cost of all models 








=        (6.6) 
 
where RCm is a model’s relative cost; N is the number of models 
 
Since Model C’s relative cost is undefined, the overall relative cost of the decision 
support system will be consist of the rest 15 models (without Model I). 
 
RCoverall  = RC15  = $47.02/% 
 
Which means, by using the decision support system, people can expect an average 
1 percent of accuracy increase compared to the baseline model C for every $47.02 
spent on testing. 
 
The relative cost of all models and the decision support system overall is shown in 
Figure 6.7. Each dot represents a model. The red line is the overall relative cost of 
the decision support system, which is $47.02/%. From cost effectiveness point of 
view, the lower the relative cost, the better the model. We can see that although the 
most comprehensive model I+C+R+WA+WC has the highest accuracy, it almost 

































































Figure 6.7 Relative Costs of Models and Overall Relative Cost of Decision Support System 
Abbreviations: RC, Relative Cost; C, Clinical Data; R, RPM Test; WA, WAIS Test; WC, 






Chapter 7  
Conclusions and Discussion 
 
Schizophrenia is a very common psychiatric disease which affects about 1% of the 
world's population. It does not only damage to the patient's health, but also is a big 
economical burden to the patient's family and the whole society. However the 
existing diagnosis of schizophrenia heavily depends on subjective criteria, such as 
family member's observation of patient's symptoms (for example, bizarre 
behaviors). There is no lab test for this disease.  
 
We aim to reveal the relationship between schizophrenia and the objective and 
quantifiable criteria from neuroinformatics and neuroimaging. 156 study subjects, 
including 92 schizophrenia patients and 64 healthy normal controls are recruited 
by our collaborating hospitals. All patients are scanned using MRI and DTI 
imaging. Some of them (84) has completed all 4 neurocognitive tests: RPM, WAIS, 
CPT and WCST. 
 
7.1 Conclusions 
7.1.1 Neuroinformatics Based Modeling 
 
Significant factors are chosen from over 50 clinical items by the feature selection 
method (Correlation-based Feature Subset). The only highly relevant (statistically 
 156
and clinically) factor selected is the fam_hx (family history). Based on that factor, 
a baseline Bayesian Network classification model is generated.  
 
Unlike RPM, WAIS and WCST tests, CPT test is found not contributing to the 
classification accuracy. Bayesian Network models are generated when RPM, 
WAIS and WCST tests results are included. All Bayesian Networks degenerate to 
Naive Bayesian Networks as the factors selected are conditionally independent of 
each other on the target node (pt_ctrl). Their classification accuracies range from 
about 75% to 85.7%.  
 
7.1.2 Neuroimaging Based Modeling 
 
We use the DTI imaging to study the brain white matter abnormalities of 
schizophrenia.  FA images (which measure the neural connectivity level) are 
generated based on the DTI image.  
 
We apply a method developed at Biomedical Imaging Lab, Agency for Science 
Technology, and Research to automatically place ROIs on brain images by 
registering the Talairach-Tournoux brain atlas to the structural MRI images and 
DTI images. 48 brain structures are identified. Each brain structure is divided into 
the left hemisphere, right hemisphere, and as a whole. So the FA values in 144 




Four factors are chosen after the feature selection: CG (cingulate gyrus), ScG_left 
(left subcallosal gyrus), ThLD_left (left thalamus: lateral dorsal nucleus) and 
ThNA_right (right thalamus: anterior nucleus). The Bayesian Network 
classification model with the 4 imaging features can achieve an accuracy of 77.4%. 
 
7.1.3 Combined Model 
 
Combined models are also constructed by using neuroimaging features and 
different neurocognitive tests results together. The accuracies of all models are 
higher than 85%. Not surprisingly, the most comprehensive model consisting of 
clinical information, all 3 neurocognitive tests results and the neuroimaging 
features achieves the highest accuracy (89.3%). Compared to the baseline model 
(where no neurocognitive test and no neuroimaging are included), the accuracy 
increases by 19.1%. 
 
This proves our hypothesis that the accuracy diagnosis of schizophrenia can be 
improved by using objective and quantitative criteria from a wider spectrum of 
modalities including neuroinformatics and neuroimaging. 
 
The schizophrenia models generated in this work combine both neuroimaging 
features and neuroinformatics features, which has never been attempted before to 
our best knowledge. The most comprehensive combined model reveals and 











Family history of psychiatric disease (fam_hx) is one of the important factors in 
schizophrenia as reported by various studies that we mentioned earlier in this thesis; 
The deficit in eductive and reproductive functions (as assessed by RPM_raw), 
deficit in verbal working memory (as assessed by DigitSpan_bwd), undue 
perseverative responses which is caused by frontal lobe deficit (as assessed by 
PersResponses_raw), and reduced neural connectivity in cingulate gyrus (CG) (for 
attention function), subcallosal gyrus (ScG) (for left prefrontal and right prefrontal 
interhemispheric communication), and thalamus lateral dorsal nucleus (ThLD) and 
anterior nucleus (ThNA) (somatosensory and visuo-spatial functions and 
modulation of alertness) are the other significant factors associated with 
schizophrenia. 
 
Although CPT test has been done, it is found to have little relation with 
schizophrenia. This suggests that the difference in capability of attention and 
impulsivity is not significant between schizophrenia patients and normal controls 
when compared to other factors.   
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7.1.4 Significant Features 
 
From the baseline model, a feature is added to build a new model, which will 
increase the classification accuracy. We use baseline model and the new model to 
classify all 84 cases in order to have a closer look at the data pattern of the 
correctly and incorrectly classified cases. 
 
A partial classification results are shown in Table 7.1. In this table, each case is 
classified by the baseline model C and the model C+R. Column pt_ctrl is the case's 
ground truth. Column "C Predict" is the classification results of model C. Column 
"C Correct?" tells if model C classification results are correct, and so as "C+R 
Predict" and "C+R Correct?". The last column "From C to C+R" shows the 
comparison between the two models classification results. If their classification 
results are the same, the value is "Same". If model C fails to classify the case, but 
model C+R successfully classifies it, the value is "Improved". In contrast, if model 
C+R fails to classify the case, but model C successfully classifies it, the is "Worse". 
 
The comparison results are visualized in Figure 7.1. The top figure shows the 
distribution of cases in the 2D plot of fam_hx and RPM_raw feature space. Black 
circles represent correctly classified cases, and red circles represent cases that are  
classified wrongly. We notice that all failed cases fall within the zone of fam_hx = 
Nil and RPM_raw range about 45 to 60. The bottom figure shows the comparison 
of the classification results of the two models. We see that there is no improvement 
of the new model C+R when RPM_raw is below 50. However, the new model 
C+R makes many improvements when RPM_raw greater than 50.  
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RPM_raw is the number of missing patterns correctly identified by a person in the 
RPM test. It seems the score of 50 is a low limit for model C+R to work well, 
which means when RPM_raw is greater than 50, it is more useful in contributing to 
the classification of schizophrenia; below that, it is not very sensitive to the 
classification.  
 










From C to 
C+R 
1 Patient Patient Yes Patient Yes Same 
2 Patient Patient Yes Patient Yes Same 
5 Patient Patient Yes Patient Yes Same 
6 Patient Patient Yes Control No Worse 
7 Patient Patient Yes Patient Yes Same 
14 Control Patient No Patient No Same 
20 Patient Patient Yes Patient Yes Same 
21 Patient Patient Yes Patient Yes Same 
23 Control Patient No Control Yes Improved 
26 Patient Patient Yes Patient Yes Same 
32 Control Patient No Control Yes Improved 
33 Control Patient No Control Yes Improved 
34 Control Patient No Control Yes Improved 
38 Patient Patient Yes Control No Worse 
39 Control Patient No Control Yes Improved 
40 Control Patient No Control Yes Improved 
42 Patient Patient Yes Patient Yes Same 
Abbreviations: C, Clinical Data; R, RPM Test; pt_ctrl, patient or control 
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Figure 7.1 Case distribution for model C+R 
Top diagram shows if the classification result is correct. Black circle, Yes; Red circle, No; 
Bottom diagram shows the comparison of the classification results of the old model C and the 
new model C+R. Cyan circle, same result; Red downwards triangle, Worse (old model is 
correct, new model is wrong); Black upward triangle, Improved (old model is wrong, new 
model is correct); Abbreviations: C, Clinical Data; R, RPM Test;  
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Similarly, the distribution of classification results and the comparison with 
baseline model C of the model C+WA is visualized in Figure 7.2. The top diagram 
shows the classification results in the fam_hx and DigitSpan_bwd space. The 
bottom diagrams shows if the results are improved by adding WAIS test into the 
baseline model. As we can see that most wrongly classified cases are in the zone of 
fam_hx = Nil and DigitSpan_bwd score 7, 8, 9. When DigitSpan_bwd is lower 
than 7, model C+WA performs the same as model C, whereas for score higher than 
9, model C+WA outperforms model C in 8 out of 10 cases. 
 
DigitSpan_bwd is the longest of number of digits that a person can repeat correctly 
in the reverse order.  It assesses the memory capacity of a person. This score 
contributes to the model classification capability when it is blower than 7, and 
higher than 9. When it is in the mid-range of 7 to 9, its contribution is mixed. A 
total of 30 cases (16 improved and 14 worse) fall in this range. A further 
investigation of the 30 cases reveals that DigitSpan_bwd is close to but not 
significantly different (p=0.058) between the improved cases (mean 7.44, SD 
0.629) and worse cases (mean 8.0, SD 0.877).  However, by using the two-tailed 
independent t test, SpatialSpan_bwd is found to be significantly different (p=0.005) 
between them: for the improved cases, the mean score is 8.94 (SD 1.436), and for 
the worse cases, it is 7.14 (SD 1.703). This suggests SpatialSpan_bwd score 
(which assesses spatial working memory) can be a good candidate to suplement the 
DigitSpan_bwd score when it fails to work in the mid-range of 7 to 9. It is 
reasonable since both tests are for the memory capacity aspects.  
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Figure 7.2 Case distribution for model C+WA 
Top diagram shows if the classification result is correct. Black circle, Yes; Red circle, No; 
Bottom diagram shows the comparison of the classification results of the old model C and the 
new model C+WA. Cyan circle, same result; Red downwards triangle, Worse (old model is 
correct, new model is wrong); Black upward triangle, Improved (old model is wrong, new 
model is correct); Abbreviations: C, Clinical Data; WA, WAIS Test; 
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The results of model C+WC is shown in Figure 7.3. The top part is the distribution 
of correctly and wrongly classified cases in fam_hx and PersResponses_raw space. 
The bottom diagrams shows whether the results are improved by adding WCST 
test into the baseline model. Please note that for the clear visualization purpose 
only, the PersResponses_raw score is rounded to the nearest 5. Otherwise the 
indicators (circles and triangles) will be packed together along the horizontal line 
since PersResponses_raw takes different integer values close to each other, which 
prevents them from being stacked along the vertical direction.  
 
We observed that almost all wrongly classified cases (20 cases) fall in the zone of 
fam_hx = Nil and PersResponses_raw below about 30, in contrast, there are 24 
correctly identified cases in the same zone.  
 
PersResponses_raw is reported to be associated with the dysfunction of frontal 
lobe. When it is higher than 30, the model can classify cases very well. When it is 
lower than 30, the model’s performance is mixed. Further investigation (using 
independent t test) of the these subset of case (PersResponses_raw less than 30) 
doesn’t find any feature from WCST test that is able to significantly improve the 




Figure 7.3 Case distribution for model C+WC 
Top diagram shows if the classification result is correct. Black circle, Yes; Red circle, No; 
Bottom diagram shows the comparison of the classification results of the old model C and the 
new model C+WC. Cyan circle, same result; Red downwards triangle, Worse (old model is 
correct, new model is wrong); Black upward triangle, Improved (old model is wrong, new 
model is correct); Abbreviations: C, Clinical Data; WC, WCST Test; Note: 
PersResponses_raw score is rounded to the nearest 5. 
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Results of model I+C are illustrated in Figure 7.4 and Figure 7.5. Since there are 4 
significant image features, CG, ScG_left, ThLD_left and ThNA_right, the case 
distributions are plotted in 2 separated 2D plots: one for CG and ScG_left space 
(Figure part A), the one for ThLD_left and ThNA_right (Figure part B). In each 
part of the figure, the top diagram shows the distribution of correctly and wrongly 
classified cases, whereas the bottom diagram depicts if the results are improved by 
adding imaging test into the baseline model. 
 
It is observed that wrongly classified cases are located within the zone of CG range 
about 0.25 to 0.275 and ScG_left range about 0.25 to 0.35, as well as ThLD_left 
range about 0.3 to 0.4 and ThNA_right range about 0.37 to 0.43. Outside of the 
zone, the model I+C can classify most cases correctly. 
 
Except for CG (where 0.25 to 0.275 is at about its middle range), the other 3 
ranges are close to the high end of values. When we place the same ranges in 
distribution of patients and controls (Figure 7.6), not surprisingly, we can see that 
these ranges cover the area with mostly mixed patients and controls. 
 
As we know, these 4 image features are FA values that are associated with the 
strength of neural connectivity. Lower values usually imply defects in the brain 
connections. We can see this from Figure 7.6 that lower left portions (low FA 
values) of both diagrams contain mostly patients. 
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Compared to baseline model, this model I+C outperforms by 24 improved cases, 
but underperforms by 8 worse cases (which are actually patients, but wrongly 
classified as controls, where as model C classifies them correctly as patients). A 
further investigation shows that this group of 8 patients has a mean ThLD_left 
value of 0.3625 (SD 0.0587) and a mean ThNA_right value of 0.3866 (SD 0.0252). 
They are even higher than overall mean value of all controls, ThLD_left 0.3497 
(SD 0.0857) and ThNA_right 0.3595 (SD 0.0408), although not statistically 
significantly. Not other difference between the rest patients is found, except for the 
weight. The mean weight of the 8 patients is 74.65kg (SD 16.94) is significantly 
higher than the rest patients (mean 61.25kg, SD 10.37). However no other 
literature reports a directly relationship between body weight and neural 
connectivity functions in thalamus. 
 
This observation reveals that some schizophrenia patients (8 out of 51, or 15.7% in 
our study) do not suffer from decreased FA values in the thalamic regions. It also 
shows that model I+C may not work in patients with high ThLD_left and 
ThNA_right values. 
 
In conclusion, in terms of increasing classification accuracy, RPM_raw performs 
better when it is greater than 50, when compared to less than 50. DigitSpan_bwd 
performs well when it is lower than 7 or greater than 9; and SpatialSpan_bwd score 
can suplement when DigitSpan_bwd is between 7 to 9. PersResponses_raw is more 
helpful in increasing the classification accuracy when it is higher than 30. Imaging 
features contributes more to classification accuracy, when outside the CG range of 
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about 0.25 to 0.275, ScG_left range of about 0.25 to 0.35, ThLD_left range of 
about 0.3 to 0.4 and ThNA_right range about 0.37 to 0.43.  
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Figure 7.4 Case distribution for model I+C (part A) 
Top diagram shows if the classification result is correct. Black circle, Yes; Red circle, No; 
Pink Rectangle, Range of most wrongly classified cases; Bottom diagram shows the 
comparison of the classification results of the old model C and the new model I+C. Cyan 
circle, same result; Red downwards triangle, Worse (old model is correct, new model is 
wrong); Black upward triangle, Improved (old model is wrong, new model is correct); 
Abbreviations: C, Clinical Data; I, Imaging Test; 
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Figure 7.5 Case distribution for model I+C (part B) 
Top diagram shows if the classification result is correct. Black circle, Yes; Red circle, No; 
Pink Rectangle, Range of most wrongly classified cases; Bottom diagram shows the 
comparison of the classification results of the old model C and the new model I+C. Cyan 
circle, same result; Red downwards triangle, Worse (old model is correct, new model is 
wrong); Black upward triangle, Improved (old model is wrong, new model is correct); 




Figure 7.6 Distribution of patients and controls 
Top: distribution cases in CG and ScG_left space; Bottom: distribution of cases in ThLD_left 
and ThNA_right space; Blue circle, Patient; Green circle, Control; Pink Rectangle, Range of 
most mixed patients and controls; 
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7.1.5 Decision Support System 
 
Based on all schizophrenia classification models, we make two decision support 
flow charts to choose suitable tests by using different strategies. One strategy is the 
highest accuracy gain. At each step, clinicians can follow the flow chart to choose 
the best further test that leads to a new model with the highest possible accuracy, 
regardless of the cost. Another strategy is the highest cost effectiveness. At each 
step, clinicians can follow the flow chart to choose a further test with the least cost 
for every percentage of accuracy gain. However, at some steps, adding a test can 
only achieve a small accuracy increment. For example, from model I+C+WC to 
model I+C+WA+WC, the accuracy increases from 85.7% to 88.1% by 2.4% only. 
Clinicians may need to make decision on whether such an increment is practically 
useful to their needs.  
 
The decision support system software based on all models is developed to support 
the decision making in schizophrenia diagnosis. The system will automatically 
choose an appropriate model depending on the available case data and classify a 
case as either patient or normal. Suggestions on what tests should be performed in 
order to get more accurate classification results will also be given. 
 
Unlike some existing schizophrenia decision support systems, (Razzouk, et al., 
2006) and (Yana, et al., 1997), that use patient clinical information only, our 
decision support system makes use of both neuroinformatics features and 
neuroimaging features. Since the criteria used in our decision support system are 
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In summary, schizophrenia classification models can be constructed using 
objective and quantifiable criteria from neuroinformatics and neuroimaging data. 
The most comprehensive model can achieve an accuracy of 89.3%. A decision 
support system based on these models can provide additional objective evidence to 
clinicians and augment the current diagnostic procedures.  
 
Despite the unique combination of neuroinformatics and neuroimaging data, our 
models and decision support system are still tentative and limited due to the 
relatively small sample size and types of data. For example, Type I Error, or False 
Positive Rate, is still at a noticeable 20% level even for the most comprehensive 
model including all 8 features. Further refinements need to consider by using more 
extensive clinical information, other types of neuroimaging data and biological 





The number of samples collected in this study is restricted by the budget because 
the data collection is very costly. For example, MRI and DTI scan costs $457 per 
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person. For a complete set of all tests (four neurocognitive tests plus 
neuroimaging), the total cost is $1,497 per person if  he/she is charged according to 
the private rate as discussed at section 3.4. This has not included the administrative 
cost yet. The actual total cost of data acquisition for this study is about $150,000. 
 
Despite that, a total of 156 study subjects are recruited. Among them, all subjects 
are scanned to acquire the MRI and DTI images, and only 89 to 95 subjects 
undergo various neurocognitive tests (see Table 3.6). Finally 84 subjects who have 
completed all neurocognitive tests and neuroimaging scans are used in our study of 
schizophrenia. 
 
To our best knowledge, this is the first project that tries to build schizophrenia 
models based on unique combination of neuroimaging and neuroinformatics data. 
Although DTI has been widely used to examine the brain white matter 
abnormalities for schizophrenia, and many qualitative results have shown brain 
white matter changes in schizophrenia, the quantitative relationship between the 
FA values in brain anatomical structures and schizophrenia has not been revealed 
yet.  
 
Furthermore, no other study has been reported to solve the non-quantifiable 
diagnosis criteria problem in the current standard diagnosis procedures. DSM-IV 
was published in 1994, and the next version DSM-V is still in the preparation stage, 
with its publication date being postponed to May 2013 as announced by American 
Psychiatric Association ("News Release," 2009). Along the way, our work shows 
interesting results and promising directions in the attempt of improving diagnosis 
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accuracy by using objective and quantitative neuroimaging and neuroinformatics 
features. 
 
7.2.2 Model Accuracies 
 
By adding a new test result to an existing model, a new model is generated. 
Usually the new model will have a higher accuracy. For example, model C+WC 
has an accuracy of 75%. After adding in WAIS test, the new model C+WA+WC 
has an accuracy of 84.5%; an accuracy gain of 9.5% is achieved. 
 
However, the following exceptions are observed: 
 
Model I+C+WA has an accuracy of 88.1%. After adding in another test result 
(WCST), it becomes model I+C+WA+WC, and the accuracy remains unchanged 
(88.1%). No accuracy gain is achieved. After adding RPM test, the model 
I+C+R+WA even has a lower accuracy (86.9%): a negative accuracy gain is 
incurred (-1.2%). New models accuracies do not increase as expected after new 
tests are added. However, the differences between the models with additional tests 
(I+C+WA+WC, I+C+R+WA) and the existing model (I+C+WA) are small: 0% 
and -1.2%, which convert to 0 or 1 case difference for the 84 training datasets. This 
fluctuation may be caused by the small number of validation cases. In this 
situations, RPM test's additional contribution to the classification accuracy is 
already small; when the number of cases is small, the irregularity of the sample 
data may affect a small number (e.g., 1 or 2 cases) of classification results, and 
cause the decreased accuracy. 
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In another case, model I+C+R has an accuracy of 88.1%. After adding in WAIS 
test, the new model I+C+R+WA has an accuracy of 86.9%, a negative accuracy 
gain is incurred (-1.2%). After adding WCST test, the new model I+C+R+WC has 
an accuracy of 85.7%, with a negative accuracy gain of -2.4%. These convert to 1 
or 2 cases difference in all the 84 training cases. The fluctuation may also be 




Each model is tested by using the 10-fold cross-validation when it is constructed. 
The accuracy of the model may be more optimized than the actual condition. 
External validation is required to test these models. In future, preferably the testing 
can be done in the hospital environment. 
 
However, before large scale external validation can be done, we can do some 
quasi-external validation. We call the validation as quasi-external, because the 
cases we want to evaluate are not used in model construction, but they have been 
collected for this study already. 
 
Remember that in this study, we have recruited 156 cases. Clinical information for 
all cases is collected; neuroimaging (sMRI and DTI) for all cases are also acquired. 
But not all of them have completed all four neurocognitive tests. Specifically, 93 
study subjects have completed RPM test, 95 for WAIS test, 89 for CPT test and 93 
for WCST test (Table 3.6). 84 subjects have completed all four tests, and they are 
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used to build schizophrenia models. The remaining 72 cases are not used in model 
construction. We can use part of these cases that have completed at least one 
neurocognitive test for validation purpose. 
 
We validate model C using all 72 cases. As we mentioned before, this model 
classifies all cases as patient, hence the accuracy is the same as the prevalent 
patient rate, and there is no accuracy gain.  
 
There are also 72 study subjects that completed the neuroimaging scan; they are 
used to validate model I+C. Among them, 46 are correctly classified, and so the 
accuracy is 63.9%.  
 
For the rest of the models, there are only 6 to 12 cases for validation. Their 
accuracies range from 55.6% to 100%. The results are summarized in Table 7.2 
and Figure 7.7 (Accuracy) and Figure 7.8 (Type I and Type II Error). Since the 
numbers of cases used in validation are small, the validation results are not very 
reliable. Large scale external validation is required before the decision support 
system can be applied in clinical practice. 
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Table 7.2 Summary of validation results 








Nr 72 9 12 9 9 6 9 6 
Cor  33 9 11 5 9 6 8 6 
Incor 39 0 1 4 0 0 1 0 
Accuracy 45.8% 100.0% 91.7% 55.6% 100.0% 100.0% 88.9% 100.0% 
Err 54.2% 0.0% 8.3% 44.4% 0.0% 0.0% 11.1% 0.0% 
Sen 100.0% 100.0% 88.9% 33.3% 100.0% 100.0% 83.3% 100.0% 
Type I  100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Spe 0.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Type II  0.0% 0.0% 11.1% 66.7% 0.0% 0.0% 16.7% 0.0% 
Pt Nr 33 6 9 6 6 3 6 3 
Ctrl Nr 39 3 3 3 3 3 3 3 













Nr 72 9 12 9 9 6 9 6 
Cor  46 8 10 5 8 5 7 5 
Incor 26 1 2 4 1 1 2 1 
Accuracy 63.9% 88.9% 83.3% 55.6% 88.9% 83.3% 77.8% 83.3% 
Err 36.1% 11.1% 16.7% 44.4% 11.1% 16.7% 22.2% 16.7% 
Sen 69.7% 100.0% 88.9% 50.0% 100.0% 100.0% 83.3% 66.7% 
Type I  41.0% 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 0.0% 
Spe 59.0% 66.7% 66.7% 66.7% 66.7% 66.7% 66.7% 100.0% 
Type II  30.3% 0.0% 11.1% 50.0% 0.0% 0.0% 16.7% 33.3% 
Pt Nr 33 6 9 6 6 3 6 3 
Ctrl Nr 39 3 3 3 3 3 3 3 
Abbreviations: Nr, Total Number of Instances; Cor, Correctly Classified Instances; Incor, Incorrectly 
Classified Instances; Acc, Accuracy; Err, Error Rate; Sen, Sensitivity; TPR, True Positive Rate (Patient 
classified as patient); Type I, Type I Error Rate (Control classified as patient); Spe, Specificity; TNR, True 
Negative Rate (Control classified as control); Type II, Type II Error Rate (Patient classified as control); Pt Nr, 







































































Figure 7.7 Validation results: accuracy 
(blue: validation accuracy, pink: model accuracy) 
 






























































Figure 7.8 Validation results: Type I and Type II error 
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However, we can estimate the overall accuracy by combining all models as 
described previously in chapter 6. 
 
 Accoverall = Acc16 = 81.7% 
 
We notice that the accuracy is 81.7%, which is close to the result of overall 
accuracy of all models, Acc16 (83.8%) as described in chapter 6.  
 
Model C takes into account of clinical information only (family history). As we 
have pointed out previously, this model classifies all cases as patients, and its type 
I error is 100%. Hence it shall not be applied in practice. If we exclude this model 
from decision support system (a more realistic situation because diagnosis should 
not solely depend on family history), the mean accuracy of all the other models 
becomes 84.1%, which is also close to the result of Acc15 (84.8%) as described in 
chapter 6. 
 
 Accoverall = Acc15 = 84.1% 
 
In summary, we validate the decision support system using limited external cases. 
The overall classification accuracies of the decision support system are 81.7% and 




7.2.4 Comparison with Other Decision Support Systems for Diagnosis 
 
We compare our decision support system with the other two schizophrenia 
diagnosis decision support systems that we have reviewed in chapter 2. The results 
are summarized in Table 7.3. 
 
We find that: 1) in terms of targeted diseases, our solution tries to diagnose 
schizophrenia from normal control; Razzouk’s solution is used for differentiating 
schizophrenia from a similar disorder, schizophreniform; and Yana’s solution is 
for the diagnosis of schizophrenia, mood disorders and neurosis. 2) Razzouk’s and 
Yana’s solutions rely on symptoms as diagnosis criteria which are subjective and 
not quantifiable, but our solution uses objective and quantifiable neurocognitive 
and neuroimaging tests results; 3) Numbers of cases used for building/testing of 
our solution and Yana’s solution are close to each other (84 and 100), and that of 
Razzouk’s solution is only 38; 4) Though the accuracy range of the three solutions 
overlap, our solution is at the high end. The accuracy of our most comprehensive 
model (including 8 features) is especially the highest (89.3%) among all solutions. 
 
Overall, our decision support system is the only one based on objective criteria and 
achieves the highest diagnosis accuracy. 
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Table 7.3 Comparison of decision support systems for schizophrenia diagnosis 
 
 Targeted Diseases Criteria Used Number of Cases Diagnosis Accuracy 
Our 
solution 
















80 Yes/no questions 
including 32 
symptoms 
100 73.3% and 77.3% 
for schizophrenia by 
two different models 
 
7.2.5 Alternative Forms of Models 
 
We also attempt to construct schizophrenia models using other algorithms, such as 
Alternating Decision Tree (Freund & Mason, 1999) and Logistic Regression 
(Cessie & Houwelingen, 1992). The results for the most comprehensive model 
(model I+C+R+WA+WC) using the 2 alternative algorithms are listed and 
compared with Bayesian Network model in Table 7.4. We find that their 
accuracies are similar (83.3%) and almost as good as that of the Bayesian Network 
model (89.3%).  
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Table 7.4 Models using different algorithms 






Nr 84 84 84 
Cor 70 70 75 
Incor 14 14 9 
Accuracy 83.3% 83.3% 89.3% 
Err 16.7% 16.7% 10.7% 
Sen 86.4% 86.4% 93.2% 
Type I  24.0% 24.0% 20.0% 
Spe 76.0% 76.0% 80.0% 
Type II  13.6% 13.6% 6.8% 
Abbreviations: Nr, Total Number of Instances; Cor, Correctly Classified Instances; Incor, Incorrectly 
Classified Instances; Acc, Accuracy; Err, Error Rate; Sen, TPR, True Positive Rate (Patient classified as 
patient); Type I, Type I Error Rate (Control classified as patient); Spe, TNR, True Negative Rate (Control 
classified as control); Type II, Type II Error Rate (Patient classified as control); I, Imaging; C, Clinical Data; R, 
RPM Test; WA, WAIS Test; WC, WCST Test 
 
The most comprehensive model based on all 8 significant features in the form of 
Alternating Decision Tree is illustrated in Figure 7.9. This decision tree has 4 
levels, and contains 10 decision nodes (represented by ovals) and 21 prediction 
nodes (represented by rectangles). A case follows all paths for which all decision 
nodes are true. The numeric values inside all prediction nodes it traversed are 
added up together. When it reaches the bottom of the decision tree, if the total of 
the numeric values along the traversal path is negative, this case is classified as a 




Figure 7.9 Alternating decision tree model on all significant features 
 
7.2.6 Decision Support 
 
The purpose of our decision support system is not meant to replace existing 
diagnosis procedures. At the current stage, it can only be used in providing 
additional support to the clinicians. The models underlying the decision support 
system need to be further verified.  
 
The cost of each neurocognitive test and the neuroimaging may vary from time to 
time, and from hospital to hospital. The suggestion on the value of tests by the 
decision support system depends on the particular actual cost of each hospital. 
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They can be adjusted as the system parameters. In addition, both model structure 
and model parameters can be enhanced when we have new training datasets.  
 
Currently in our decision support system uses 16 different models. The complexity 
of the model repository is at O(2n), where n is the number of tests. The searching 
for suitable model for classification and suggested further tests is linear, which 
means it accesses the model repository O(2n) times. With current computer storage 
capacity and computing speed, when n is small, the computing performance of the 
decision support system is still acceptable. However, at the model construction 
stage, all models are constructed manually. When n is large, constructing of 
models becomes difficult. Some automated methods for dynamic Bayesian 
Network model construction need to be applied (Poh, Fehling, & Horvitz, 1994; 
Xiang & Poh, 2005; S. S. Xu & Poh, 2002). 
 
7.2.7 Limitations of the Image Processing Algorithm 
 
There are some limitations in our ROI selection method. Firstly the resolution of 
current atlas is not high enough, e.g., typical slice distance is 2 to 5 mm in axial 
orientation. This restricts the precision of the atlas based ROI placement. This 
limitation can be overcome by a high resolution atlas which is currently under 
development. 
 
Secondly, the Fast Talairach-Transformation (FTT) method divides the whole 
brain into 24 small cuboids. Within each cuboid, linear transformation is used to 
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warp the atlas. More accurate registration method such as non-linear warping (M. 
Xu & Nowinski, 2001) should be used in order to get higher registration accuracy.  
 
Furthermore, multiple atlases such as Schaltenbrand and Wahren electronic brain 
atlas (W. L. Nowinski, et al., 1997; W. L. Nowinski, Liu, & Thirunavuukarasuu, 
2006; Schaltenbrand & Wahren, 1977) co-registered with the Talairach atlas and 
the 3-dimensional detailed brain atlas for structures, vasculatures and tracts (W.L. 
Nowinski, et al., 2009) can be used for automatically identifying more deep brain 
structures and brain connections at higher resolution. 
 
7.2.8 Limitations of Study Samples 
 
Among 156 recruited study subjects, only 84 are selected as training datasets. 72 
are not used because they do not fulfill the requirements for completion of all 
neurocognitive tests. If we can have more study subjects, we will be able to 
achieve better results, in terms of higher precision of model parameters.  
 
Furthermore, our sample data are collected in Singapore. The ethnics are mainly 
Chinese. This may restrict the generality of our findings in wider geographical and 




7.2.9 Future Work Direction 
 
Model Maintenance: Our models are constructed from training datasets 
consisting of 84 cases. Eight features are selected in total.  The ratio of case to 
feature is about 10 to 1. In future, new datasets need to be collected in order to 
enhance the Bayesian model structures as well as parameters. And the decision 
support flow charts can be re-organized automatically according to the new 
parameters of each model. 
 
Other Imaging Features: We also found the first episode schizophrenia patients 
had reduced brain white volume in right temporal-occipital region compared to 
normal controls (Chan, et al., 2010) in another sub-project of this study. In addition 
to the FA values, the volumetric changes of brain structures shall also be included 
in the schizophrenia modeling. 
 
Genomic Data: Genetic studies have attempted to identify the genes that are 
related to certain disease. According to a review report (Lakhan, 2006), genes 
related to schizophrenia have been found in several chromosomal regions. Since 
more than 500 genes that have been reported to be associated with schizophrenia, 
effective feature selection methods such as (Fan, Poh, & Zhou, 2009) and factor 
grouping technology (Li & Leong, 2005) should be explored to improve the 
performance of Bayesian Network Models. For example, (J. Sun, Kuo, Riley, 
Kendler, & Zhao, 2008) uses a combined odds ratio method to ranks the genes and 
generates a list of highly related genes, including Disrupted-in-Schizophrenia 1 
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(DISC1), Dystrobrevin-Binding Protein 1 (DTNBP1), Catechol-O-methyl 
Transferase (COMT), etc. 
 
As such, genomic data shall also be combined with existing source of data in the 
constructing of more complete models in order to achieve better understanding of 
the pathophysiology and biological markers related to schizophrenia.  
 
Subtypes and Other Mental Diseases: We have built binary models for 
classifications of schizophrenia patients and healthy controls. The approach 
described in this thesis may also be applied to the model construction and decision 
support in classification of subtypes of schizophrenia, as well as other mental 
diseases (such as schizoaffective disorder, schizophreniform disorder, bipolar 
disorder, and unipolar depression) where neurocognitive tests and neuroimaging 
test are used. Furthermore, classifying of different mental diseases can be 
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Appendix A  
Collected Data Items and Descriptions 
 
Data Item Description 
age Age 
age_onset Age of First Onset of Illness 
alcohol Alcohol Use (past or current) 
antichol Anticholinergics (Type/ Dose) 
antidepr Antidepressants (Type/ Dose) 
atypical_antipsy1 Atypical Antipsychotics 1 
atypical_antipsy2 Atypical Antipsychotics 2 
benzo Benzodiazepines (Type/ Dose) 
BlockDesign_raw Block design raw score 
BlockDesign_scaled Block design scaled score 
broug_sp Brought By (specify) 
brought Brought By 
Categories_percentiles Categories completed percentiles 
Categories_raw Categories completed raw scores 
CDNo CD no: Compact Disc Number 
Comments Comments on the data entry 
Commissions_percentile Number of Commissions percentile 
Commissions_tscore Number of Commissions t score 
ConceptualLevel Conceptual Level responses 
dadmisn Date of Admission to Ward 
depot_antipsy Depot Antipsychotics 
Detect_percentile Detectability percentile 
Detect_tscore Detectability t score 
DigitSpan_bwd Digit span backward score 
DigitSpan_fwd Digit span forward score 
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Data Item Description 
DigitSpan_total Digit span total score 
DigitSpan_total_scaled Digit span total scaled score 
dob Date of Birth 
drug_use Drug Use (past or current) 
dsmaxis1 Diagnosis Axis 1 (DSM IV) 
dup_yrs Duration of Untreated Psychosis (in years) 
dur_psyc Duration of Psychiatric Illness (years) 
edulevel Educational Level 
ethnic Ethnicity 
Failure_percentiles Failure to maintain set percentiles 
Failure_raw Failure to maintain set raw scores 
fam_hx Family History of Mental Illness 
fam_hxsp Family History of Mental Illness (specify) 
father Father's Ethnicity 
first_ep First Episode? 
gaf_disa Global Assessment of Functioning Scale - Disability 
gaf_symp Global Assessment of Functioning Scale - Symptoms 
gaf_tot Global Assessment of Functioning Scale Total 
handed Handedness 
height Height 
HitRT_percentile Hit RT percentile 
HitRT_StdError_percentile Hit RT std error percentile 
HitRT_StdError_tscore Hit RT std error t score 
HitRT_tscore Hit RT t score 
Learning_percentiles Learning to learn percentiles 
Learning_raw Learning to learn raw scores 
liv_spec Living Arrangements (specify) 
livingar Living Arrangements 
marital Marital Status 
mdstabil Mood Stabilizers (Type/ Dose) 
med_prob Medical Problems (past or current) 
med_spec Medical Problems (specify) 
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Data Item Description 
mgfather Maternal Grandfather's Ethinicity 
mgmother Maternal Grandmother's Ethnicity 
mother Mother's Ethnicity 
mri_date Date of MRI appt 
mri_done MRI Done? 
neurocog Neurocog Done? 
no_hosps Number of Hospitalizations 
nohosp12 Number of Hospitalizations in Last 12 Months 
NonpersErrors_percentiles Nonperseverative Errors percentiles 
NonpersErrors_raw Nonperseverative Errors raw scores 
NonpersErrors_standard Nonperseverative Errors standard scores 
NonpersErrors_tscores Nonperseverative Errors t scores 
occ_dad Father's Occupation 
occ_mum Mother's Occupation 
occupatn Occupation 
Omissions_percentile Number of Omissions percentile 
Omissions_tscore Number of Omissions t score 
others1 Other Medications 1 (Type/ Dose) 
others2 Other Medications 2 (Type/ Dose) 
pangps1 PANSS GPS 1 
pangps10 PANSS GPS 10 
pangps11 PANSS GPS 11 
pangps12 PANSS GPS 12 
pangps13 PANSS GPS 13 
pangps14 PANSS GPS 14 
pangps15 PANSS GPS 15 
pangps16 PANSS GPS 16 
pangps2 PANSS GPS 2 
pangps3 PANSS GPS 3 
pangps4 PANSS GPS 4 
pangps5 PANSS GPS 5 
pangps6 PANSS GPS 6 
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Data Item Description 
pangps7 PANSS GPS 7 
pangps8 PANSS GPS 8 
pangps9 PANSS GPS 9 
panssn1 PANSS Negative 1 
panssn2 PANSS Negative 2 
panssn3 PANSS Negative 3 
panssn4 PANSS Negative 4 
panssn5 PANSS Negative 5 
panssn6 PANSS Negative 6 
panssn7 PANSS Negative 7 
panssp1 PANSS Positive 1 
panssp2 PANSS Positive 2 
panssp3 PANSS Positive 3 
panssp4 PANSS Positive 4 
panssp5 PANSS Positive 5 
panssp6 PANSS Positive 6 
panssp7 PANSS Positive 7 
Passivity Case of Passivity? 
PercentConceptualLevel_percentiles % Conceptual Level responses percentiles 
PercentConceptualLevel_raw % Conceptual Level responses raw scores 
PercentConceptualLevel_standard % Conceptual Level responses standard scores 
PercentConceptualLevel_tscores % Conceptual Level responses t scores 
PercentErrors_percentiles % errors percentiles 
PercentErrors_raw % errors raw scores 
PercentErrors_standard % errors standard scores 
PercentErrors_tscores % errors t scores 
PercentNonpersErrors_percentiles % Nonperseverative Errors percentiles 
PercentNonpersErrors_raw % Nonperseverative Errors raw scores 
PercentNonpersErrors_standard % Nonperseverative Errors standard scores 
PercentNonpersErrors_tscores % Nonperseverative Errors t scores 
PercentPersErrors_percentiles % Perseverative Errors percentiles 
PercentPersErrors_raw % Perseverative Errors raw scores 
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Data Item Description 
PercentPersErrors_standard % Perseverative Errors standard scores 
PercentPersErrors_tscores % Perseverative Errors t scores 
PercentPersResponses_percentiles % Perseverative Responses percentiles 
PercentPersResponses_raw % Perseverative Responses raw scores 
PercentPersResponses_standard % Perseverative Responses standard scores 
PercentPersResponses_tscores % Perseverative Responses t scores 
PersErrors_percentiles Perseverative Errors percentiles 
PersErrors_raw Perseverative Errors raw scores 
PersErrors_standard Perseverative Errors standard scores 
PersErrors_tscores Perseverative Errors t scores 
Persev_percentile Perseverations percentile 
Persev_tscore Perseverations t score 
PersResponses_percentiles Perseverative Responses 
PersResponses_raw Perseverative Responses raw scores 
PersResponses_standard Perseverative Reponses standard scores 
PersResponses_tscores Perseverative Reponses t scores 
pgfather Paternal Grandfather's Ethnicity 
pgmother Paternal Grandmother's Ethnicity 
pt_ctrl Patient or Control 
Response_percentile Response Style percentile 
Response_tscore Response Style t score 
RPM_percentile Raven's percentile 
RPM_raw Raven's raw score 
sapp_tot Scale for the Assessment of Passivity Phenomena Total Score 
sapp1 
Scale for the Assessment of Passivity Phenomena 1- Made 
Emotions 
sapp1a Scale for the Assessment of Passivity Phenomena 1a - Time Frame 
sapp2 
Scale for the Assessment of Passivity Phenomena 2 - Made 
Movements 
sapp3 
Scale for the Assessment of Passivity Phenomena 3 - Made 
Impulses/ Decisions to Act 
sapp4 Scale for the Assessment of Passivity Phenomena 4 - Somatic 
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Data Item Description 
Passivity 
sex Sex 
SpatialSpan_bwd Spatial span backward raw score 
SpatialSpan_bwd_scaled Spatial span backward scaled score 
SpatialSpan_fwd Spatial span forward raw score 
SpatialSpan_fwd_scaled Spatial span forward scaled score 
SpatialSpan_total Spatial span total score 
study_no Study Number (corresponds to Excel document) 
sumd1 SUMD 1 - Awareness of Mental Disorder 
sumd2 SUMD 2 - Awareness of Consequences of Mental Disorder 
sumd3 SUMD 3 - Awareness of Effects of Medication 
sumd4 SUMD 4 - Awareness of Hallucinatory Experiences 
sumd5 SUMD 5 - Awareness of Delusions 
sumd6 SUMD 6 - Awareness of Thought Disorder 
sumd7 SUMD 7 - Awareness of Flat or Blunt Affect 
sumd8 SUMD 8 - Awareness of Anhedonia 
sumd9 SUMD 9 - Awareness of Asociality 
sur_prob Surgical Problems (past or current) 
sur_spec Surgical Problems (specify) 
tcu_reg Regularity of Outpatient Attendance in Last 12 Months 
Total_correct Total correct 
TotalErrors_percentiles Total errors percentiles 
TotalErrors_raw Total errors raw scores 
TotalErrors_standard Total errors standard scores 
TotalErrors_tscores Total errors t scores 
Trials_administered Trials administered 
Trials_percentiles Trails to complete 1st category percentile 
Trials_raw Trials to complete 1st category raw scores 
typical_antipsy1 Typical Antipsychotics 1 
typical_antipsy2 Typical Antipsychotics 2 
Variability_percentile Variability percentile 
Variability_tscore Variability t score 
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Data Item Description 
weight Weight 
whoqol1 WHO QOL-BREF 1 (World Health Organization Quality of Life) 
whoqol10 WHO QOL-BREF 10 
whoqol11 WHO QOL-BREF 11 
whoqol12 WHO QOL-BREF 12 
whoqol13 WHO QOL-BREF 13 
whoqol14 WHO QOL-BREF 14 
whoqol15 WHO QOL-BREF 15 
whoqol16 WHO QOL-BREF 16 
whoqol17 WHO QOL-BREF 17 
whoqol18 WHO QOL-BREF 18 
whoqol19 WHO QOL-BREF 19 
whoqol2 WHO QOL-BREF 2 
whoqol20 WHO QOL-BREF 20 
whoqol21 WHO QOL-BREF 21 
whoqol22 WHO QOL-BREF 22 
whoqol23 WHO QOL-BREF 23 
whoqol24 WHO QOL-BREF 24 
whoqol25 WHO QOL-BREF 25 
whoqol26 WHO QOL-BREF 26 
whoqol3 WHO QOL-BREF 3 
whoqol4 WHO QOL-BREF 4 
whoqol5 WHO QOL-BREF 5 
whoqol6 WHO QOL-BREF 6 
whoqol7 WHO QOL-BREF 7 
whoqol8 WHO QOL-BREF 8 
whoqol9 WHO QOL-BREF 9 
yrsedu Years of Education 
yrsedu_dad Years of Edu Dad 




Appendix B  
Brain Anatomical Structures and Full Names 
 
Brain Structure Full Name 
AB Amygdaloid body 
AC Anterior commissure 
AGIPL Angular gyrus and inferior parietal lobule 
BA Brodmann's area 
C Cortical areas 
CA Cerebral aqueduct 
CC Corpus callosum 
CG Cingulate gyrus 
Ci Cingulum 
Cl Claustrum 
CN Caudate nucleus 
CSTF Corticospinal tract: Face 
CSTIL Corticospinal tract: Inferior limb 
CSTMC Corticospinal tract: Motor cortex 
CSTSL Corticospinal tract: Superior limb 
Cu Cuneus 
FG Fusiform gyrus 
Fo Fornix 
FOF Fronto-occipital fasciculus 
GPL Globus pallidus lateral segment 
GPM Globus pallidus medial segment 
HG Hippocampal gyrus 
Hi Hippocampus 
HyD Hypothalamus: Dorsal nucleus 
HyL Hypothalamus: Lateral nucleus 
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Brain Structure Full Name 
HyLPO Hypothalamus: Lateral preoptic nucleus 
HyMPO Hypothalamus: Medial preoptic nucleus 
HyP Hypothalamus: Posterior nucleus 
HyPaV Hypothalamus: Paraventricular nucleus 
HyPV Hypothalamus: Periventricular nucleus 
HySO Hypothalamus: Supra-optic nucleus 
HyVM Hypothalamus: Ventromedial nucleus 
IA Interthalamic adhesion 
IFG Inferior frontal gyrus 
ILF Inferior longitudinual fasciculus 
Ins Insula 
IOG Inferior occipital gyrus 
IPL Inferior parietal lobule 
ITG Inferior temporal gyrus 
LG Lingual gyrus 
LGB Lateral geniculate body 
MB Mamillary body 
MeFG Medial frontal gyrus 
MiFG Middle frontal gyrus 
MF Major forceps 
MGB Medial geniculate body 
MiFG Middle frontal gyrus 
MOG Middle occipital gyrus 
MT Motor tract 
MTG Middle temporal gyrus 
NA Nucleus accumbens 
OC Optic chiasm 
OF Olfactory fasciculus 
OG Occipital gyri 
OlT Olfactory tract 
ON Optic nerve 
OpT Optic tract 
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Brain Structure Full Name 
ORad Optic radiations 
OrG Orbital gyri 
PB Pineal body 
PC Posterior commissure 
Pcu Precuneus 
PHG Parahippocampal gyri 
PL Paracentral lobule 
PoCG Postcentral gyrus 
PrCG Precentral gyrus 
PrCOG Precentral opercular gyrus 
Pu Putamen 
RNB Red nucleus: Bottom 
RNT Red nucleus: Top 
ScG Subcallosal gyrus 
SFG Superior frontal gyrus 
SG Straight gyrus 
SLF Superior longitudinual fasciculus 
SmG Supramarginal gyrus 
SmGIPL Supramarginal gyrus and Inferior parietal lobule 
SN Substantia nigra 
SOG Superior occipital gyrus 
SPL Superior parietal lobule 
SpR Suprapineal recess 
STG Superior temporal gyrus 
STN Subthalamic nucleus 
T Tapetum 
ThCM Thalamus: Centromedian nucleus 
ThDM Thalamus: Dorsomedial nucleus 
ThLD Thalamus: Lateral dorsal nucleus 
ThLP Thalamus: Lateral posterior nucleus 
ThNA Thalamus: Anterior nucleus 
ThO Thalamus: Other structures 
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Brain Structure Full Name 
ThP Thalamus: Pulvinar nucleus 
ThVA Thalamus: Ventral anterior nucleus 
ThVL Thalamus: Ventral lateral nucleus 
ThVPL Thalamus: Ventral posterolateral nucleus 
ThVPM Thalamus: Ventral posteromedial nucleus 
TTG Transverse temporal gyri 
U Uncus 
UF Uncinate fasciculus 
Ven Ventricle(s) 
 
